{
    "questions": [
        {
            "body": "Is it possible to determine the proteome of a formalin fixed and paraffin embedded  (FFPE) tissue?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016610"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22352854", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22318899", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22188123", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22081483", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21370020", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21337705", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22387116", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22015969", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21117664", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20604508", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20597554", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20469934", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17409379", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20373500", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20373499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19637237", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19522851", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19471015", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19467989", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19128014", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16091476"
            ], 
            "id": "511a1e12df1ebcce7d000009", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21370020", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 212, 
                    "offsetInEndSection": 426, 
                    "text": "ver the last few years, advances in methodology have made it possible to recover peptides from FFPE tissues that yield a reasonable representation of the proteins recovered from identical fresh or frozen specimens."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081483", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1552, 
                    "offsetInEndSection": 1665, 
                    "text": "Thus, laser capture microdissection of FFPE tissue coupled with downstream proteomic analysis is a valid approach"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22387116", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 128, 
                    "text": "Qualitative proteome profiling of formalin-fixed, paraffin-embedded (FFPE) tissue is advancing the field of clinical proteomics."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22352854", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 121, 
                    "text": "Pressure-assisted protein extraction: a novel method for recovering proteins from archival tissue for proteomic analysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22352854", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 834, 
                    "offsetInEndSection": 951, 
                    "text": "provements in techniques such as mTRAQ have\nmade relative quantitation of disease biomarkers in FFPE tissue possible."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22352854", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1604, 
                    "offsetInEndSection": 2189, 
                    "text": "A variety of methods for profiling FFPE tissue\nhave been employed\nrecently. Some are practical for slide-mounted FFPE tissue, such as\nquantitative fluorescence imaging analysis (QFIA), which is reproducible\nand sensitive for specific standardized proteins,12\u221214 or MALDI-imaging\nmass spectrometry (MS).15\u221217 Other encouraging mass spectrometry\n(MS)-based proteomic studies of FFPE tissues have appeared in the\nrecent literature;2\u22127,9,18\u221220 however, these investigations have typically been\nrestricted to minute tissue specimens, such as those obtained by laser\ncapture microdissection."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22352854", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 623, 
                    "offsetInEndSection": 794, 
                    "text": "Although the FFPE proteomic literature is still quite limited, it\nis not unreasonable to propose that the same situation applies to\nthe proteomic analysis of FFPE tissues."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22352854", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2179, 
                    "offsetInEndSection": 2431, 
                    "text": "The ability of elevated pressure to significantly\nimprove the recovery of intact proteins from FFPE tissues over the\nuse of heat alone has great potential for broad application to top-down\nproteomic studies for the identification of disease biomarkers."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318899", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 80, 
                    "text": "Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188123", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 202, 
                    "offsetInEndSection": 472, 
                    "text": "Recent improvements in proteomics technologies, from the 2D gel analysis of intact proteins to the \"shotgun\" quantification of peptides and the use of isobaric tags for absolute and relative quantification (iTRAQ) method, have made the analysis of FFPE tissues possible."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21337705", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 173, 
                    "text": "The ability to investigate the proteome of formalin-fixed, paraffin-embedded (FFPE) tissues can be considered a major recent achievement in the field of clinical proteomics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22387116", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1174, 
                    "offsetInEndSection": 1362, 
                    "text": "The label-free approach enables the quantitative measurement of radiation-induced alterations in FFPE tissue and facilitates retrospective biomarker identification using clinical archives."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22015969", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 126, 
                    "text": "Proteomic analysis of formalin-fixed paraffin-embedded pancreatic tissue using liquid chromatography tandem mass spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22015969", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1352, 
                    "offsetInEndSection": 1522, 
                    "text": "We report that differentially expressed proteins can be identified among FFPE tissue specimens originating from individuals with different pancreatic histologic findings."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21117664", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 174, 
                    "text": "Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20604508", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "Formalin-fixed paraffin-embedded (FFPE) proteome analysis using gel-free and gel-based proteomics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20604508", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1119, 
                    "offsetInEndSection": 1313, 
                    "text": "This study will facilitate the development of future proteomic analysis of FFPE tissue and provide a tool for the validation in archival samples of biomarkers of exposure, prognosis and disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20597554", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1241, 
                    "offsetInEndSection": 1426, 
                    "text": "The CAAR method presented here complements previously described antigen-retrieval protocols and is an important step in being able to fully analyze the proteome of archived FFPE tissue."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469934", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 171, 
                    "text": "Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469934", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 132, 
                    "offsetInEndSection": 339, 
                    "text": "It has only recently been shown that proteins in FFPE tissues can be identified by mass spectrometry-based proteomics but analysis of post-translational modifications is thought to be difficult or impossible"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469934", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 694, 
                    "offsetInEndSection": 846, 
                    "text": "Results from the FFPE-FASP procedure do not indicate any discernible changes due to storage time, hematoxylin staining or laser capture microdissection."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469934", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1310, 
                    "offsetInEndSection": 1443, 
                    "text": "Thus, FFPE biobank material can be analyzed by quantitative proteomics at the level of proteins and post-translational modifications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16091476", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 429, 
                    "offsetInEndSection": 722, 
                    "text": "A novel tissue microdissection technique has been developed and combined with a method to extract soluble peptides directly from FFPE tissue for mass spectral analysis of prostate cancer (PCa) and benign prostate hyperplasia (BPH). Hundreds of proteins from PCa and BPH tissue were identified,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19128014", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1467, 
                    "offsetInEndSection": 1627, 
                    "text": "espite using tissue blocks stored for as many as 28 years, high confidence and comparative proteome analysis between the leiomyomas and the sarcoma is achieved."
                }, 
                {
                    "beginSection": "sections.9", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467989", 
                    "endSection": "sections.9", 
                    "offsetInBeginSection": 7801, 
                    "offsetInEndSection": 7933, 
                    "text": "we expect that our conclusions regarding the equivalence of FFPE and frozen tissues apply to laser capture microdissected specimens."
                }, 
                {
                    "beginSection": "sections.9", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467989", 
                    "endSection": "sections.9", 
                    "offsetInBeginSection": 8617, 
                    "offsetInEndSection": 8722, 
                    "text": "These results provide evidence that use of archival FFPE specimens for retrospective studies is possible."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467989", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 245, 
                    "offsetInEndSection": 609, 
                    "text": "In 2005, Hood et al. (7) first described the successful application of shotgun proteome analysis to FFPE tissue. Using laser capture microdissected cells and an optimized extraction method, hundreds of proteins were identified from a cancerous prostate lesion and benign prostate hyperplasia, thus opening the door to comparative proteomic analyses of FFPE tissue."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19471015", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1725, 
                    "offsetInEndSection": 1943, 
                    "text": "These findings demonstrate that formalin fixation, paraffin processing, and LCM do not negatively impact protein quality and quantity as determined by MS and that FFPE samples are amenable to global proteomic analysis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19471015", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 118, 
                    "text": "Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "How many tissue kallikrein genes are present in the human genome?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007610", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020840"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1697365", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11006094", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21741862", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20354523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20103546", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17210241", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16829021", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16800744", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16800742", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15588589", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15015574", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14710225", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12925213", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12727843", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12725528", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12439720", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12439719", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11522960", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11478802"
            ], 
            "id": "511a3573df1ebcce7d000018", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1697365", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 129, 
                    "text": "Tissue kallikreins are a group of closely related serine proteinases that are represented by multigene families in mice and rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11006094", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1075, 
                    "offsetInEndSection": 1221, 
                    "text": "Our map specifies the distance between genes to one base pair accuracy, the relative location, and the direction of transcription of all 15 genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21741862", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 160, 
                    "text": "The human tissue Kallikrein family consists of 15 genes with the majority shown to be differentially expressed in cancers and/or indicators of cancer prognosis."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20354523", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 428, 
                    "offsetInEndSection": 636, 
                    "text": "The prognostic value of at least 11 out of 15 members of the human kallikrein family in ovarian cancer has been also published (Clements et al, 2004; Yousef et al, 2005; Prezas et al, 2006; Dorn et al, 2007)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20103546", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 155, 
                    "text": "The 15 members of the kallikrein-related serine peptidase (KLK) family have diverse tissue-specific expression profiles and putative proteolytic functions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210241", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 205, 
                    "offsetInEndSection": 382, 
                    "text": "The 15 human and 24 mouse kallikreins have been implicated in pathophysiology of brain, kidney, and respiratory and reproductive systems and often are used as cancer biomarkers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16829021", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 180, 
                    "text": "Kallikrein gene families have been identified previously in genomes of the human, the mouse, and the rat, and individual kallikrein-like genes have been found in many more species."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16800744", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 146, 
                    "text": "The human tissue kallikrein family of serine proteases (hK1-hK15 encoded by the genes KLK1-KLK15) is involved in several cancer-related processes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16800742", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 101, 
                    "text": "The tissue kallikrein gene family consists of 15 genes tandemly arranged on human chromosome 19q13.4."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15015574", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 184, 
                    "text": "Human kallikreins are a cluster of 15 serine protease genes located in the chromosomal band 19q13.4, a non-randomly rearranged region in many solid tumors, including pancreatic cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12925213", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 102, 
                    "offsetInEndSection": 224, 
                    "text": "Tissue kallikrein genes (KLKs) are found on chromosome 19q13.3-4 as a gene cluster encoding 15 different serine proteases."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14710225", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 198, 
                    "text": "Kallikreins are a family of 15 genes clustered together on chromosome 19 (Yousef and Diamandis, 2001,2003) and encode for serine protease enzymes (Clements et al, 2001; Yousef and Diamandis, 2002b)."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14710225", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 664, 
                    "offsetInEndSection": 843, 
                    "text": "The mRNA sequences of the 15 human kallikrein genes were used to identify unique sequence tags of UniGene clusters for each kallikrein (the GenBank reference sequences were used)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12727843", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 305, 
                    "offsetInEndSection": 450, 
                    "text": "Project to perform in silico analyses of the expression pattern of the 15 human KLK genes in normal and cancerous ovarian tissues and cell lines."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12725528", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 85, 
                    "offsetInEndSection": 250, 
                    "text": "Novel kallikrein genes were cloned recently, and it was shown that the human kallikrein family contains 15 genes tandemly aligned on chromosomal locus 19q13.3-q13.4."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12439720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 100, 
                    "text": "The human kallikrein gene family includes 15 serine protease genes, clustered on chromosome 19q13.4."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12439719", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1658, 
                    "offsetInEndSection": 1838, 
                    "text": "The kallikrein genes, denoted KLK1\u2013KLK15, are located on chromosome 19q13.4 and encode for corresponding kallikrein enzymes, hK1\ufffd\ufffd\ufffdhK15 (Diamandis et al, 2000a; Yousef et al, 2000b)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11522960", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 65, 
                    "text": "The human kallikrein gene family consists of 15 serine proteases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11478802", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 434, 
                    "offsetInEndSection": 555, 
                    "text": "We have recently characterized the human kallikrein gene locus on chromosome 19q13.4, which includes 15 kallikrein genes."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which are the plant DNA (cytosine-5) methyltransferase families?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248", 
                "http://www.uniprot.org/uniprot/CMT1_DICDI"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17689048", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19132393", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20331964", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21542302", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8152926", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10845458", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9680985", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10781108", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18640997"
            ], 
            "id": "511a4d391159fa8212000003", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17689048", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 370, 
                    "offsetInEndSection": 760, 
                    "text": "The topologies of the trees were overall congruent: four monophyletic groups corresponding to the four plant C5-MTase families were clearly distinguished. In addition, sequence analyses of the plant C5-MTase target recognition domain sequences were performed and phylogenetic trees were reconstructed showing that there is good conservation among but not within the plant C5-MTase families."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19132393", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 399, 
                    "offsetInEndSection": 605, 
                    "text": "To determine the inheritance of DNA methyltransferase genes and their expression patterns we examined three major DNA methyltransferase families (MET1, CMT3 and DRM) from tobacco and the progenitor species."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3204, 
                    "offsetInEndSection": 3342, 
                    "text": "However, phylogenetic analysis indicates that the Dnmt3 and DRM protein families diverged independently in plants and mammals (Figure 1A)."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1734, 
                    "offsetInEndSection": 1967, 
                    "text": "Although an intriguing parallel exists between the functional relationships of DRM2/DRM3 and Dnmt3a/Dnmt3L, phylogenetic analysis strongly suggests that these protein families diverged independently in plants and animals (Figure 1A)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21542302", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1060, 
                    "offsetInEndSection": 1475, 
                    "text": "The comparative investigation of transcription levels of different genes of cytosine DNA methyltransferase family MET (MET1, MET2a, MET2b, MET3) and their methylation patterns shows that there may exist some mechanisms defending the most actively transcribed gene MET1 of this family from methylation mediated silencing. In contrast to DRM2 gene we could not find any adenine methylated GATC sites in the MET1 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8152926", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 246, 
                    "text": "Using the 1kb 3' terminal DNA fragment of the mouse methyltransferase cDNA as a probe and low stringent hybridisation conditions, a new potential methyltransferase (MTase) gene family was isolated from an Arabidopsis thaliana genomic DNA library."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781108", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 292, 
                    "offsetInEndSection": 752, 
                    "text": "The Dnmt3 family of de novo DNA methyltransferases has recently been characterized in animals. Here we describe DNA methyltransferase genes from both Arabidopsis and maize that show a high level of sequence similarity to Dnmt3, suggesting that they encode plant de novo methyltransferases. Relative to all known eukaryotic methyltransferases, these plant proteins contain a novel arrangement of the motifs required for DNA methyltransferase catalytic activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9680985", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1296, 
                    "offsetInEndSection": 1417, 
                    "text": "These results provide the first direct demonstration that DNA-METases of a higher eukaryote are encoded by a gene family."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20331964", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 183, 
                    "offsetInEndSection": 312, 
                    "text": "Here we show that Arabidopsis DNA methyltransferase2 (AtDNMT2) is localized in nucleus and associates with histone deacetylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18640997", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 344, 
                    "offsetInEndSection": 651, 
                    "text": "To explore possible relationships between DNA methylation level and accumulation of DNA-(cytosine-5) methyltransferase (DNMT) transcripts, the full-length coding sequences corresponding to three different DNMT families in oil palm, namely the MET, CMT, and DRM classes, have been isolated and characterized."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is the function of the viral KP4 protein?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/KP4T_UMV4", 
                "http://www.biosemantics.org/jochem#4265993", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014764"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21303448", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21116630", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17849147", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17522822", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11901234", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11532143", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10748529", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8809749", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8616260", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7582897", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7966296", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8145639"
            ], 
            "id": "511a51331159fa8212000009", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303448", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 359, 
                    "offsetInEndSection": 381, 
                    "text": "antifungal protein KP4"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116630", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 221, 
                    "text": "Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849147", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 390, 
                    "offsetInEndSection": 645, 
                    "text": "Our previous work on a virally encoded fungal toxin, KP4, from Ustilago maydis and subsequently with the plant defensin, MsDef1, from Medicago sativa demonstrated that some of these proteins specifically blocked calcium channels in both fungi and animals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849147", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 646, 
                    "offsetInEndSection": 838, 
                    "text": "The results presented here demonstrate that KP4 and three plant defensins, MsDef1, MtDef2, and RsAFP2, all inhibit root growth in germinating Arabidopsis seeds at low micromolar concentrations"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8809749", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 148, 
                    "offsetInEndSection": 447, 
                    "text": ". There are three well-characterized killer toxins in U. maydis-KP1, KP4, and KP6-which are secreted by the P1, P4, and P6 subtypes, respectively. These killer toxins are small polypeptides encoded by segments of an endogenous, persistent double-stranded RNA (dsRNA) virus in each U. maydis subtype."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17522822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 89, 
                    "text": "The viral gene for the killer protein 4 (KP4) has been explored for its antifungal effect"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10748529", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 22, 
                    "offsetInEndSection": 81, 
                    "text": "antifungal protein KP4 from Ustilago maydis-infecting virus"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10748529", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 399, 
                    "offsetInEndSection": 473, 
                    "text": "The antifungal activity correlated with the presence of the KP4 transgene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532143", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 951, 
                    "offsetInEndSection": 1078, 
                    "text": "These results suggest that KP4 may inhibit cell growth and division by blocking calcium-regulated signal transduction pathways."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532143", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 90, 
                    "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11901234", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 90, 
                    "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11901234", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 999, 
                    "offsetInEndSection": 1214, 
                    "text": "Our results defining the type of mammalian channel affected by this fungal toxin further support our contention that KP4 inhibits fungal growth by blocking transmembrane calcium flux through fungal calcium channels,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8145639", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 236, 
                    "text": "Killer toxins are polypeptides secreted by some fungal species that kill sensitive cells of the same or related species. In the best-characterized cases, they function by creating new pores in the cell membrane and disrupting ion fluxes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7966296", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 114, 
                    "text": "KP4 is a virally encoded and highly specific toxin that kills fungi closely related to the fungus Ustilago maydis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7582897", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 167, 
                    "text": "The P4 strain of the corn smut fungus, Ustilago maydis, secretes a fungal toxin, KP4, encoded by a fungal virus (UMV4) that persistently infects its cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7582897", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1307, 
                    "offsetInEndSection": 1438, 
                    "text": "These results led to experiments demonstrating that the toxin specifically inhibits voltage-gated Ca2+ channels in mammalian cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8616260", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 209, 
                    "text": "Ustilago maydis killer toxins are small polypeptides (7-14 kDa) which kill susceptible cells of closely related fungal species. The KP4 toxin is a single polypeptide subunit with a molecular weight of 11.1 kDa"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Are viruses involved in the etiology of human subacute thyroiditis?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013964", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.biosemantics.org/jochem#4054494", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019467", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0050690", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013957", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050033", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007453", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013958", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003831", 
                "http://www.uniprot.org/uniprot/PERT_RAT", 
                "http://www.uniprot.org/uniprot/PERT_PIG", 
                "http://www.uniprot.org/uniprot/PERT_HUMAN", 
                "http://www.uniprot.org/uniprot/PERT_MOUSE", 
                "http://www.uniprot.org/uniprot/PERT_CANFA", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013962", 
                "http://www.disease-ontology.org/api/metadata/DOID:7165", 
                "http://www.disease-ontology.org/api/metadata/DOID:7187", 
                "http://www.disease-ontology.org/api/metadata/DOID:7166", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013190", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014780", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013966", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013968"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18421188", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17511280", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15332726", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12608662", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10971829", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10525005", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1856259", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9790279", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1691523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22527824", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22459018", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20960165", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20671410", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19138419", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18422033", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16279854", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11109652", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9915102", 
                "http://www.ncbi.nlm.nih.gov/pubmed/4936649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20886354", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19627727", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19497087", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22819125", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23227861", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22136271"
            ], 
            "id": "513711055274a5fb0700000e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1856259", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 180, 
                    "text": "he etiology of subacute (de Quervain's) thyroiditis (SAT) is uncertain, although it probably represents a nonspecific inflammatory response by the thyroid to a variety of viruses."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109652", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 93, 
                    "text": "Subacute thyroiditis is an inflammatory disorder of the thyroid caused probably by viruses. I"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109652", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 713, 
                    "offsetInEndSection": 853, 
                    "text": "We believe that the etiologic agent was the Epstein-Barr virus because heterophile and Epstein-Barr virus-specific antibodies were positive."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1691523", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 711, 
                    "offsetInEndSection": 1051, 
                    "text": "ltogether, these results indicate that the mechanism of inhibition of Spumavirinae infection by interferon differs from that described for the other Retroviridae, and particularly for types B, C and D viruses. Our data is of therapeutic interest since Spumavirinae have been linked to pathological processes such as de Quervain thyroiditis."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which is the process that Conserved noncoding elements mostly regulate?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017124"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23042552", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21731768", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21478460", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21175683", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19704032", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19492354", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19073165", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18334644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18282512", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18056681", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17442748", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16533910", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19698106", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16630819", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17096848"
            ], 
            "id": "51387022bee46bd34c000002", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042552", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1058, 
                    "offsetInEndSection": 1308, 
                    "text": "Putative HCNE peak targets are characterized by a tight association with particular promoter motifs, higher incidence of severe mutant phenotypes, and evidence of a more precise regulation of gene expression during important developmental transitions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21478460", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 507, 
                    "offsetInEndSection": 681, 
                    "text": "Much evidence suggests that CNEs are selectively constrained and not mutational cold-spots, and there is evidence that some CNEs play a role in the regulation of development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21478460", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1463, 
                    "offsetInEndSection": 1676, 
                    "text": "This result suggests that there is widespread adaptation in mammalian conserved noncoding DNA elements, some of which have been implicated in the regulation of crucially important processes, including development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175683", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 143, 
                    "offsetInEndSection": 345, 
                    "text": "Some characteristics of CNEs include their high frequency in mammalian genomes, their potential regulatory role in gene expression, and their enrichment in gene deserts nearby master developmental genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704032", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "Animal genomes possess highly conserved cis-regulatory sequences that are often found near genes that regulate transcription and development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073165", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 585, 
                    "offsetInEndSection": 677, 
                    "text": "HCNEs of both human and zebrafish function as specific developmental enhancers in zebrafish."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073165", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1185, 
                    "offsetInEndSection": 1391, 
                    "text": "HCNEs from the same area often drive overlapping patterns, suggesting that multiple regulatory inputs are required to achieve robust and precise complex expression patterns exhibited by developmental genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1401, 
                    "offsetInEndSection": 1596, 
                    "text": "These results suggest important roles for SINEs in the development of the mammalian neuronal network, a part of which was initiated with the exaptation of AmnSINE1 in a common mammalian ancestor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282512", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 480, 
                    "offsetInEndSection": 648, 
                    "text": "Further positional analysis of these conserved noncoding elements (CNEs) in the genome demonstrates that they cluster around genes involved in developmental regulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 669, 
                    "offsetInEndSection": 849, 
                    "text": "Several lines of evidence indicate that these highly conserved noncoding elements (HCNEs) play a fundamental role in regulating animal development and constraining genome evolution"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056681", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1277, 
                    "offsetInEndSection": 1412, 
                    "text": "The majority of tetrapod-specific UCEs are noncoding and associated with genes involved in regulation of transcription and development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16533910", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 304, 
                    "text": "Fish-mammal genomic comparisons have proved powerful in identifying conserved noncoding elements likely to be cis-regulatory in nature, and the majority of those tested in vivo have been shown to act as tissue-specific enhancers associated with genes involved in transcriptional regulation of development"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16533910", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 792, 
                    "offsetInEndSection": 955, 
                    "text": "In 74% of cases, we were able to assign a specific set of paralogous genes with annotation relating to transcriptional regulation and/or development to each family"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698106", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 316, 
                    "offsetInEndSection": 532, 
                    "text": "HCNEs typically cluster around one particular gene in the region, most often encoding a transcription factor involved in the regulation of embryonic development and differentiation, referred to as the GRB target gene"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698106", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 2689, 
                    "offsetInEndSection": 2811, 
                    "text": "A GRB target gene, which is often a developmental transcription factor, is spanned by a synteny-maintaining array of HCNEs"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16630819", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 276, 
                    "text": "The most highly conserved noncoding elements (HCNEs) in mammalian genomes cluster within regions enriched for genes encoding developmentally important transcription factors (TFs). This suggests that HCNE-rich regions may contain key regulatory controls involved in development"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17096848", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1108, 
                    "offsetInEndSection": 1356, 
                    "text": "The identification of a large number of putative novel regulatory elements in a subset of synaptic genes provides an important list of novel functional 'targets' for gene regulation during nervous system development and for dysregulation in disease"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21731768", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1532, 
                    "offsetInEndSection": 1729, 
                    "text": "CRCNE000111095 may show a more accurate representation of the function of the CNE with this CNE being responsible for enhancing limb development in human but having little enhancer activity in Fugu"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5159, 
                    "offsetInEndSection": 5398, 
                    "text": "Functional assay of such elements in transgenic mouse and zebrafish have indeed indicated that a large number of them function as transcriptional enhancers directing tissue-specific expression of reporter genes during embryonic development"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 19477, 
                    "offsetInEndSection": 19659, 
                    "text": "This inference is in agreement with our previous findings that genes that are involved in development, in particular development of the central nervous system, are enriched with CNEs"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 26827, 
                    "offsetInEndSection": 26929, 
                    "text": "This suggests that CNE4 may be active in the central nervous system at some other stage of development"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "title", 
                    "offsetInBeginSection": 37, 
                    "offsetInEndSection": 168, 
                    "text": "highly conserved noncoding elements and their association with developmental regulatory genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 669, 
                    "offsetInEndSection": 849, 
                    "text": "Several lines of evidence indicate that these highly conserved noncoding elements (HCNEs) play a fundamental role in regulating animal development and constraining genome evolution"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 886, 
                    "offsetInEndSection": 957, 
                    "text": "HCNEs tend to cluster in the vicinity of developmental regulatory genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1099, 
                    "offsetInEndSection": 1286, 
                    "text": "many HCNE sequences have shown the ability to induce part of the embryonic expression pattern of a developmental regulatory gene located in the genomic neighborhood of the endogenous HCNE"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1297, 
                    "offsetInEndSection": 1360, 
                    "text": "These experiments have associated HCNEs and developmental genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1499, 
                    "offsetInEndSection": 1643, 
                    "text": "Hundreds of HCNEs have now been characterized as developmental enhancers in transgenic mice, frogs or zebrafish, and the list is growing rapidly"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 5066, 
                    "offsetInEndSection": 5258, 
                    "text": "Plots of HCNE density along chromosomes highlight regions that harbor large HCNE arrays and, thus, are likely to contain key developmental regulatory genes and correspond to regulatory domains"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 8496, 
                    "offsetInEndSection": 8586, 
                    "text": "Since there is a strong association between HCNE arrays and developmental regulatory genes"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 8594, 
                    "offsetInEndSection": 8696, 
                    "text": "it is likely that most regions of high HCNE-density contain at least one developmental regulatory gene"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 9114, 
                    "offsetInEndSection": 9209, 
                    "text": "They found 41 of these regions to contain a gene known to be involved in embryonic development."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 9660, 
                    "offsetInEndSection": 9831, 
                    "text": "Inspection of other HCNE-dense regions has revealed that several coincide with microRNA gene loci [18], a class of regulators implicated in multiple aspects of development"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 11709, 
                    "offsetInEndSection": 11829, 
                    "text": "the GRB of PAX7, a transcription factor gene implicated in muscle development [37] and situated within an array of HCNEs"
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 2539, 
                    "offsetInEndSection": 2692, 
                    "text": ". A valuable section of CONDOR provides developmental expression patterns for about 100 HCNEs that have been investigated by reporter assays in zebrafish"
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 7, 
                    "offsetInEndSection": 142, 
                    "text": "Ancora is a new web resource that provides data and tools for exploring HCNEs and their association with developmental regulatory genes"
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279518", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 811, 
                    "offsetInEndSection": 926, 
                    "text": "The GRBs typically coincide with loci of developmental regulatory genes, for which HCNEs appear to act as enhancers"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Do Conserved noncoding elements act as enhancers?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004742", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0035326", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017124", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024861", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026801"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21081479", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20494938", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19805301", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19782672", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19704032", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19492354", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19171877", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19073165", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18562680", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17989259", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17940009", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17210927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16533910", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15859353"
            ], 
            "id": "5139ec51bee46bd34c000006", 
            "snippets": [
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 19862, 
                    "offsetInEndSection": 20621, 
                    "text": "transcriptional enhancers in developing mouse embryos, found that the enhancers directed reporter expression most frequently in the brain and neural tube. More recently, a similar association between ultraconserved noncoding elements (noncoding sequences exceedingly conserved in human, chimp and mouse) and genes that preferentially express in the central nervous system has been described [51]. Using the GNF Human GeneAtlas, this study found that nine out of the ten tissues that express genes most significantly associated with ultraconserved noncoding elements constitute various members of the central nervous system.10.1371/journal.pone.0020088.g007Figure 7TF-encoding genes predominantly expressed in the central nervous system are enriched with CNEs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4617, 
                    "offsetInEndSection": 5724, 
                    "text": "In this study we have used evolutionary constraint as an indicator of putative enhancers in the vertebrate Lhx2 locus. Due to selective pressure, noncoding functional elements such as enhancers tend to evolve slowly compared to their neighboring sequences and hence can be identified as conserved noncoding elements in comparisons of related genomes. This strategy has been effectively used to identify a large number of putative enhancers conserved in distantly related vertebrates such as mammals and teleost fishes [26], [27], [28], [29]. Functional assay of such elements in transgenic mouse and zebrafish have indeed indicated that a large number of them function as transcriptional enhancers directing tissue-specific expression of reporter genes during embryonic development [26], [28], [29]. We have aligned sequences of the Lhx2 locus from human, mouse and pufferfish (fugu) genomes and predicted conserved noncoding elements (CNEs) in the locus. Functional assay of these CNEs in a transgenic mouse assay system showed that half of them function as tissue-specific enhancers at embryonic day 11.5."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 8827, 
                    "offsetInEndSection": 9134, 
                    "text": "A CNE was classified as a transcriptional enhancer if it directed reproducible reporter gene expression in the same anatomical structure in at least three independent transgenic mouse embryos.CNE1CNE1 is a 76-bp sequence located approximately 619 kb upstream of human LHX2 within the 20th intron of DENND1A."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 9585, 
                    "offsetInEndSection": 9818, 
                    "text": "We therefore concluded that CNE1 does not act as a transcriptional enhancer at stage E11.5.CNE2/3CNE2/3 is a combination of two CNEs, CNE2 and CNE3, which were tested together due to their close proximity to each other (41 bp apart)."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 11605, 
                    "offsetInEndSection": 11819, 
                    "text": "Hence, CNE4 is not an enhancer at E11.5.CNE5/6CNE5/6 is a combination of two CNEs, CNE5 and CNE6, that are 38 bp apart and are located approximately 269 kb upstream of human LHX2 within the fifth intron of DENND1A."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 13585, 
                    "offsetInEndSection": 13758, 
                    "text": "This CNE does not act as an enhancer at E11.5, because no lacZ expression was detected in four out of the six (67%) transgenic embryos obtained for this developmental stage."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 14398, 
                    "offsetInEndSection": 14571, 
                    "text": "Hence, CNE9 does not act as an enhancer at E11.5.CNE10CNE10 is a 145-bp element that has the highest percentage identity (\u223c90%) in human and fugu among all the CNEs assayed."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 13239, 
                    "offsetInEndSection": 13301, 
                    "text": "Hence, CNE7 acts as a transcriptional enhancer at stage E11.5."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 15128, 
                    "offsetInEndSection": 15189, 
                    "text": "Indeed, CNE10 was found to act as a transcriptional enhancer."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 15783, 
                    "offsetInEndSection": 16016, 
                    "text": "Summary of the expression patterns of CNEsIn summary, four out of the eight elements (50%) that we assayed for enhancer activity in transgenic mouse embryos, directed reproducible reporter gene expression in specific tissues at E11.5"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 22679, 
                    "offsetInEndSection": 22826, 
                    "text": "Finally, a third study searched 13 forebrain enhancers conserved in human and zebrafish and identified five hexamer motifs that were enriched [54]."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 28028, 
                    "offsetInEndSection": 28169, 
                    "text": "Hence, through the mutation of the predicted motif, the enhancer activity of CNE2/3 was either significantly reduced or completely abolished."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2147, 
                    "offsetInEndSection": 2307, 
                    "text": "The four CNEs that were showed to be functional enhancers in our transgenic mouse assay directed expression, among other domains, to the midbrain and hindbrain."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4490, 
                    "offsetInEndSection": 4895, 
                    "text": "Out of the four CNEs that showed expression in the central nervous system and the dorsal root ganglia, three showed overlapping expression in the hindbrain and all showed similar expression in the neural tube. These overlapping expression patterns of the different enhancers suggest that they are either associated with different genes in this locus or alternatively, redundant enhancers of the same gene."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629789", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4896, 
                    "offsetInEndSection": 5105, 
                    "text": "Similar enhancers showing overlapping patterns of expression have been previously identified in the screening of mammal-chicken CNEs in the Sox10 locus [59] and in a 1-Mb region surrounding the Shh locus [61]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081479", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1169, 
                    "offsetInEndSection": 1216, 
                    "text": "The aCNEs are rich in tissue-specific enhancers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081479", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1397, 
                    "offsetInEndSection": 1483, 
                    "text": "Transgenic zebrafish assay of some human CNE enhancers that have been lost in teleosts"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 313, 
                    "offsetInEndSection": 535, 
                    "text": "strong DNA sequence conservation of enhancers of developmental regulator genes [3-8] implies purifying selection to keep such regions preserved across species and functionally constrained in their cis-regulatory functions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1860, 
                    "offsetInEndSection": 2044, 
                    "text": "The orthologous Otx2 enhancers FM and AM [24] and the HoxC8 early enhancer [25] revealed strong conservation in DNA sequence and in enhancer expression in mouse transgenic experiments."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3075, 
                    "offsetInEndSection": 3630, 
                    "text": "In our report, we demonstrate that the Latimeria menadoensis shh locus contains all conserved proximal enhancers shared nonuniformly by fishes and land vertebrates. We provide experimental verification for enhancer activity of the putative Latimeria enhancers in transgenic zebrafish and electroporated chick embryos. From DNA sequence comparison of the shh locus of different vertebrate lineages, we infer that Latimeria conserved noncoding elements represent the ancestral gnathostome set of enhancers that diverged variably during vertebrate evolution."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 2011, 
                    "offsetInEndSection": 2296, 
                    "text": "Several noncoding conserved sequences were detected in intronic and upstream regions of shh, and the distribution and frequency of these conserved blocks followed recognizable patterns. They overlap with the previously characterized enhancer regions of zebrafish and mouse (Figure 2a)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4130, 
                    "offsetInEndSection": 4249, 
                    "text": "Furthermore, the ar-D enhancer is not conserved in pufferfishes (e.g., Takifugu rubripes) and medaka (Oryzias latipes)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4539, 
                    "offsetInEndSection": 4646, 
                    "text": "This result suggests that the ar-B enhancer has been lost independently in the different tetrapod lineages."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 5008, 
                    "offsetInEndSection": 5151, 
                    "text": "In summary, Latimeria has retained conservation of all four putative enhancers that were previously described in the actinopterygian zebrafish."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 6315, 
                    "offsetInEndSection": 6353, 
                    "text": "Conserved Latimeria enhancer sequences"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7018, 
                    "offsetInEndSection": 7156, 
                    "text": "we examined the rates of divergence within conserved shh enhancer sequences among sarcopterygian species with the relative rate test [51]."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7492, 
                    "offsetInEndSection": 7957, 
                    "text": "Congruent to the overall conservation, the mammalian enhancer sequences showed elevated rates of divergence compared to chick or Latimeria, with opossum putative enhancer sequences at intermediate rates and the placental mammalian species at highest rates (Table 1). In conclusion, all CNEs that were previously identified either in mouse or in zebrafish are present in Latimeria and thus are candidate enhancers of shh expression in the Latimeria embryonic midline"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 9259, 
                    "offsetInEndSection": 9336, 
                    "text": "is too large to suggest that the CNE within contains the functional enhancer."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 10244, 
                    "offsetInEndSection": 10396, 
                    "text": "The region that is responsible for the ar-D enhancer effect overlaps fully with a CNE that is present in all the other compared sarcopterygian sequences"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 10935, 
                    "offsetInEndSection": 11109, 
                    "text": "Conserved noncoding elements of Latimeria shh intron 1 located between exon 1 and the intronic enhancer ar-A did not drive specific reporter gene expression (data not shown)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 12178, 
                    "offsetInEndSection": 12368, 
                    "text": "These results indicate that the CNE in the Latimeria upstream region is a functional midline enhancer which has similar but not identical activity in zebrafish to the zebrafish ar-D enhancer"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 273, 
                    "text": "Conservation of Latimeria shh noncoding DNAThe shh genomic region of Latimeria menadoensis reveals conservation of all four actinopterygian shh midline enhancers, which indicates an ancestral-like and rather unchanged cis-regulatory architecture of Latimeria shh."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 767, 
                    "offsetInEndSection": 925, 
                    "text": "The Latimeria orthologous Otx2 enhancers FM and AM [24] as well as the HoxC8 early enhancer [25] revealed strong DNA sequence conservation across vertebrates."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1576, 
                    "offsetInEndSection": 1797, 
                    "text": "Conservation of the four enhancers ar-A, ar-B, ar-C and ar-D in Latimeria and zebrafish reveals preservation of an ancestral set of enhancers that originated before the split between ray-finned and lobe-finned vertebrates"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047394", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 178, 
                    "text": "The Latimeria menadoensis shh genomic region represents a locus with the ancestral set of enhancers that emerged before the split of lobe-finned and ray-finned fishes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20494938", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 95, 
                    "text": "Conserved noncoding elements (CNEs) in vertebrate genomes often act as developmental enhancers,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20494938", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1433, 
                    "offsetInEndSection": 1727, 
                    "text": "In all four cases where the zebra fish and human CNE display a similar expression pattern in zebra fish, the human CNE also displays a similar expression pattern in mouse. This suggests that the endogenous enhancer activity of \u223c30% of human CNEs can be determined from experiments in zebra fish"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1278, 
                    "offsetInEndSection": 1530, 
                    "text": "If these ancient CNEs are indeed enhancers directing tissue-specific expression of Hox genes, divergence of their sequences in vertebrate lineages might have led to altered expression patterns and presumably the functions of their associated Hox genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 635, 
                    "offsetInEndSection": 887, 
                    "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704032", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "Animal genomes possess highly conserved cis-regulatory sequences that are often found near genes that regulate transcription and development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704032", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 755, 
                    "offsetInEndSection": 914, 
                    "text": "We test 42 of our PCNEs in transgenic zebrafish assays--including examples from vertebrates and amphioxus--and find that the majority are functional enhancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 214, 
                    "text": "The genomes of vertebrates, flies, and nematodes contain highly conserved noncoding elements (CNEs). CNEs cluster around genes that regulate development, and where tested, they can act as transcriptional enhancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171877", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 443, 
                    "offsetInEndSection": 1004, 
                    "text": ", we identified 17 highly conserved noncoding elements, 9 of which revealed specific acetylation marks in chromatin-immunoprecipitation and microarray (ChIP-chip) assays performed across 250 kb of the Lmo2 locus in 11 cell types covering different stages of hematopoietic differentiation. All candidate regulatory regions were tested in transgenic mice. An extended LMO2 proximal promoter fragment displayed strong endothelial activity, while the distal promoter showed weak forebrain activity. Eight of the 15 distal candidate elements functioned as enhancers,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073165", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 216, 
                    "text": "Pan-vertebrate developmental cis-regulatory elements are discernible as highly conserved noncoding elements (HCNEs) and are often dispersed over large areas around the pleiotropic genes whose expression they control."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073165", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 585, 
                    "offsetInEndSection": 677, 
                    "text": "HCNEs of both human and zebrafish function as specific developmental enhancers in zebrafish."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18562680", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1048, 
                    "offsetInEndSection": 1165, 
                    "text": "several transcriptional enhancers are conserved between amphioxus and vertebrates--a very wide phylogenetic distance."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 3999, 
                    "offsetInEndSection": 4288, 
                    "text": "The same was shown by Woolfe and coworkers [6] by using 1,373 regions extracted from a direct comparison of the genomes of human and fish. The same report also provided the first systematic experimental evidence of enhancer activity for a subset of these elements in zebrafish (see below)."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 287, 
                    "text": "Recognition and testing of individual highly conserved noncoding elementsThere is mounting evidence for the regulatory role of HCNEs. Soon after their genome wide discovery, it was realized that a significant number of previously characterized developmental enhancers overlap with HCNEs."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 991, 
                    "offsetInEndSection": 1126, 
                    "text": "G\u00f6ttgens and coworkers [31] reported the discovery of enhancers that are highly conserved between human and mouse, and some in chicken."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1332, 
                    "offsetInEndSection": 1467, 
                    "text": "several such elements conserved between human and fugu near the SOX9 gene, of which they considered at least three candidate enhancers."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1970, 
                    "offsetInEndSection": 2033, 
                    "text": "isolated two HCNEs upstream of the mouse Pax3 gene as enhancers"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2454, 
                    "offsetInEndSection": 2574, 
                    "text": "the question of whether the conservation is essential for the transcription factor binding properties of those enhancers"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4443, 
                    "offsetInEndSection": 4607, 
                    "text": "a large number of HCNEs from the vertebrate iroquois clusters were tested in zebrafish and Xenopus, and the majority of them were shown to act as specific enhancers"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4724, 
                    "offsetInEndSection": 4848, 
                    "text": "tested 167 HCNEs in a mouse transgenic enhancer assay. Seventy-five (43%) of the tested elements exhibited enhancer activity"
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 3276, 
                    "offsetInEndSection": 3392, 
                    "text": "wo equivalent regions of a genomic sequence in human and zebrafish are both able to act as an enhancer in zebrafish,"
                }, 
                {
                    "beginSection": "sections.6", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.6", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 157, 
                    "text": "Mechanism of enhancer activity of highly conserved noncoding elementsWe still have no adequate explanation for the mechanism by which HCNEs act as enhancers,"
                }, 
                {
                    "beginSection": "sections.7", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047696", 
                    "endSection": "sections.7", 
                    "offsetInBeginSection": 5541, 
                    "offsetInEndSection": 5697, 
                    "text": "Five conserved noncoding sequences (>80% human-mouse identity) were identified within the 17 kb intergenic sequence. That some of these enhancers are shared"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 382, 
                    "offsetInEndSection": 463, 
                    "text": "We recently described GRBs in vertebrates, where most HCNEs function as enhancers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 688, 
                    "offsetInEndSection": 762, 
                    "text": "Besides developmental regulators that are likely targets of HCNE enhancers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17940009", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 734, 
                    "text": "We identify and characterize highly conserved noncoding elements flanking the TNF gene, which undergo activation-dependent intrachromosomal interactions. These elements, hypersensitive site (HSS)-9 and HSS+3 (9 kb upstream and 3 kb downstream of the TNF gene, respectively), contain DNase I hypersensitive sites in naive, T helper 1, and T helper 2 primary T cells. Both HSS-9 and HSS+3 inducibly associate with acetylated histones, indicative of chromatin remodeling, bind the transcription factor nuclear factor of activated T cells (NFAT)p in vitro and in vivo, and function as enhancers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1032, 
                    "offsetInEndSection": 1420, 
                    "text": "We used the sequence signatures identified by this approach to successfully assign tissue-specific predictions to approximately 328,000 human-mouse conserved noncoding elements in the human genome. By overlapping these genome-wide predictions with a data set of enhancers validated in vivo, in transgenic mice, we were able to confirm our results with a 28% sensitivity and 50% precision."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16533910", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 305, 
                    "text": "Fish-mammal genomic comparisons have proved powerful in identifying conserved noncoding elements likely to be cis-regulatory in nature, and the majority of those tested in vivo have been shown to act as tissue-specific enhancers associated with genes involved in transcriptional regulation of development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15859353", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 749, 
                    "offsetInEndSection": 1016, 
                    "text": "uncovered two anciently conserved noncoding sequences (CNS) upstream of COUP-TFII (CNS-62kb and CNS-66kb). Testing these two elements using reporter constructs in liver cells (HepG2) revealed that CNS-66kb, but not CNS-62kb, yielded robust in vitro enhancer activity."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is paramyxovirus involved in human subacute thyroiditis?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013968", 
                "http://www.disease-ontology.org/api/metadata/DOID:7165", 
                "http://www.disease-ontology.org/api/metadata/DOID:7187", 
                "http://www.disease-ontology.org/api/metadata/DOID:7166", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018109"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22819125", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22459018", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20960165", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20886354", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16279854", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9637274", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1691523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2998895", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9797", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1180050", 
                "http://www.ncbi.nlm.nih.gov/pubmed/806773"
            ], 
            "id": "513efe01bee46bd34c00000e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 95, 
                    "offsetInEndSection": 310, 
                    "text": "Most cases of subacute thyroiditis are caused by a variety of viruses, for example, Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus. Influenza immunization or infection may cause subacute thyroiditis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20886354", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 396, 
                    "offsetInEndSection": 483, 
                    "text": "Coxsackie virus has been reported to be one of the viruses associated with the disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9637274", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 154, 
                    "text": "The etiology of subacute granulomatous thyroiditis (SAT) is obscure, although it is postulated to be associated with viral infections and genetic factors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9637274", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1511, 
                    "offsetInEndSection": 1587, 
                    "text": "The results suggest that SAT is not usually associated with acute infections"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9637274", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1589, 
                    "offsetInEndSection": 1699, 
                    "text": "No evidence was obtained to support the proposed role of enteroviruses as an important etiologic agent of SAT."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2998895", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 802, 
                    "offsetInEndSection": 1400, 
                    "text": "The viral antibodies evaluated were those of Influenza A and B, Coxsackie A9, B1, B2, B3, B4, B5 and B6, Echo 3, 7, 11 and 12, Parainfluenza 1, 2, 3 and 4, and Adeno 8 virus. The following results were obtained: In class I HLA typing, the frequency of HLA-Bw35 in SAT was 67.4%, which was significantly (p less than 0.0001) higher than that in the control (14.1%). On the other hand, the frequency of Cw1 in SAT (14.6%) was significantly (p less than 0.01) lower than that of the control (32.1%), and that of Cw3 (65.2%) was significantly (p less than 0.01) higher than that of the control (46.5%)."
                }
            ], 
            "triples": [
                {
                    "o": "Granulomatous thyroiditis", 
                    "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                    "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:7165"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Do proton pump inhibitors affect thyroxine absorption?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054328", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017494"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20694403", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19942153", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16971728", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16477543", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22019751", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9416973", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7865648", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15073769", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23565522", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18942671", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16918738", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17669709", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18996189"
            ], 
            "id": "513f3ab6bee46bd34c00000f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20694403", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 562, 
                    "offsetInEndSection": 653, 
                    "text": "Proton-pump inhibitors, antacids and a long list of drugs may decrease thyroxine absorption"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19942153", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 313, 
                    "offsetInEndSection": 580, 
                    "text": "Many commonly used drugs, such as bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, raloxifene and proton-pump inhibitors, have also been shown to interfere with the absorption of levothyroxine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7865648", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1477, 
                    "offsetInEndSection": 1582, 
                    "text": "Pantoprazole did not influence endocrine function in healthy male volunteers during short-term treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17669709", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1744, 
                    "offsetInEndSection": 2088, 
                    "text": "PPIs should be added to the list of medications affecting the level of thyroid hormone in patients with hypothyroidism treated with LT4 replacement. Patients with hypothyroidism and normal TSH values during LT4 replacement therapy may need additional thyroid function testing after treatment with PPIs and may need adjustment of their LT4 dose."
                }
            ], 
            "triples": [
                {
                    "o": "Proton Pump Inhibitors", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A6850734"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which drugs may interfere thyroxine absorption?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000042", 
                "http://www.biosemantics.org/jochem#4250045"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22908106", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19942153", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19789374", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18466075", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19119983", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17725434", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12796075", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1728914", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23154888", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23264396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21748540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21516059", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20012189", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19191742", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18996189", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16641395", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16898074", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22374714", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19108789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15301044", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15142360", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22238404", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21633823", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21468525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21435090", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19733399", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19226259", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17093176", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22099156", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15927726", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14751040", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18511320", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11668059", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21933675", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21595516", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17446037", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10838651", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18845642", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17931806", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17711927"
            ], 
            "id": "513f3d1fbee46bd34c000010", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19942153", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 319, 
                    "offsetInEndSection": 579, 
                    "text": "ommonly used drugs, such as bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, raloxifene and proton-pump inhibitors, have also been shown to interfere with the absorption of levothyroxine"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17725434", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1074, 
                    "offsetInEndSection": 1272, 
                    "text": "Hypothyroid patients taking sevelamer hydrochloride or chromium picolinate should be advised to separate the time of ingestion of these drugs from their thyroid hormone preparation by several hours."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is microRNA(miRNA) 29 involved in post-ischemic cardiac remodeling?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0035196", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010586", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010587"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22038740", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20971881", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20959496", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20733099", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18723672"
            ], 
            "id": "513f4025bee46bd34c000011", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 197, 
                    "text": "Myocardial ischaemia/reperfusion (I/R)-induced remodelling generally includes cell death (necrosis and apoptosis), myocyte hypertrophy, angiogenesis, cardiac fibrosis, and myocardial dysfunction. I"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 590, 
                    "offsetInEndSection": 754, 
                    "text": "In addition, miR-21, -24, -133, -210, -494, and -499 appear to protect myocytes against I/R-induced apoptosis, whereas miR-1, -29, -199a, and -320 promote apoptosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 756, 
                    "offsetInEndSection": 813, 
                    "text": "Myocardial fibrosis can be regulated by the miR-29 family"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20959496", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 810, 
                    "offsetInEndSection": 1053, 
                    "text": "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18723672", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 620, 
                    "offsetInEndSection": 1357, 
                    "text": "Among the MI-regulated miRNAs are members of the miR-29 family, which are down-regulated in the region of the heart adjacent to the infarct. The miR-29 family targets a cadre of mRNAs that encode proteins involved in fibrosis, including multiple collagens, fibrillins, and elastin. Thus, down-regulation of miR-29 would be predicted to derepress the expression of these mRNAs and enhance the fibrotic response. Indeed, down-regulation of miR-29 with anti-miRs in vitro and in vivo induces the expression of collagens, whereas over-expression of miR-29 in fibroblasts reduces collagen expression. We conclude that miR-29 acts as a regulator of cardiac fibrosis and represents a potential therapeutic target for tissue fibrosis in general."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is microRNA(miRNA) 30 involved in post-ischemic cardiac remodeling?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010586"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22352753", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22038740", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21434842", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19096030"
            ], 
            "id": "513f4249bee46bd34c000012", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 206, 
                    "text": "The myocardium of the failing heart undergoes a number of structural alterations, most notably hypertrophy of cardiac myocytes and an increase in extracellular matrix proteins, often seen as primary fibrosi"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 209, 
                    "offsetInEndSection": 345, 
                    "text": "Connective tissue growth factor (CTGF) is a key molecule in the process of fibrosis and therefore seems an attractive therapeutic target"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 571, 
                    "offsetInEndSection": 659, 
                    "text": "CTGF is importantly regulated by 2 major cardiac microRNAs (miRNAs), miR-133 and miR-30."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 667, 
                    "offsetInEndSection": 1060, 
                    "text": "the expression of both miRNAs was inversely related to the amount of CTGF in 2 rodent models of heart disease and in human pathological left ventricular hypertrophy. Second, in cultured cardiomyocytes and fibroblasts, knockdown of these miRNAs increased CTGF levels. Third, overexpression of miR-133 or miR-30c decreased CTGF levels, which was accompanied by decreased production of collagens."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1249, 
                    "offsetInEndSection": 1296, 
                    "text": "miR-30 importantly limit the production of CTGF"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1531, 
                    "offsetInEndSection": 1733, 
                    "text": "miR-30 directly downregulate CTGF, a key profibrotic protein, and thereby establish an important role for these miRNAs in the control of structural changes in the extracellular matrix of the myocardium."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Does triiodothyronine (T3) has cardiac angiogenic effects?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045766", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045765", 
                "http://www.biosemantics.org/jochem#4275389", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043925", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018919", 
                "http://www.biosemantics.org/jochem#4005955", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043924", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0002040"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22681587", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20100314", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19286941", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19074585", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2530972"
            ], 
            "id": "513f4892bee46bd34c000014", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22681587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1664, 
                    "offsetInEndSection": 1802, 
                    "text": "T3-induced cardiac sprouting angiogenesis in adult hypothyroid mice was associated with PDGF-BB, PDGFR-\u03b2 and downstream activation of Akt."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100314", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 916, 
                    "offsetInEndSection": 1073, 
                    "text": "L-T3 significantly increased angiogenesis and cell survival and enhanced the expression of nuclear-encoded transcription factors involved in these processes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074585", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 761, 
                    "offsetInEndSection": 854, 
                    "text": "T(3) administration restored TRbeta mRNA expression level in AAC hearts to the control level."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074585", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 907, 
                    "offsetInEndSection": 1049, 
                    "text": "Rbeta knockout and TRalpha/TRbeta double-knockout mice both exhibited significantly less capillary density in LV compared with wild-type mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074585", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1406, 
                    "offsetInEndSection": 1597, 
                    "text": "TRbeta in the coronary ECs regulates capillary density during cardiac development, and down-regulation of TRbeta results in coronary microvascular rarefaction during pathological hypertrophy."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What kind of affinity purification would you use in order to isolate soluble lysosomal proteins?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000345", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002846", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008247", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005764"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18507433", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18977398", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18370023", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17258946", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16709564", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16399764", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16145712", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15789345", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19383612", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22158965", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11079561"
            ], 
            "id": "5140569623fec90375000003", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18507433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 257, 
                    "text": "Most luminal lysosomal proteins are synthesized as precursors containing mannose 6-phosphate (Man6-P) and a number of recent studies have conducted affinity purification of Man6-P containing proteins as a step toward defining the composition of the lysosome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18370023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 356, 
                    "text": "This chapter describes the process of production, purification, separation, and mass spectrometry identification of soluble lysosomal proteins. The rationale for purification of these proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptor (MPR"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16145712", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 419, 
                    "offsetInEndSection": 616, 
                    "text": "ecretions of these cells were affinity purified using an affinity matrix derivatized with MPR46 and MPR300. In the protein fraction bound to the affinity matrix and eluted with mannose 6-phosphate,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15789345", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 643, 
                    "offsetInEndSection": 850, 
                    "text": "Proteins containing mannose 6-phosphate (Man6-P), a carbohydrate modification used for targeting resident soluble lysosomal proteins to the lysosome, were affinity-purified using immobilized Man6-P receptor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19383612", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 710, 
                    "offsetInEndSection": 784, 
                    "text": ". We purified mannose 6-phosphorylated proteins by affinity chromatography"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11079561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 683, 
                    "offsetInEndSection": 852, 
                    "text": "Since lysosomal soluble proteins are characterized by the presence of mannose-6-phosphate, they were purified on an affinity support bearing mannose-6-phosphate receptor"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22158965", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 617, 
                    "offsetInEndSection": 744, 
                    "text": "The most abundant lysosomal substrates of Acp2 and Acp5 were identified by Man6P affinity chromatography and mass spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17258946", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 761, 
                    "offsetInEndSection": 834, 
                    "text": "urinary proteins were affinity purified on immobilized Man-6-P receptors,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16399764", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 212, 
                    "offsetInEndSection": 391, 
                    "text": "A number of proteomic studies have focused on lysosomal proteins, exploiting the fact that Man-6-P-containing forms can be purified by affinity chromatography on immobilized MPRs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16709564", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 463, 
                    "offsetInEndSection": 589, 
                    "text": "In this study, we purified the Man-6-P glycoforms of proteins from human plasma by affinity chromatography on immobilized MPRs"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which is the defective protein causing the lysosomal storage disease Fabry?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:14499", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000795", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008247", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005764", 
                "http://www.disease-ontology.org/api/metadata/DOID:3211", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016464"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19202000", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19146893", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15702403", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15533650", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9395081", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9323559"
            ], 
            "id": "51405cd123fec90375000005", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19202000", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 339, 
                    "text": "The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. Defective lysosomal alpha-galactosidase A (Gla) is responsible for excessive Gb3 accumulation, and one cell sensitive to the effects of Gb3 accumulation is vascular endothelium."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702403", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 282, 
                    "text": "Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9323559", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 245, 
                    "text": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9395081", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 174, 
                    "text": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What is known as the cause of subacute thyroiditis?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22819125", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19497087", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16284433"
            ], 
            "id": "51406d6923fec90375000007", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 95, 
                    "offsetInEndSection": 241, 
                    "text": "Most cases of subacute thyroiditis are caused by a variety of viruses, for example, Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the treatment of subacute thyroiditis?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013968", 
                "http://www.disease-ontology.org/api/metadata/DOID:7165", 
                "http://www.disease-ontology.org/api/metadata/DOID:7187", 
                "http://www.disease-ontology.org/api/metadata/DOID:7166", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004364", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013959", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042493", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013956"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23227861", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22313427", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22138076", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17923793"
            ], 
            "id": "51406dd123fec90375000008", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23227861", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 108, 
                    "text": "Oral glucocorticoids are administered in moderate and severe cases of subacute thyroiditis (SAT)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23227861", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1841, 
                    "offsetInEndSection": 1984, 
                    "text": "he treatment protocol that we employed had 15 mg/day of PSL as the initial dosage for the treatment of SAT, with tapering by 5 mg every 2 weeks"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Does metformin interfere thyroxine absorption?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008687", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000042"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23554450", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23264396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23244059", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23154888", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23072197", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21748540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21633823", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21435090", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21468525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21041167"
            ], 
            "id": "51406e6223fec90375000009", 
            "type": "yesno"
        }, 
        {
            "body": "The CXCR2 receptor is targeted in cancer. Name five antagonists.", 
            "concepts": [
                "http://www.uniprot.org/uniprot/CXCR2_HUMAN", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045238", 
                "http://www.disease-ontology.org/api/metadata/DOID:162", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0048019", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046817", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006605"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23359652", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23204236", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23019013", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22590561", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22391039", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21670971", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21328342", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21035946", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20967859", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20652010", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19809428", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19549892", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19293256", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18790747", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18780829", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18289803", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17634442", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16540656", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15805273", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15623601", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12753603", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12244149", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11700073"
            ], 
            "id": "5141bcd423fec9037500000d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359652", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 150, 
                    "text": "Recent evidence indicates that CXCR2 signaling is crucial for cancer progression, and its antagonist SB225002 induces apoptosis in Wilms' tumor cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204236", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 517, 
                    "offsetInEndSection": 559, 
                    "text": "CXCR2 small-molecule antagonist (SB225002)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019013", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 121, 
                    "text": "G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22391039", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 130, 
                    "text": "The CXCR2 antagonist, SCH-527123, shows antitumor activity"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20652010", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 15, 
                    "offsetInEndSection": 40, 
                    "text": "CXCR2 Antagonist SB225002"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20652010", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1995, 
                    "offsetInEndSection": 2116, 
                    "text": "The use of a small selective antagonist for CXCR2 (SB225002) represents an attractive targeted therapeutic approach [26]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18790747", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 761, 
                    "offsetInEndSection": 809, 
                    "text": "retreatment with the CXCR2 antagonist AZ10397767"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22391039", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 477, 
                    "offsetInEndSection": 690, 
                    "text": "The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035946", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 196, 
                    "offsetInEndSection": 441, 
                    "text": "we report that targeting CXCR2 and CXCR1 activity using orally active small molecule antagonist (SCH-527123, SCH-479833) inhibits human colon cancer liver metastasis mediated by decreased neovascularization and enhanced malignant cell apoptosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328342", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 593, 
                    "offsetInEndSection": 720, 
                    "text": "CXCR2-specific small molecule inhibitor (AZ10397767) to investigate the recruitment and function of human neutrophils in tumors"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "The protein NONO forms heterodimers. With which proteins?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/NONO_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019281", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055503", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046982", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043497"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22416126", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22102035", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22101825", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20421735", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19423654", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18655028", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16148043"
            ], 
            "id": "514241fcd24251bc05000006", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102035", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 162, 
                    "text": "The paraspeckle component 1 (PSPC1) and non-POU-domain-containing octamer-binding protein (NONO) heterodimer is an essential structural component of paraspeckles,"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22101825", 
                    "endSection": "title", 
                    "offsetInBeginSection": 117, 
                    "offsetInEndSection": 257, 
                    "text": "PSPC1-NONO heterodimer."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102035", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 64, 
                    "text": "Crystallization of a paraspeckle protein PSPC1-NONO heterodimer"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22101825", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 143, 
                    "offsetInEndSection": 409, 
                    "text": "difficult heterodimeric complex of two human proteins, paraspeckle component 1 (PSPC1) and non-POU domain-containing octamer-binding protein (NONO), that are involved in gene regulation and the structural integrity of nuclear bodies termed paraspeckles is described."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20421735", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 272, 
                    "offsetInEndSection": 495, 
                    "text": "SFPQ (PSF) and NONO (p54) are nuclear proteins that interact with each other and have diverse roles in nucleic acids metabolism. The SFPQ/NONO heterodimer was previously found to enhance DNA strand break rejoining in vitro."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18655028", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 181, 
                    "offsetInEndSection": 225, 
                    "text": "We identified a heterodimer, p54nrb and PSF,"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16148043", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 95, 
                    "text": "P54nrb forms a heterodimer with PSP1 that localizes to paraspeckles in an RNA-dependent manner."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19423654", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 402, 
                    "offsetInEndSection": 581, 
                    "text": "e demonstrated that the PSF heterodimer partner, p54nrb (non-POU-domain-containing, octamer binding protein), can also function as a transcription corepressor, independent of PSF."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416126", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1010, 
                    "offsetInEndSection": 1080, 
                    "text": "The PSPC1/NONO heterodimer has a right-handed antiparallel coiled-coil"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416126", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 133, 
                    "text": "Structure of the heterodimer of human NONO and paraspeckle protein component 1"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is single-cell analysis (SCA) possible in proteomics?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059010", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005623"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23445532", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23256674", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22921068", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22498881", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22468600", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22203961", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20680590", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21708264", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21347466", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20434785", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18682362", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18664433", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18657818", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18392595", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17953400", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17560583", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17439240", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17109634", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16806894", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16098176", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15174138"
            ], 
            "id": "5144bc8fd24251bc0500000e", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23445532", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 109, 
                    "text": "Toward Single Cell Analysis by Plume Collimation in Laser Ablation Electrospray Ionization Mass Spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23256674", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 244, 
                    "offsetInEndSection": 399, 
                    "text": "he advent of proteomics and genomics at a single-cell level has set the basis for an outstanding improvement in analytical technology and data acquisition."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23256674", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 613, 
                    "offsetInEndSection": 1125, 
                    "text": "The new-generation technology of single-cell analysis is able to better characterize a cell's population, identifying and differentiating outlier cells, in order to provide both a single-cell experiment and a corresponding bulk measurement, through the identification, quantification and characterization of all system biology aspects (genomics, transcriptomics, proteomics, metabolomics, degradomics and fluxomics). The movement of omics into single-cell analysis represents a significant and outstanding shift."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20680590", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 264, 
                    "text": "Laser ablation electrospray ionization (LAESI) is a novel method for the direct imaging of biological tissues by mass spectrometry. By performing ionization in the ambient environment, this technique enables in vivo studies with potential for single-cell analysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22498881", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1244, 
                    "offsetInEndSection": 1484, 
                    "text": "Other approaches for MS-based chemical imaging and profiling include those based on near-field laser ablation and inductively-coupled plasma MS analysis, which offer complementary capabilities for subcellular chemical imaging and profiling."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22498881", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 56, 
                    "text": "Mass spectrometry imaging and profiling of single cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20434785", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 221, 
                    "offsetInEndSection": 560, 
                    "text": "his is rapidly changing with the recent examples of single cell genomics, transcriptomics, proteomics and metabolomics. The rate of change is expected to accelerate owing to emerging technologies that range from micro/nanofluidics to microfabricated interfaces for mass spectrometry to third- and fourth-generation automated DNA sequencers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22468600", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 325, 
                    "text": "Single-cell analysis (SCA) has been increasingly recognized as the key technology for the elucidation of cellular functions, which are not accessible from bulk measurements on the population level. Thus far, SCA has been achieved by miniaturization of established engineering concepts to match the dimensions of a single cell"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22203961", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 96, 
                    "text": "Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21708264", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 139, 
                    "offsetInEndSection": 335, 
                    "text": "The amount of single proteins in single cells can be as low as one copy per cell and is for most proteins in the attomole range or below; usually considered as insufficient for proteomic analysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21708264", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 517, 
                    "offsetInEndSection": 818, 
                    "text": "n Arabidopsis thaliana, we have successfully identified nine unique proteins in a single-cell sample and 56 proteins from a pool of 15 single-cell samples from glucosinolate-rich S-cells by nanoLC-MS/MS proteomic analysis, thus establishing the proof-of-concept for true single-cell proteomic analysis"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21347466", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 112, 
                    "text": "A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is miR-126 involved in heart failure?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006333", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", 
                "http://www.disease-ontology.org/api/metadata/DOID:114", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003015"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23465244", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21157109"
            ], 
            "id": "51485008d24251bc05000028", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23465244", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1479, 
                    "offsetInEndSection": 1714, 
                    "text": "he miRNAs miR-126 and miR-508-5p are associated with the outcome of ICM and NICM patients with CHF. These two miRNAs could be useful in the diagnosis of CHF patients, and might provide novel targets for prevention and treatment of CHF."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157109", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1099, 
                    "offsetInEndSection": 1236, 
                    "text": "The plasma concentration of miR-126 was negatively correlated with age and NYHA class, and could be a useful biomarker for heart failure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157109", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 949, 
                    "offsetInEndSection": 1085, 
                    "text": "In 10 patients with heart failure, plasma concentrations of miR-126 were up-regulated with improvement of the NYHA class from IV to III."
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11659990"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11659990", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1537773"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17697100"
                }, 
                {
                    "o": "mmu-mir-126", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17400039"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17400039", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2741955"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17697100", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2825936"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A15584100", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2351954"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A15584100"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17399048"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18459725", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2934296"
                }, 
                {
                    "o": "miR-126, zebrafish", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18459725"
                }, 
                {
                    "o": "hsa-mir-126 microRNA", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A16480760"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A0418144", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0018801"
                }, 
                {
                    "o": "HEART FAILURE", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0418144"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What is the clinical value of MammaPrint?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015510", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008495", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019411", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003695", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013677"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20975745", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20110242", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19825882", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18159035"
            ], 
            "id": "51485b9ad24251bc0500002b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1118, 
                    "offsetInEndSection": 1280, 
                    "text": "In the intermediate-risk subgroup, the 70-gene signature could be useful to decide in elderly patients whether they may benefit from adjuvant chemotherapy or not."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1193, 
                    "offsetInEndSection": 1309, 
                    "text": "One of the new prognostic markers is the 70-gene prognostic signature (MammaPrint\u2122; Agendia, Amsterdam, Netherlands)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1311, 
                    "offsetInEndSection": 1411, 
                    "text": "Analysis of gene expression patterns has led to the discovery of this prognostic gene signature [6]."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 420, 
                    "offsetInEndSection": 584, 
                    "text": "This signature has been validated in many studies as a more powerful prognostic factor for distant metastasis and death than the current clinicopathological factors"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 699, 
                    "offsetInEndSection": 885, 
                    "text": "Many recent studies have shown that this signature can be used to classify postmenopausal women (older age women), neoadjuvant chemotherapy patients and node-positive patients [9,22,23]."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 3645, 
                    "offsetInEndSection": 3774, 
                    "text": "this signature is a more powerful predictor of disease outcome than the currently used clinicopathological guidelines [7,9,10,19]"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21847392", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 3824, 
                    "offsetInEndSection": 3953, 
                    "text": "using this signature could result in a substantial reduction of the number of patients who would be recommended for chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975745", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 209, 
                    "offsetInEndSection": 401, 
                    "text": "Adjuvant assessment tools for prognosis and prediction of treatment benefit, including Adjuvant! Online, the St Gallen Consensus, Oncotype DX(\u00ae) and MammaPrint(\u00ae), aid clinical decision making"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110242", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1108, 
                    "offsetInEndSection": 1368, 
                    "text": "The 70-gene MammaPrint prognosis profile accurately identified Japanese breast cancer patients at low risk of developing recurrences. In fact, 100% of the individuals in the low-risk category remained metastasis-free for the duration of the observation period."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110242", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 965, 
                    "offsetInEndSection": 1094, 
                    "text": "he probability of distant metastasis-free survival at five years was 100% for the low-risk group and 94% for the high-risk group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19825882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1114, 
                    "offsetInEndSection": 1350, 
                    "text": "The 70-gene prognosis signature can accurately select postmenopausal patients at low risk of breast cancer-related death within 5 years of diagnosis and can be of clinical use in selecting postmenopausal women for adjuvant chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 881, 
                    "offsetInEndSection": 1036, 
                    "text": "A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2090, 
                    "offsetInEndSection": 2349, 
                    "text": "The EWG found adequate evidence to characterize the association of MammaPrint with future metastases, but inadequate evidence to assess the added value to standard risk stratification, and could not determine the population to which the test would best apply."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2458, 
                    "offsetInEndSection": 2665, 
                    "text": "he EWG found no evidence regarding the clinical utility of the MammaPrint and Quest H:I Ratio tests, and inadequate evidence regarding Oncotype DX. These technologies have potential for both benefit and harm"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18159035", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 965, 
                    "offsetInEndSection": 1323, 
                    "text": "MammaPrint, an oligonucleotide microassay performed on fresh-frozen tumor samples, analyzes the expression of 70 genes. Studies have found that MammaPrint allows young patients (<61 years) with early-stage breast cancer to be categorized as having a high or low risk of distant metastasis. High-risk patients may then be managed with more aggressive therapy."
                }
            ], 
            "triples": [
                {
                    "o": "Clinic", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7746488"
                }, 
                {
                    "o": "Clinical", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A8316941"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which protein is affected by dusp8 activation?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/DUS8_MOUSE", 
                "http://www.uniprot.org/uniprot/DUS8_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23159405", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23032483", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22100391", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12598532", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11948422", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11566103", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11313966"
            ], 
            "id": "5148691bd24251bc0500002d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032483", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1270, 
                    "offsetInEndSection": 1417, 
                    "text": "Thus, rosiglitazone's neuroprotective effect after ischemia is mediated by blocking JNK phosphorylation induced by ischemia via DUSP8 upregulation."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032483", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 164, 
                    "text": "Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11313966", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1219, 
                    "offsetInEndSection": 1337, 
                    "text": "These results suggest that JNK activation by H(2)O(2) plus PDTC resulted from the down-regulation of JNK phosphatases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566103", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 637, 
                    "offsetInEndSection": 693, 
                    "text": "M3/6 is a dual-specificity phosphatase selective for JNK"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 100, 
                    "text": "Phosphorylation of the M3/6 dual-specificity phosphatase enhances the activation of JNK by arsenite."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 447, 
                    "text": "Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11948422", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 432, 
                    "offsetInEndSection": 536, 
                    "text": "Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159405", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 416, 
                    "offsetInEndSection": 676, 
                    "text": "M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12598532", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1062, 
                    "offsetInEndSection": 1211, 
                    "text": ". We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which pharmacogenetic test is available for abacavir?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010597", 
                "http://www.biosemantics.org/jochem#4274473", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005820", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025202", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057069"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23204921", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21691271", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21521028", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21354501", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21142908", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20602616", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20487194", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20070406", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19514905", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19351209", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19207023", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18680696", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18680695", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18923406", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18784465", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18673126", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18444831", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18332899", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18256392", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18192781", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17534855", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19372817", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16609367", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15247625"
            ], 
            "id": "51487dead24251bc05000030", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204921", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 268, 
                    "offsetInEndSection": 726, 
                    "text": "Pharmacogenetic studies have revealed that abacavir HSRs are highly associated with the major histocompatibility complex class I. Large studies established the effectiveness of prospective HLA-B*57:01 screening to prevent HSRs to abacavir. Accordingly to these results the abacavir label has been modified: the European Medicines Agency (EMA) and the FDA recommend/suggested that the administration of abacavir must be preceded by a specific genotyping test."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21691271", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 256, 
                    "text": "Pharmacogenomic tests offer a promising strategy to improve the safety and efficacy of drug treatment. Compelling examples, such as HLA-B*5701 testing to identify patients at risk for abacavir-associated hypersensitivity, are already changing clinical care"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21521028", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 336, 
                    "text": "International HIV treatment guidelines recommend HLA-B*57:01 typing before abacavir administration, in order to reduce the incidence of abacavir hypersensitivity reactions, the major cause of early therapy discontinuation. A fast, sensitive and specific test for HLA-B*57:01 detection has been developed in the present study."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354501", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 701, 
                    "offsetInEndSection": 872, 
                    "text": "The rollout of HLA-B\u22175701 into routine clinical practice as a genetic screening test to prevent abacavir hypersensitivity provides a translational roadmap for other drugs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21142908", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 528, 
                    "offsetInEndSection": 857, 
                    "text": "he aim of the session, using real-world examples (KRAS/panitumumab and HLA-B*5701/abacavir), was to identify good scientific principles that would guide the design of studies to identify subgroups of responders during development programs (including marketed drugs), which could subsequently be used to guide treatment decisions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20602616", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 812, 
                    "offsetInEndSection": 965, 
                    "text": "HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20487194", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 296, 
                    "offsetInEndSection": 481, 
                    "text": "Successful results that have been achieved within the field of pharmacogenomics so far are, to name a few, HLA-B*5701 screening to avoid hypersensitivity to the antiretroviral abacavir,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20070406", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 234, 
                    "text": "Prospective pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 allele can significantly reduce the number of cases of abacavir-related hypersensitivity among HIV-infected patients treated with this drug."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19514905", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 27, 
                    "offsetInEndSection": 190, 
                    "text": "development of HLA-B*5701 genetic screening as a means of preventing drug hypersensitivity reactions caused by a commonly prescribed antiretroviral drug, abacavir."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351209", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 615, 
                    "text": "Abacavir hypersensitivity syndrome (AHS) is a potentially life-threatening illness occurring in 4-8% of those initiating the drug. Early studies identified a strong association between the MHC class I allele HLA-B*5701 and AHS. These studies suggested that HLA-B*5701 holds promise as a screening test to prevent AHS, but concern arose from HLA-B*5701-negative cases with a clinical diagnosis of AHS, and particularly from early reports of apparently low sensitivities of HLA-B*5701 for AHS in patients of non-White race. However, open screening studies suggested that HLA-B*5701 screening can largely eliminate AHS"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351209", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 988, 
                    "offsetInEndSection": 1167, 
                    "text": "Current HIV treatment guidelines have been revised to reflect the recommendation that HLA-B*5701 screening be incorporated into routine care for patients who may require abacavir."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351209", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1750, 
                    "offsetInEndSection": 1896, 
                    "text": "The research approach applied to AHS has led to a genetic screening test being successfully implemented globally in primary HIV clinical practice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19207023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 434, 
                    "offsetInEndSection": 736, 
                    "text": "The clinical utility of prospective HLA-B*5701 screening was demonstrated in a blinded randomized clinical trial and in open-label cohorts. Screening has been incorporated into clinical practice and the ABC HSR pharmacogenetics program has been highlighted as a success by pharmacogenetics researchers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19207023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 139, 
                    "text": "Abacavir hypersensitivity (ABC HSR) is a treatment-limiting adverse event associated with the use of the antiretroviral medicine, abacavir."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19207023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 302, 
                    "offsetInEndSection": 433, 
                    "text": "The major histocompatibility complex allele, HLA-B*5701, was identified retrospectively and confirmed with independent sample sets."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18680696", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1490, 
                    "offsetInEndSection": 1968, 
                    "text": "he most significant advance for clinical practice is the correlation between the presence of the HLA-B*5701 allele and hypersensitivity reaction to abacavir. In particular, one clinical trial with a large number of patients from distinct ethnic groups found that the probability of not developing hypersensitivity reaction (immunologically confirmed) was 100% if the patient was HLA-B*5701-negative. These data suggest the need to implement this test in daily clinical practice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18680695", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 300, 
                    "text": "The aim of the PREDICT-1 study was to determine the clinical utility of the pharmacogenetic test identifying HLA-B*5701 to reduce the incidence of hypersensitivity reaction to abacavir, diagnosed clinically and with immunological confirmation, as well as to reduce unwarranted withdrawal of this drug"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923406", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1949, 
                    "offsetInEndSection": 2116, 
                    "text": "the identification of HLA-B(*)5701 as a highly sensitive and specific predictive marker for abacavir treated patients who will develop hypersensitivity syndrome (HSS)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923406", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2881, 
                    "offsetInEndSection": 3144, 
                    "text": "Clinical consensus panels rapidly recommended abacavir as the preferred therapy along with HLA-B(*)5701 pre-testing, immediately increasing the market share of abacavir with respect to other reverse transcriptases that are associated with there own adverse events"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18784465", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1889, 
                    "offsetInEndSection": 2041, 
                    "text": "Pharmacogenetic testing for HLA-B*5701 is cost-effective only if abacavir-based treatment is as effective and costs less than tenofovir-based treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18784465", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1621, 
                    "offsetInEndSection": 1875, 
                    "text": "HLA-B*5701 testing remained the preferred strategy only if abacavir-based treatment had equal efficacy and cost less per month than tenofovir-based treatment. Results were also sensitive to the cost of HLA-B*5701 testing and the prevalence of HLA-B*5701."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673126", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 492, 
                    "offsetInEndSection": 685, 
                    "text": "The strong association of the abacavir hypersensitivity reaction with HLA-B*5701 permits testing patients for the allele, and if present avoiding the drug and therefore preventing the reaction."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18444831", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 243, 
                    "text": "Although the human leukocyte antigen (HLA)-B*5701 is highly associated with a hypersensitivity reaction (HSR) to abacavir (ABC), variable sensitivities have been reported when clinical data alone have been used to define an ABC HSR"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18444831", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1867, 
                    "offsetInEndSection": 2132, 
                    "text": "Although IC ABC HSRs are uncommon in black persons, the 100% sensitivity of HLA-B*5701 as a marker for IC ABC HSRs in both US white and black patients suggests similar implications of the association between HLA-B*5701 positivity and risk of ABC HSRs in both races."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18332899", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 351, 
                    "offsetInEndSection": 535, 
                    "text": "A strong statistical association between the major histocompatibility complex allele, HLA-B*5701, and clinically diagnosed ABC HSR was identified but varied between racial populations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18332899", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 650, 
                    "offsetInEndSection": 1137, 
                    "text": "In a randomized, prospective study evaluating the clinical utility of HLA-B*5701 screening, avoidance of ABC in HLA-B*5701-positive patients significantly reduced clinically diagnosed ABC HSR and eliminated patch test-positive ABC HSR. Finally, a retrospective PGx study supports the generalizability of the association across races. Prospective HLA-B*5701 screening should greatly reduce the incidence of ABC HSR by identifying patients at high risk for ABC HSR before they are treated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18256392", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 115, 
                    "text": "Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18256392", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1648, 
                    "offsetInEndSection": 2014, 
                    "text": "HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir. Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192781", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 729, 
                    "offsetInEndSection": 950, 
                    "text": "For abacavir in particular, the use of HLA-B*5701 as a screening test appears to be generalizable across racially diverse populations and has been supported by both observational, and blinded randomized controlled trials."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192781", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1296, 
                    "offsetInEndSection": 1597, 
                    "text": "HLA-B*5701 screening to prevent abacavir hypersensitivity is currently the most relevant to clinical practice and highlights that the promise of cost-effective testing can be facilitated by robust laboratory methodology and quality assurance programs that can be applied to diverse treatment settings."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17534855", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 623, 
                    "offsetInEndSection": 773, 
                    "text": "the major histocompatibility complex HLA-B*5701 allele has been associated with hypersensitivity to abacavir (ABC) by several independent researchers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372817", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1110, 
                    "offsetInEndSection": 1284, 
                    "text": "The strong association between HLA-B5701 and abacavir hypersensitivity reaction shows promise for a genetic screening test to be feasibly incorporated into clinical practice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16609367", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 399, 
                    "text": "Abacavir hypersensitivity reaction (ABC HSR) is a potentially life-threatening adverse reaction that affects approximately 8% of patients that initiate this antiretroviral drug. Independent groups have shown a strong predictive association between ABC HSR and HLA-B*5701, indicating that exclusion of HLA-B*5701 positive individuals from abacavir treatment would largely prevent ABC HSR."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15247625", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 253, 
                    "text": "Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15247625", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1618, 
                    "offsetInEndSection": 1788, 
                    "text": "Abacavir hypersensitivity is associated with HLA B*5701, and pre-prescription pharmacogenetic testing for this appears to be a cost-effective use of healthcare resources."
                }
            ], 
            "triples": [
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01048", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://data.linkedct.org/resource/intervention/61980"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01048", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://data.linkedct.org/resource/intervention/755"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01048", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://data.linkedct.org/resource/intervention/29655"
                }, 
                {
                    "o": "{(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol", 
                    "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                    "s": "http://linkedlifedata.com/resource/chebi/id/CHEBI:421707"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A1350342", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0663655"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1350342"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18243547"
                }, 
                {
                    "o": "abacavir", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1350341"
                }, 
                {
                    "o": "Abacavir", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11833020"
                }, 
                {
                    "o": "ABACAVIR", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12783493"
                }, 
                {
                    "o": "abacavir", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17883542"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1350340"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which genes are involved in patient response to warfarin?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014859", 
                "http://www.biosemantics.org/jochem#4250139", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005823", 
                "http://www.biosemantics.org/jochem#4044131", 
                "http://www.biosemantics.org/jochem#4044132", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005826", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005820", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D036281", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005815", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005819", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014644", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011110", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056426", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0047057", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0047058"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23342320", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23208322", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22952875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22321278", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22122181", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22023024", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21713343", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21651319", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21590310", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20854800", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20615525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20210733", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19794411", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19752777", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19538716", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19135231", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19069171", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18752379", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18464049", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18034618", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17496169", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16611750", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11213860"
            ], 
            "id": "5148885ad24251bc05000032", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342320", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 659, 
                    "offsetInEndSection": 917, 
                    "text": "There are two identified genes that are responsible for the main proportion of the genetic effect: CYP2C9, which codes for the enzyme cytochrome P450 2C9 that metabolizes S-warfarin, and VKORC1, which codes for warfarin's target, vitamin K epoxide reductase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23208322", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1005, 
                    "offsetInEndSection": 1199, 
                    "text": "We identified ORM1 as another polymorphic gene affecting warfarin dose requirements. ORM1 *S carriers require lower maintenance doses to achieve and maintain an optimal level of anticoagulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952875", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 856, 
                    "offsetInEndSection": 1048, 
                    "text": "Many of these studies have identified significant associations with two genes in particular, the cytochrome-P450 gene CYP2C9 and the vitamin K epoxide reductase complex subunit 1 gene, VKORC1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952875", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1307, 
                    "offsetInEndSection": 1388, 
                    "text": "it is widely accepted that genotype at CYP2C9 and VKORC1 affect dose requirements"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952875", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4320, 
                    "offsetInEndSection": 4431, 
                    "text": "Variants in another gene, CYP4F2, have also been associated with warfarin dose requirements in several studies."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952875", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 111, 
                    "text": "The evidence base for the effect of CYP2C9 and VKORC1 genotype on response to warfarin is substantial"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22321278", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1877, 
                    "offsetInEndSection": 2078, 
                    "text": "Detecting genetic polymorphism of CYP2C9 and VKORC1 could guide clinical use of warfarin to reduce the risk of adverse reactions including bleeding in patients receiving chronic anticoagulation therapy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122181", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 406, 
                    "offsetInEndSection": 622, 
                    "text": "The genes encoding for cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) are the major genetic determinants of warfarin pharmacokinetics and pharmacodynamics, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122181", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 623, 
                    "offsetInEndSection": 914, 
                    "text": "Numerous studies have demonstrated significant contributions of these genes to warfarin dose requirements. The CYP2C9 gene has also been associated with bleeding risk with warfarin. The CYP4F2 gene influences vitamin K availability and makes minor contributions to warfarin dose requirements"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 367, 
                    "offsetInEndSection": 685, 
                    "text": "There are other genetic polymorphisms that may further explain the response to warfarin. The VKORC1 genotype is an important determinant of response to warfarin in Chinese, but some genetic variants found in other ethnic groups that have a large effect on warfarin response and dosing are not commonly found in Chinese"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21713343", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1186, 
                    "offsetInEndSection": 1379, 
                    "text": "the alleles rs1799853 (*2) and rs1057910 (*3) of the CYP2C9 gene, as well as rs9923231 of the VKORC1 gene were associated with warfarin dose required to achieve anticoagulation with INR of 2-3."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21651319", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 200, 
                    "text": "Polymorphisms in the genes encoding the cytochrome P450 2C9 enzyme (CYP2C9) and the vitamin K epoxide reductase (VKORC1) are known to contribute to variability in sensitivity to coumarins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21590310", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1217, 
                    "offsetInEndSection": 1329, 
                    "text": "VKORC1 and CYP2C9 polymorphisms are important factors that influence warfarin dose response in Sudanese patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20854800", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 13, 
                    "offsetInEndSection": 136, 
                    "text": "he response to the anticoagulant drug warfarin is greatly affected by genetic polymorphisms in the VKORC1 and CYP2C9 genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20854800", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1093, 
                    "offsetInEndSection": 1339, 
                    "text": "The HDA-based assays demonstrated a clinically acceptable performance for genotyping the VKORC1 -1639G>A SNP and two SNPs (430C>T and 1075A>C) for the CYP2C9 enzyme (CYP2C9*2 and CYP2C9*3), all of which are relevant in warfarin pharmacogenentics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20615525", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 92, 
                    "offsetInEndSection": 192, 
                    "text": "Genetic variability in the VKORC1 and CYP2C9 genes is associated with increased warfarin sensitivity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20210733", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 74, 
                    "offsetInEndSection": 139, 
                    "text": "CYP2C9 and VKORC1 polymorphisms known to affect warfarin response"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19794411", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 542, 
                    "offsetInEndSection": 720, 
                    "text": "genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26.6% of dose variability."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19752777", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 561, 
                    "offsetInEndSection": 1032, 
                    "text": "CYP2C9 was the most important gene determining initial anticoagulant control, whereas VKORC1 was more important for stable anticoagulation. Novel associations with some clinical outcomes were found with single nucleotide polymorphisms in the cytochrome 450 genes CYP2C18 and CYP2C19, which were independent of the associations observed with CYP2C9 and in genes encoding CYP3A5, protein S and clotting factor V, although the variability explained by these genes was small."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538716", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2481, 
                    "offsetInEndSection": 2701, 
                    "text": "Warfarin pharmacogenetic studies demonstrated that variants in the CYP2C9 (Cytochrome P450 2C9) and VKORC1 (Vitamin K epoxide reductase complex subunit 1) genes account for approximately 50\u201360% of drug dosing variability"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538716", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2976, 
                    "offsetInEndSection": 3387, 
                    "text": "hese last two are associated with decreased metabolic efficiency of the CYP2C9 enzyme and increased risk of bleeding when administrated initial dosages of warfarin [15]. A G>A variation at position 1639 in the promoter region of the VKORC1 gene results in decreased mRNA transcription and increased sensitivity to warfarin inhibition of hepatic synthesis of functional vitamin K-dependent coagulation factors [1"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538716", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 5031, 
                    "offsetInEndSection": 5142, 
                    "text": "Polymorphisms within VKORC1, a target of warfarin inhibition, may explain 23% of this drug dosage variability ["
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538716", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4766, 
                    "offsetInEndSection": 4892, 
                    "text": "Those who are CYP2C9 PMs may exhibit different pharmacokinetics than wild-type individuals if they are medicated with warfarin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1460, 
                    "offsetInEndSection": 2150, 
                    "text": "The metabolism of warfarin and the other coumarin anticoagulants is well understood, with the cytochrome P450 enzyme CYP2C9 having a major role in their phase I metabolism (reviewed in [3]). CYP2C9 is subject to a genetic polymorphism affecting its activity, and the fact that this polymorphism contributes to individual anticoagulant dose requirement is now well established, although its effect on phenprocoumon metabolism is less pronounced than that on either warfarin or acenocoumarol [2,4-7]. Coumarin anticoagulants exert their effect by inhibiting the enzyme vitamin K epoxide reductase, which regenerates vitamin K following its oxidation in the gamma glutamyl carboxylase reaction"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2381, 
                    "offsetInEndSection": 2576, 
                    "text": "Polymorphisms in this gene's non-coding sequences have been shown to affect levels of gene expression, resulting in inter-individual variation in the amount of this protein present in hepatocytes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2888, 
                    "offsetInEndSection": 3099, 
                    "text": "A clear association between the G-1639A polymorphism and warfarin dose requirement has been reported in many independent studies [10,13,14], and similar associations for acenocoumarol and phenprocoumon also occu"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3676, 
                    "offsetInEndSection": 3901, 
                    "text": "An important recent development is the inclusion of reference to genetic factors affecting response (both CYP2C9 and VKORC1) in the prescribing information for warfarin in the USA by the Food and Drug Administration (FDA) [18"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 741, 
                    "offsetInEndSection": 1039, 
                    "text": "ne possible exception to this is the cytochrome P450 CYP4F2 gene. This gene was shown to contribute to warfarin dose requirement in a study using the Affymetrix ADME gene chip, which includes a single nucleotide polymorphism (SNP) in CYP4F2 that is associated with the amino acid change V433M [22]."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 1806, 
                    "offsetInEndSection": 2020, 
                    "text": "owever, its relevance to warfarin action is still unclear, although a role for CYP4F2 in vitamin K metabolism has been suggested [22] and it also remains possible that it contributes directly to warfarin metabolism"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19348697", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 2300, 
                    "offsetInEndSection": 2532, 
                    "text": "The effect of CYP4F2 on warfarin dose requirement is biologically interesting, but the overall 1-2% contribution to dose requirement confirmed so far [22] may be too small for genotyping for the relevant SNP to be clinically useful."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19135231", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 956, 
                    "offsetInEndSection": 1075, 
                    "text": "VKORC1 -1639 G>A polymorphism, body weight, age, and serum albumin were found to affect the inter-individual variabilit"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19069171", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 332, 
                    "offsetInEndSection": 423, 
                    "text": "the CYP2C9 and VKORC1 genes have been demonstrated to be determinants of warfarin response."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19069171", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 817, 
                    "offsetInEndSection": 1063, 
                    "text": "On the basis of these observations, the Food and Drug Administration (FDA) approved a labeling change for warfarin that includes the genetic information of VKORC1 and CYP2C9 as factors influencing interindividual variability in warfarin dosing. T"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18752379", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 275, 
                    "offsetInEndSection": 424, 
                    "text": "the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, on warfarin response"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18752379", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 498, 
                    "offsetInEndSection": 708, 
                    "text": "The influence of CYP2C9 and VKORC1 genotypes on warfarin dose requirements has been consistently demonstrated in diverse racial and ethnic patient groups in observational studies and randomized clinical trials."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18464049", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 445, 
                    "offsetInEndSection": 701, 
                    "text": "genetic factors influencing drug pharmacokinetics (CYP2C9) and pharmacodynamic response (VKORC1). In particular, the discovery of polymorphisms in the VKORC1 gene that strongly impact oral anticoagulant dose has heightened expectations that genetic testing"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18034618", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1402, 
                    "offsetInEndSection": 1686, 
                    "text": "Our data suggest that CYP2C9 genotype, age and body size are important determinants of warfarin dose requirements in African-Americans. Our data further suggest that the VKORC1 G6853C polymorphism alone may not be useful for predicting warfarin dose requirements in this racial group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496169", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 764, 
                    "offsetInEndSection": 1015, 
                    "text": "A strong association was found between genetic polymorphisms in six genes, including VKORC1, CYP2C9, PROC, EPHX1, GGCX, and ORM1, and interindividual variability in the anticoagulant effect of warfarin; the strongest predictors were VKORC1 and CYP2C9."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16611750", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 786, 
                    "offsetInEndSection": 961, 
                    "text": "Three of six VKORC1 SNPs were found to be very strongly associated with the average warfarin dose required to achieve the target international normalised ratio (INR; p<0.0001)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16611750", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1280, 
                    "offsetInEndSection": 1741, 
                    "text": "These results are of considerable clinical interest and confirm recently published results regarding the role of these two genes in modifying warfarin metabolism and maintenance dosage. The consistent findings regarding the role of VKORC1 and CYP2C9 in warfarin metabolism and maintenance dosage represent a clinically useful proof of principal for the use of pharmacogenomic information in medicine and may lead to improved understanding of warfarin's actions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11213860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 571, 
                    "offsetInEndSection": 780, 
                    "text": "Clinical studies showed an increased plasma level of S-warfarin, decreased clearance of S-warfarin, increased frequency of bleeding, and prolongation of hospitalization in patients with variant CYP2C9 alleles."
                }
            ], 
            "triples": [
                {
                    "o": "http://purl.uniprot.org/core/Gene", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/#_5131303833330011"
                }, 
                {
                    "o": "Gene", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/pubmed/10524252"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/10524252", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/citations/10524252"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/10974568", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/citations/10974568"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/11587856", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/citations/11587856"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/11587856", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/pubmed/11587856"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Can PLN mutations lead to dilated cardiomyopathy?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002311", 
                "http://www.disease-ontology.org/api/metadata/DOID:12930", 
                "http://www.uniprot.org/uniprot/PPLA_BOVIN", 
                "http://www.uniprot.org/uniprot/PPLA_PIG", 
                "http://www.uniprot.org/uniprot/PPLA_RAT", 
                "http://www.uniprot.org/uniprot/PPLA_CANFA", 
                "http://www.uniprot.org/uniprot/PPLA_RABIT", 
                "http://www.uniprot.org/uniprot/PPLA_CHICK", 
                "http://www.uniprot.org/uniprot/PPLA_MOUSE", 
                "http://www.uniprot.org/uniprot/PPLA_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004106", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009202", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", 
                "http://www.disease-ontology.org/api/metadata/DOID:0050700", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004108", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020125", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054643", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016368", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018389", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017384", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017354", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004252"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23349452", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22820313", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22427649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21282613", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20634894", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19324307", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17998275", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17019811", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17010801", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16432188", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16235537", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15769782", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15336969", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12639993", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12610310"
            ], 
            "id": "5148e42cd24251bc0500003b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349452", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 674, 
                    "offsetInEndSection": 826, 
                    "text": "A PLN founder mutation (43 cases) and LMNA mutations (19 cases, 16 different mutations) were most prevalent and often demonstrated a specific phenotype."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820313", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 350, 
                    "offsetInEndSection": 441, 
                    "text": "PLN mutation R14del was identified in 12 (12 %) ARVC patients and in 39 (15 %) DCM patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820313", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1337, 
                    "offsetInEndSection": 1453, 
                    "text": "The PLN R14del founder mutation is present in a substantial number of patients clinically diagnosed with DCM or ARVC"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 147, 
                    "offsetInEndSection": 272, 
                    "text": "Arg(9) \u2192 Cys (R9C) and Arg(14) deletion (R14del) mutations in PLN are associated with lethal dilated cardiomyopathy in humans"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 306, 
                    "offsetInEndSection": 443, 
                    "text": "We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 157, 
                    "offsetInEndSection": 252, 
                    "text": "Mutations in the gene encoding PLN have been associated with idiopathic dilated cardiomyopathy;"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1429, 
                    "offsetInEndSection": 1565, 
                    "text": "Mutations in the PLN gene are a rare cause of heart failure, present almost exclusively in patients with dilated cardiomyopathy etiology"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282613", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 172, 
                    "offsetInEndSection": 294, 
                    "text": "A missense mutation in PLN cytoplasmic domain (R9C) triggers dilated cardiomyopathy in humans, leading to premature death."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634894", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 725, 
                    "offsetInEndSection": 894, 
                    "text": "Recently, a mutation of PLN in which one of the N-terminal di-arginine residues at positions 13 and 14 was deleted led to a severe, early onset dilated cardiomyopathy [4"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324307", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 465, 
                    "offsetInEndSection": 599, 
                    "text": "Complete genetic and clinical analyses were performed in a family with familial dilated cardiomyopathy due to the PLN-R14Del mutation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324307", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 753, 
                    "offsetInEndSection": 1090, 
                    "text": "A candidate gene approach resulted in identification of a heterozygous deletion of arginine 14 in the gene encoding phospholamban (PLN-R14Del) segregating with dilated cardiomyopathy in the family pedigree. Mutation carriers suffered from familial dilated cardiomyopathy associated with cardiac death between the ages of 26 and 50 years."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324307", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 522, 
                    "offsetInEndSection": 599, 
                    "text": "a family with familial dilated cardiomyopathy due to the PLN-R14Del mutation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17998275", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1103, 
                    "offsetInEndSection": 1320, 
                    "text": "For the phospholamban (PLN) and titin cap (TTN) genes, a direct mutation screening approach was used. DNA sequence analysis of all exons showed no evidence that these genes are involved in DCM in the Newfoundland dog."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17019811", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1096, 
                    "offsetInEndSection": 1229, 
                    "text": "two human PLN mutations, associated with either absence or sustained dephosphorylation of PLN, were linked to dilated cardiomyopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17010801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 215, 
                    "offsetInEndSection": 379, 
                    "text": "Mutations in the gene encoding PLN have been associated with dilated cardiomyopathy characterized by early onset and the presence of lethal ventricular arrhythmias."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17010801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 962, 
                    "offsetInEndSection": 1143, 
                    "text": "The identical PLN mutation can be associated with both mild and severe forms of dilated cardiomyopathy. Additionally, PLN mutations should be considered in late onset cardiomyopathy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16432188", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 223, 
                    "offsetInEndSection": 466, 
                    "text": "Through genetic screening of dilated cardiomyopathy patients, we identified a previously uncharacterized deletion of arginine 14 (PLN-R14Del) in the coding region of the phospholamban (PLN) gene in a large family with hereditary heart failure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16235537", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 742, 
                    "offsetInEndSection": 922, 
                    "text": "No PLN gene mutation was found in patients with DCM in Chengdu. This result indicated that PLN gene mutation may not be a common cause for DCM in the Chinese population in Chengdu."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15769782", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1341, 
                    "offsetInEndSection": 1352, 
                    "text": "none in PLN"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15336969", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 955, 
                    "offsetInEndSection": 1027, 
                    "text": "the recent discoveries of human PLN mutations leading to disease states."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12639993", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 612, 
                    "offsetInEndSection": 768, 
                    "text": "Strikingly, both individuals homozygous for L39stop developed dilated cardiomyopathy and heart failure, requiring cardiac transplantation at ages 16 and 27."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12639993", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1320, 
                    "offsetInEndSection": 1377, 
                    "text": "humans lacking PLN develop lethal dilated cardiomyopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610310", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 188, 
                    "offsetInEndSection": 386, 
                    "text": "Here we report that an inherited human dilated cardiomyopathy with refractory congestive heart failure is caused by a dominant Arg --> Cys missense mutation at residue 9 (R9C) in phospholamban (PLN)"
                }
            ], 
            "triples": [
                {
                    "o": "Dilated cardiomyopathy", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17851795"
                }, 
                {
                    "o": "Cardiomyopathies, Dilated", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0035199"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11995504"
                }, 
                {
                    "o": "Dilated Cardiomyopathy", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17895723"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0048982"
                }, 
                {
                    "o": "Cardiomyopathy, Dilated", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12058799"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A13286677"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "How many genes are in the gene signature screened by MammaPrint?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23371464", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23347730", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22738860", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21347257", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21291290", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21081926", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20359886", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20204499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20094918", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19126254", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18483364"
            ], 
            "id": "514a0f4ad24251bc05000053", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371464", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 35, 
                    "text": "The 70-gene signature (MammaPrint\u2122)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23347730", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 138, 
                    "text": "The 70 gene-signature (MammaPrint(\u00ae)) is a prognostic profile of distant recurrence and survival of primary breast cancer (BC)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22738860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 501, 
                    "offsetInEndSection": 552, 
                    "text": "The 70-gene signature was analysed using MammaPrint"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 52, 
                    "offsetInEndSection": 104, 
                    "text": "the prognostic value of the MammaPrint(TM) signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 474, 
                    "offsetInEndSection": 498, 
                    "text": "by the 70-gene signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 477, 
                    "offsetInEndSection": 498, 
                    "text": "the 70-gene signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1433, 
                    "offsetInEndSection": 1484, 
                    "text": "n FDA-cleared 70-gene signature of MammaPrint panel"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21347257", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 15723, 
                    "offsetInEndSection": 15803, 
                    "text": "MammaPrint (the commercial test of the 70 genes, marketed by Agendia, Amsterdam)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21291290", 
                    "endSection": "title", 
                    "offsetInBeginSection": 22, 
                    "offsetInEndSection": 104, 
                    "text": "70-gene MammaPrint signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21291290", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 470, 
                    "offsetInEndSection": 487, 
                    "text": "70-gene signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2528, 
                    "offsetInEndSection": 2638, 
                    "text": "MammaPrint genes indeed capture these six steps, we examined the biological functions of each of the 70 genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 183, 
                    "offsetInEndSection": 233, 
                    "text": "The 70 genes that make up the MammaPrint signature"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 26, 
                    "offsetInEndSection": 41, 
                    "text": "70-gene profile"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 747, 
                    "offsetInEndSection": 762, 
                    "text": "70 gene profile"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 34, 
                    "offsetInEndSection": 57, 
                    "text": "the 70 MammaPrint genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 582, 
                    "offsetInEndSection": 599, 
                    "text": "a set of 70 genes"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1276, 
                    "offsetInEndSection": 1314, 
                    "text": "the 70 genes in the MammaPrint profile"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 6064, 
                    "offsetInEndSection": 6108, 
                    "text": "in the MammaPrint 70 gene expression profile"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21151591", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 58, 
                    "text": "he MammaPrint 70-gene tumor expression profile"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081926", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 969, 
                    "offsetInEndSection": 1084, 
                    "text": "the 70-gene prognosis signature (MammaPrint, Agendia Inc., Huntington Beach, CA, USA and Amsterdam, The Netherlands"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081926", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 2574, 
                    "offsetInEndSection": 2606, 
                    "text": "the 70-gene MammaPrint signature"
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081926", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 289, 
                    "offsetInEndSection": 321, 
                    "text": "The 70-gene MammaPrint signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20359886", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 156, 
                    "text": "The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20359886", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 917, 
                    "offsetInEndSection": 935, 
                    "text": "70-gene signature."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20359886", 
                    "endSection": "title", 
                    "offsetInBeginSection": 26, 
                    "offsetInEndSection": 143, 
                    "text": "70-gene signature"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20359886", 
                    "endSection": "title", 
                    "offsetInBeginSection": 26, 
                    "offsetInEndSection": 143, 
                    "text": "70-gene signature"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20359886", 
                    "endSection": "title", 
                    "offsetInBeginSection": 26, 
                    "offsetInEndSection": 143, 
                    "text": "70-gene signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 158, 
                    "offsetInEndSection": 220, 
                    "text": "the 70-gene MammaPrint signature for chemotherapy (CT) benefit"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20094918", 
                    "endSection": "title", 
                    "offsetInBeginSection": 61, 
                    "offsetInEndSection": 155, 
                    "text": "the 70-gene MammaPrint signature"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214742", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 214, 
                    "offsetInEndSection": 233, 
                    "text": "the 70-gene profile"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19126254", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 287, 
                    "offsetInEndSection": 373, 
                    "text": "the 70-gene prognosis signature (MammaPrint) for node-negative breast cancer patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19126254", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 642, 
                    "offsetInEndSection": 660, 
                    "text": "70-gene signature."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19126254", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 642, 
                    "offsetInEndSection": 659, 
                    "text": "70-gene signature"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4677, 
                    "offsetInEndSection": 4869, 
                    "text": "The Amsterdam 70-gene expression signature as breast cancer prognosis marker has been validated in follow-up studies [39,40], and a clinical assay MammaPrint\u00ae has recently been cleared by FDA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483364", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 836, 
                    "offsetInEndSection": 868, 
                    "text": "The MammaPrint 70-gene signature"
                }
            ], 
            "triples": [
                {
                    "o": "MammaPrint", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17680439"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which diseases can Oncotype DX be used for?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001941", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003108", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003109"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23371261", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22590486", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22361999", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21934103", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21370017", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21278441", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21221771", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21176237", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22811953", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20877447", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20564629", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20200857", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19946260", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19536946", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19101988", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18347556", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18942607", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18072276"
            ], 
            "id": "514a11add24251bc05000054", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371261", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 243, 
                    "offsetInEndSection": 276, 
                    "text": "Prognostic and predictive markers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371261", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 366, 
                    "offsetInEndSection": 440, 
                    "text": "Oncotype DX\u00ae currently allow avoidance of an over therapy or under therapy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590486", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 432, 
                    "offsetInEndSection": 489, 
                    "text": "a high score on the Oncotype DX gene expression profile r"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590486", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 191, 
                    "offsetInEndSection": 267, 
                    "text": "poor-prognosis ER-positive breast cancers in need of more aggressive therapy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590486", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 316, 
                    "offsetInEndSection": 331, 
                    "text": "luminal B class"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22361999", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 232, 
                    "text": "The 21-gene recurrence score (Oncotype DX: RS) appears to augment clinico-pathologic prognostication and is predictive of adjuvant chemotherapy benefit in node-negative (N-) and node-positive (N+), endocrine-sensitive breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21934103", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 263, 
                    "text": "Half of all breast cancers are early stage, lymph node negative, and hormone receptor positive. A 21-gene (Oncotype DX\u00ae; Genomic Health, Inc., Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 270, 
                    "offsetInEndSection": 503, 
                    "text": "We hypothesized that a distinct network of immune function genes at the tumor site can predict a low risk versus high risk of distant relapse in breast cancer patients regardless of the status of ER, PR, or HER-2/neu in their tumors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1350, 
                    "offsetInEndSection": 1694, 
                    "text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21370017", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 620, 
                    "offsetInEndSection": 880, 
                    "text": "Molecular tests such as the Oncotype DX(\u00ae) breast cancer test are proving to be more effective tools for individualized patient stratification and treatment planning than traditional methods such as patient demographic variables and histopathology indicators."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278441", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1546, 
                    "offsetInEndSection": 1763, 
                    "text": "Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278441", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1222, 
                    "offsetInEndSection": 1325, 
                    "text": "The oncotype DX\u00ae genomic assay has also been used to help prognosis estimation and treatment decisions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221771", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 149, 
                    "text": "The Oncotype DX Recurrence Score (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 661, 
                    "offsetInEndSection": 968, 
                    "text": "The Oncotype DX Breast Cancer Assay has met this standard as an analytically and clinically validated high complexity, multi-analyte, RT-PCR test to predict the likelihood of recurrence and response to chemotherapy in estrogen receptor-positive, node-negative and node-positive breast cancer patients [1,2]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1175, 
                    "offsetInEndSection": 1318, 
                    "text": "the Oncotype DX Breast Cancer Assay has become standard of care for individualized treatment decision-making in early stage breast cancer [3-5]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2007, 
                    "offsetInEndSection": 2561, 
                    "text": "study of the 12 gene Oncotype DX Colon Cancer Assay [7], stage II colon cancer patients (particularly those with T3 disease and mismatch repair proficient (MMR-P) tumors) are now empowered to make more informed treatment decisions with quantitative, individualized recurrence risk information based on the molecular profile of their tumor.The seven cancer-related genes in the Oncotype DX Colon assay were selected from a panel of 761 genes for their consistent association with colon cancer recurrence in 4 large and independent development studies [6]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 7775, 
                    "offsetInEndSection": 8041, 
                    "text": "Oncotype DX, which produces a quantitative RS between 0 and 100, is a molecular assay that has been clinically validated to predict the likelihood of 10-year distant recurrence and the expected benefit from adjuvant chemotherapy for early-stage, ER+ BCa patients.[1]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 371, 
                    "offsetInEndSection": 589, 
                    "text": "Prognosis and treatment in early stage ER+ BCa are often guided by the Oncotype DX genomic assay (Genomic Health, Inc.), which produces a quantitative recurrence score (RS) correlated with likelihood for recurrence.[1]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 188, 
                    "text": "Clinical ScenarioOncotype DX is used for profiling tumor gene expression in patients with Stage-II colon cancer to predict recurrence risk and\u00a0inform treatment decisions following surgery."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20564629", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 148, 
                    "text": "The 21-gene signature has been intensively studied and incorporated into major guidelines for treatment decision in early breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200857", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1467, 
                    "offsetInEndSection": 1611, 
                    "text": "Among early-stage breast cancer patients who received Oncotype DX, we found low knowledge about many aspects of genomic recurrence risk testing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 699, 
                    "offsetInEndSection": 1137, 
                    "text": "the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples. This remarkable congruence suggests a biological interdependence of poor-prognosis gene signatures, breast cancer subtypes, genomic instability, and clinical outcome."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 453, 
                    "text": "The Oncotype DX assay is one of the molecular tests that provide predictive and prognostic information to breast cancer patients with estrogen receptor (ER)-positive and node-negative disease. This study evaluates the association of Forkhead-box protein A1 (FOXA1) and GATA-binding protein 3 (GATA3) expressions with Oncotype DX recurrences scores in 77 cases of patients with ER-positive node-negative breast carcinomas diagnosed at Indiana University."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19536946", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 30, 
                    "offsetInEndSection": 485, 
                    "text": "the use of the Oncotype DX assay in estrogen receptor-positive node-negative breast cancer patients were incorporated into guidelines from both the American Society of Clinical Oncology and the National Comprehensive Cancer Network. The Oncotype DX assay is a diagnostic test which measures changes in a set of 21 genes in order to predict the likelihood of disease recurrence and also to predict which patients are most likely to respond to chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1920, 
                    "offsetInEndSection": 2089, 
                    "text": "The EWG found adequate evidence regarding the association of the Oncotype DX Recurrence Score with disease recurrence and adequate evidence for response to chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 53, 
                    "offsetInEndSection": 239, 
                    "text": "EWG) found insufficient evidence to make a recommendation for or against the use of tumor gene expression profiles to improve outcomes in defined populations of women with breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18347556", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 230, 
                    "offsetInEndSection": 424, 
                    "text": "confirmed the clinical validity of the Oncotype DX breast cancer assay, not only as a way to predict recurrence but also as a tool for determining therapeutic benefit from adjuvant chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072276", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 186, 
                    "text": "Over several decades, investigators working through National Cancer Institute-sponsored Cooperative Groups have contributed to major advances in the endocrine treatment of breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072276", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 586, 
                    "offsetInEndSection": 775, 
                    "text": "Cooperative Group studies have contributed to the development of a molecular profiling test, Oncotype Dx, which identifies women who have an excellent prognosis with hormonal therapy alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221771", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 359, 
                    "offsetInEndSection": 485, 
                    "text": "In this report we compare the prognostic and predictive utility of these two tools in node-negative, ER-positive breast cancer"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2732, 
                    "offsetInEndSection": 3135, 
                    "text": "The Oncotype-DX Breast Cancer Assay (Genomic Health, Redwood City, CA) quantifies gene expression for 21 genes in breast cancer tissue by performing reverse transcription polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded (FFPE) tumour blocks that are obtained during initial surgery (lumpectomy, mastectomy, or core biopsy) of women with early breast cancer that is newly diagnosed."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200857", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 297, 
                    "offsetInEndSection": 478, 
                    "text": "78 women, treated for early-stage, estrogen receptor-positive breast cancer with 0-3 positive lymph nodes, whose medical records indicated they received Oncotype DX testing earlier."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18942607", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 226, 
                    "offsetInEndSection": 427, 
                    "text": "A retrospective chart review of 58 T1/T2, node-negative, estrogen-receptor positive breast cancer patients that underwent Oncotype DX gene assay testing between January and December 2006 was performed."
                }
            ], 
            "triples": [
                {
                    "o": "Oncotype DX", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10812803"
                }, 
                {
                    "o": "NCI Thesaurus", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7568412"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A0049608", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0012634"
                }, 
                {
                    "o": "Diseases", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0015570"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18169310"
                }, 
                {
                    "o": "Diseases", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0015569"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is there a pharmacogenetic test for trastuzumab?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010597", 
                "http://www.biosemantics.org/jochem#4002084"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22065003", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21632460", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22461093", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17947471", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17184417", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16235569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15217485", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11097337", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15970231", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22112244", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20590449", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17785760", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17159499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16809727", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15510616", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11838648", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11579337", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11265171"
            ], 
            "id": "514a1469d24251bc05000056", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461093", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 302, 
                    "offsetInEndSection": 518, 
                    "text": "The clinical need for novel approaches to improve drug therapy derives from the high rate of adverse reactions to drugs and their lack of efficacy in many individuals that may be predicted by pharmacogenetic testing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461093", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1429, 
                    "offsetInEndSection": 1549, 
                    "text": "the assessment of the human epidermal growth factor receptor (HER-2) expression for trastuzumab therapy of breast cancer"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17184417", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 379, 
                    "offsetInEndSection": 440, 
                    "text": "HER2 positive breast cancer and the use of the drug Herceptin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16235569", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 696, 
                    "offsetInEndSection": 988, 
                    "text": "The dependence on gene copy number or expression levels of HER2 and epidermal growth factor receptor (EGFR) for therapeutic efficacy of trastuzumab and cetuximab (Erbitux), respectively, supports the importance of selecting suitable patient populations based on their pharmacogenetic profile."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15970231", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 289, 
                    "offsetInEndSection": 718, 
                    "text": "to explore informed consent issues surrounding the use of the drug Herceptin, widely cited as an example of a novel approach to drug development called pharmacogenetics. Drawing on qualitative semi-structured interviews with 25 UK-based breast cancer specialists, this paper explores Herceptin's disputed epistemological status, as an example of pharmacogenetics or as something out of the ordinary in terms of clinical practice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22065003", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 177, 
                    "text": "There have been several success stories in the field of pharmacogenetics in recent years, including the analysis of HER2 amplification for trastuzumab selection in breast cancer"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21632460", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 133, 
                    "text": "Trastuzumab is standard of care in the treatment of human epidermal growth factor receptor (HER)-2\u207a early and advanced breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17947471", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 107, 
                    "offsetInEndSection": 169, 
                    "text": "HER-2 overexpression as a predictor of response to trastuzumab"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15217485", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11368, 
                    "offsetInEndSection": 11620, 
                    "text": "New evidence for the role of trastuzumab comes from the updated results of the M77001 study, showing 8-month median survival improvement in Her2-positive metastatic disease patients administered trastuzumab and docetaxel, compared with docetaxel alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11097337", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 191, 
                    "text": "Pharmacogenomic analysis aspires to identify individuals with specific genetic characteristics in order to predict a positive response or reduce a negative response to a therapeutic modality."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11097337", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 792, 
                    "offsetInEndSection": 998, 
                    "text": "Assays are available to detect the HER2 protein receptor or copies of the HER2 gene sequence to determine eligibility for Herceptin treatment or adriamycin treatment in node positive patients, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11265171", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 204, 
                    "text": "Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin), which has recently been licensed for the treatment of metastatic disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11579337", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 190, 
                    "text": "Laboratory testing of HER2/neu in breast carcinoma has become vital to patient care following the approval of trastuzumab as the first therapy to target the HER2/neu oncoprotein."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11838648", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 337, 
                    "offsetInEndSection": 474, 
                    "text": "Immunohistochemical (IHC) analysis was performed with use of a diagnostic test for the assessment of HER2 overexpression, the HercepTest."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15510616", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 270, 
                    "offsetInEndSection": 490, 
                    "text": "To test for HER-2/neu overexpression in patients with non-Hodgkin's lymphoma and the possible role of the recombinant monoclonal anti-HER-2/neu antibody trastuzumab (Herceptin) in the treatment of non-Hodgkin's lymphoma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16809727", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 195, 
                    "text": "To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16809727", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1559, 
                    "offsetInEndSection": 1749, 
                    "text": "These findings support the importance of using high-volume, experienced laboratories for HER2 testing to improve the process of selecting patients likely to benefit from trastuzumab therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17159499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 256, 
                    "offsetInEndSection": 617, 
                    "text": "we measured trastuzumab levels in the serum and in cerebrospinal fluid of metastatic breast cancer patients with brain metastases receiving trastuzumab for HER2-overexpressing metastatic breast cancer. In a pilot study, metastatic breast cancer patients with brain metastases and HER2-overexpressing tumors (HercepTest; Dako, Copenhagen, Denmark) were included."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17159499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1687, 
                    "offsetInEndSection": 1966, 
                    "text": "Monitoring of trastuzumab levels in the serum and cerebrospinal fluid may enable individualized therapy strategies in metastatic breast cancer patients with brain metastases, and lead to a better understanding of trastuzumab pharmacokinetics in the cerebrospinal fluid and serum."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17785760", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 102, 
                    "text": "Biotin-labeled trastuzumab (BiotHER) can be used to test for HER2 by immunohistochemistry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17785760", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1395, 
                    "offsetInEndSection": 1547, 
                    "text": "The results support a role for BiotHER testing in better tailoring trastuzumab-based treatments in patients with advanced HER2-amplified breast cancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20590449", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 308, 
                    "offsetInEndSection": 393, 
                    "text": "response to anti-human epidermal growth factor receptor 2 (HER2) therapy trastuzumab."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22112244", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 560, 
                    "offsetInEndSection": 876, 
                    "text": "Although breast cancers that overexpress human epidermal growth factor receptor-2 (HER2) are characterized by a poor prognosis [4,5], higher rates of complete responses are currently achieved in HER2+ patients by standard chemotherapy, mainly in association with trastuzumab [6,7], in comparison with HER2- patients."
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10771788"
                }, 
                {
                    "o": "trastuzumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1545807"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A10771788", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0728747"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A8438296"
                }, 
                {
                    "o": "TRASTUZUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A16756458"
                }, 
                {
                    "o": "http://dbpedia.org/resource/Trastuzumab", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00072"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What are the generic versions of Viagra", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4266960"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22386826", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21591526", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21054594"
            ], 
            "id": "5150b1f4d24251bc0500006a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22386826", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 36, 
                    "text": "Sildenafil citrate (SIL)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21591526", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 242, 
                    "offsetInEndSection": 470, 
                    "text": "generic sildenafil (Unison Laboratories, Thailand) was proved to have the same bioequivalent as in the original formula. The authors conducted a 12-week case series to study the efficacy and safety of Elonza (generic sildenafil)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054594", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 227, 
                    "offsetInEndSection": 291, 
                    "text": "Viagra tablets or generic versions containing sildenafil citrate"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the influence of patent expiry on  ACE inhibitor prescribing.", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000806"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21738055", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16309337", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22521158"
            ], 
            "id": "5150b5c4d24251bc05000070", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21738055", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 151, 
                    "text": "Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16309337", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1130, 
                    "offsetInEndSection": 1333, 
                    "text": "The costs per DDD decreased for all three drugs and, as expected, these costs decrease more rapidly after patent expiry. Significant differences in the trend lines were found for enalapril and fluoxetine"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521158", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 5948, 
                    "offsetInEndSection": 6219, 
                    "text": "Our study demonstrated that prescription switching was from cheaper drugs to more expensive agents, and our patients, with a complexity of clinical conditions, were more likely to be treated with both drugs (subsequent or concurrent use of ACEI and ARB) than ACEIs alone."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521158", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 698, 
                    "text": "The implementation of Taiwan\u2019s stepwise price adjustments, with different adjustment strategies applied to patented and off-patent drugs, has achieved cost savings for off-patent ACEIs, but not for patented ACEI, ARBs and overall renin-angiotensin drugs in the long term. Increases in incident ARB users and possible switching from ACEIs to ARBs have emerged. These results indicate that policy makers in Taiwan should reconsider the appropriateness of the current adjustment strategies applied to patented and off-patent products, since they result in a difference in the profit margin that physicians obtain from these two classes of drugs and affect physicians\u2019 prescribing decisions."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which gene test can be used for the X-linked myotubular myopathy?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020914", 
                "http://www.disease-ontology.org/api/metadata/DOID:14717", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18434328", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11001925", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23346162", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22068590", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9541111", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8664565", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23390130", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22987702", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22435031", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21488203", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20682747", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20434914", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19846786", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19084976", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18358876", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17621527", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17005396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14660569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12391329", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12031625", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11456308", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10714588", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10502779", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10323249", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10063835", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9781038", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9736772", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9305655", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9450905"
            ], 
            "id": "51542dabd24251bc0500007d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23346162", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 122, 
                    "offsetInEndSection": 248, 
                    "text": "Mutations in the myotubularin 1 gene (MTM1) have been identified in the most of the patients with the X-linked recessive form."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23346162", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 475, 
                    "offsetInEndSection": 534, 
                    "text": "their conditions were diagnosed by genetic testing of MTM1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068590", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 175, 
                    "text": "X-linked myotubular myopathy (MTM) is a severe neuromuscular disease of infancy caused by mutations of MTM1, which encodes the phosphoinositide lipid phosphatase, myotubularin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9541111", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 169, 
                    "offsetInEndSection": 338, 
                    "text": "As a gene for X linked MTM was recently identified in Xq28, we screened the obligatory carrier mothers for mutation. We found a 4 bp deletion in exon 4 of the MTM1 gene,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8664565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 88, 
                    "offsetInEndSection": 266, 
                    "text": "X-linked Myotubular Myopathy has clearly shown the benefits to be gained from a multinational research consortium with a common interest in identifying and cloning the MTM1 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434328", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 450, 
                    "text": "Myotubular myopathy (XLMTM, OMIM 310400) is the X-linked and most severe form of a group of muscular disorders, named centronuclear myopathies (CNM), characterized by the presence of hypotrophic myofibers with central nuclei in skeletal muscle (1). Myotubular myopathy, which affects one newborn male in 50\u00a0000 is caused by mutations in the ubiquitously expressed MTM1 gene that codes for a phosphoinositide phosphatase named myotubularin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11001925", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 303, 
                    "text": "Myotubular myopathy (MTM1) is an X-linked disease, characterized by severe neonatal hypotonia and generalized muscle weakness, with pathological features suggesting an impairment in maturation of muscle fibres. The MTM1 gene encodes a protein (myotubularin) with a phosphotyrosine phosphatase consensus."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390130", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 154, 
                    "offsetInEndSection": 272, 
                    "text": "myotubular myopathy (XLMTM), a severe congenital muscular disorder due to loss-of-function mutations in the MTM1 gene,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987702", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 276, 
                    "text": "We established a colony of dogs that harbor an X-linked MTM1 missense mutation.Muscle from affected male dogs exhibits reduction and altered localization of the MTM1 gene product, myotubularin, and provides a model analogous to X-linked myotubular myopathy (XLMTM)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22435031", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 281, 
                    "text": "X-linked myotubular myopathy (XLMTM) is a rare congenital myopathy, usually characterized by severe hypotonia and respiratory insufficiency at birth, in affected, male infants. The disease is causally associated with mutations in the MTM1 gene, coding for phosphatase myotubularin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21488203", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 667, 
                    "offsetInEndSection": 865, 
                    "text": "XLMTM pathogenesis is due to a mutation in the MTM1 gene on Xq28;4,5 it encodes a phosphoinositide lipid phosphatase, which is known as myotubularin and appears to be important in muscle maintenance"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20682747", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 148, 
                    "text": "Mutations in the MTM1 gene encoding myotubularin cause X-linked myotubular myopathy (XLMTM), a well-defined subtype of human centronuclear myopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20682747", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 690, 
                    "offsetInEndSection": 908, 
                    "text": "MTM1 gene sequencing revealed a unique exon 7 variant in all seven affected males, causing a nonconservative missense change, p.N155K, which haplotype data suggest derives from a recent founder in the local population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20434914", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 338, 
                    "text": "X-linked centronuclear myopathy (XLMTM), also called myotubular myopathy, is a severe congenital myopathy characterized by generalized hypotonia and weakness at birth and the typical histological finding of centralization of myo-nuclei. It is caused by mutations in the MTM1 gene encoding the 3-phosphoinositides phosphatase myotubularin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20434914", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 551, 
                    "offsetInEndSection": 576, 
                    "text": "sequencing all MTM1 exons"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19846786", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 377, 
                    "offsetInEndSection": 620, 
                    "text": "X-linked myotubular myopathy (XLMTM), a severe congenital disorder due to loss of function mutations in the MTM1 gene, encoding myotubularin, a phosphoinositide phosphatase thought to have a role in plasma membrane homeostasis and endocytosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19084976", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 357, 
                    "text": "Mutations in the gene encoding the phosphoinositide phosphatase myotubularin 1 protein (MTM1) are usually associated with severe neonatal X-linked myotubular myopathy (XLMTM). However, mutations in MTM1 have also been recognized as the underlying cause of \"atypical\" forms of XLMTM in newborn boys, female infants, female manifesting carriers and adult men."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18358876", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 273, 
                    "text": "X-linked myotubular myopathy (XLMTM), a recessive disorder, is caused by mutations affecting the myotubulatin (MTM1) gene located on the X chromosome. Most of the affected males die in the early postnatal period whereas female carriers are usually asymptomatic."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17621527", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 114, 
                    "offsetInEndSection": 197, 
                    "text": "The authors present a patient with the most severe X-linked recessive type (XLMTM)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17621527", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 380, 
                    "offsetInEndSection": 542, 
                    "text": "The diagnosis was confirmed and further specified by genetic analysis, revealing a novel frameshift mutation (1314-1315insT) of the myotubularin-coding MTM1 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17005396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 106, 
                    "text": "X-linked myotubular myopathy (XLMTM) is a congenital muscle disorder caused by mutations in the MTM1 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14660569", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 135, 
                    "text": "MTM1, the gene encoding myotubularin (MTM1), is mutated in the X-linked myotubular myopathy (XLMTM), a severe genetic muscular disorder"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12391329", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 408, 
                    "text": "Myotubularin is a ubiquitously expressed phosphatase that acts on phosphatidylinositol 3-monophosphate [PI(3)P], a lipid implicated in intracellular vesicle trafficking and autophagy. It is encoded by the MTM1 gene, which is mutated in X-linked myotubular myopathy (XLMTM), a muscular disorder characterized by generalized hypotonia and muscle weakness at birth leading to early death of most affected males."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12031625", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "<div class=\"row\"><div class=\"span7\"><h2 id=\"docTitle\"></h2> </div> </div> <div class=\"row\"> <div class=\"span7\"> <div id=\"viewer\"> <p>X-linked myotubular myopathy (XLMTM; OMIM# 310400) is a severe congenital muscle disease caused by mutations in the myotubularin (MTM1) gene.</p></div></div></div>"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12031625", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 776, 
                    "offsetInEndSection": 870, 
                    "text": "The entire coding sequence of the gene was screened in 10 XLMTM patients using this technique."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12031625", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "X-linked myotubular myopathy (XLMTM; OMIM# 310400) is a severe congenital muscle disease caused by mutations in the myotubularin (MTM1) gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11456308", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 91, 
                    "text": "Mutations in the MTM1 gene cause X-linked recessive myotubular myopathy (XLMTM; MIM310400)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11456308", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 445, 
                    "offsetInEndSection": 666, 
                    "text": "We screened 29 independant patients with XLMTM phenotype and four with centronuclear myopathy. 87% (21/24) of patients with known MTM1 mutations showed abnormal myotubularin levels, including some with missense mutations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714588", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 210, 
                    "text": "X-linked myotubular myopathy (XLMTM) characteristically causes severe or fatal muscle weakness in male infants. Mutations in the gene MTM1, encoding the protein myotubularin, can be identified in most families."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502779", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 336, 
                    "text": "X-linked myotubular myopathy (XLMTM) is a congenital muscular disease characterized by severe hypotonia and generalized muscle weakness, leading in most cases to early postnatal death. The gene responsible for the disease, MTM1, encodes a dual specificity phosphatase, named myotubularin, which is highly conserved throughout evolution."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10323249", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 251, 
                    "text": "X-linked recessive myotubular myopathy (XLMTM) is a muscle disorder usually affecting newborn males. In the majority of cases, muscle weakness and hypotonia lead to a rapid demise at neonatal age. The responsible MTM1 gene is located in proximal Xq28."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9736772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 110, 
                    "text": "X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disorder due to mutations in the MTM1 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9305655", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 313, 
                    "text": "X-linked recessive myotubular myopathy (XLMTM) is characterized by severe hypotonia and generalized muscle weakness, with impaired maturation of muscle fibres. The gene responsible, MTM1, was identified recently by positional cloning, and encodes a protein (myotubularin) with a tyrosine phosphatase domain (PTP)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9450905", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 557, 
                    "text": "X-linked recessive myotubular myopathy (XLMTM; MTM1) is a severe neonatal disorder often causing perinatal death of the affected males. The responsible gene, designated MTM1, was localized to proximal Xq28 and recently isolated. The characterization of MTM1 allowed us to screen for causing mutations in three families, previously investigated by linkage analysis. Using exon amplification, single strand conformation polymorphism, and subsequent sequencing analysis, three new mutations and their mutational origin were characterized by analyzing 10 exons."
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A16765414"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10788614"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11987180", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0410203"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What are the symptoms of abacavir hypersensitivity?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006967", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004342", 
                "http://www.biosemantics.org/jochem#4274474", 
                "http://www.biosemantics.org/jochem#4274473", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0002524", 
                "http://www.biosemantics.org/jochem#4239946"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18855539", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17245797", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12719670", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12869229"
            ], 
            "id": "51542dc3d24251bc0500007e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855539", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 148, 
                    "offsetInEndSection": 286, 
                    "text": "patients receiving abacavir develop a hypersensitivity reaction, characterized by rash, fever and, occasionally, multisystemic involvement"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17245797", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 861, 
                    "offsetInEndSection": 1127, 
                    "text": "The predictors included any one of several specific symptoms commonly found with this reaction, a claims diagnosis of adverse effect of drug, anaphylactic shock or unspecified allergy, and a discontinuation in abacavir prior to completing a 90-day course of therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12719670", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 176, 
                    "offsetInEndSection": 615, 
                    "text": "patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17245797", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 161, 
                    "text": "Abacavir is associated with an infrequent but potentially serious hypersensitivity reaction (HSR) that can include a wide range of signs and symptoms."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869229", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 229, 
                    "offsetInEndSection": 515, 
                    "text": "Rash was associated with hypersensitivity (odds ratio [OR] = 13.1, P = 0.02) as was the presence of nausea (OR = 30, P < 0.001), vomiting (OR = 17.1, P = 0.001) or diarrhoea (OR = 22, P < 0.001). The number of gastrointestinal symptoms was also predictive of hypersensitivity reaction ("
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869229", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 747, 
                    "offsetInEndSection": 957, 
                    "text": "the number of gastrointestinal symptoms (OR = 8.6, P = 0.0032), cough (OR = 0.039, P = 0.02) and rash (OR = 16.9, P = 0.07). Abacavir hypersensitivity is strongly associated with gastrointestinal (GI) symptoms."
                }
            ], 
            "triples": [
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Immunological", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/class", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1297"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12061804"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12061804", 
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1840547"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11948761"
                }, 
                {
                    "o": "ABACAVIR HYPERSENSITIVITY, SUSCEPTIBILITY TO", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11994170"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17030126"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7589770"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A7589770", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1457887"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Mutations in which gene determine response to both erlotinib and gefitinib?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4274201", 
                "http://www.biosemantics.org/jochem#4241662", 
                "http://www.biosemantics.org/jochem#4241661"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23332287", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22738915", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22263058", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21904575", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21777765", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21430269", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20948254", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20705455", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20007486", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19808904", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18997733", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16730855", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16705038", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16049312", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15737014", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23507588", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22920167", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22806307", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20647703", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20512075", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19063875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18799900", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18726117", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17575237", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17145836", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16199108", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16009451", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15329413"
            ], 
            "id": "51542e44d24251bc05000081", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 124, 
                    "text": "Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in non-small-cell lung cancer (NSCLC),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 223, 
                    "offsetInEndSection": 445, 
                    "text": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22738915", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 53, 
                    "offsetInEndSection": 361, 
                    "text": "Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22263058", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 341, 
                    "text": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer (NSCLC). Patients with somatic activating mutations in the EGFR gene have dramatic response initially, but would eventually develop resistance to these TKIs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21904575", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 242, 
                    "offsetInEndSection": 546, 
                    "text": "NSCLCs with EGFR mutations (exon 19 deletions or the exon 21 L858R) attain responses to EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, with improved response rate (RR), progression-free survival (PFS) and in some reports overall survival (OS) when compared with EGFR wildtype (WT) cases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21777765", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 216, 
                    "text": "Patients presenting with non-small cell lung cancer (NSCLC) and active EGFR mutation have a high response rate (60-70%) to EGFR tyrosine kinase inhibitors (TKI) with little immediate progression (primary resistance)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21430269", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 163, 
                    "text": "Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948254", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 141, 
                    "text": "EGFR-TKI yields a long survival period in cases of non-small cell lung cancer (NSCLC), especially those with EGFR gene mutations,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948254", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 582, 
                    "offsetInEndSection": 706, 
                    "text": "Efficacy of erlotinib was recognized in the cases in which disease control was obtained by initial treatment with gefitinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20705455", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 205, 
                    "text": "Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20007486", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 24, 
                    "offsetInEndSection": 188, 
                    "text": "lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib;"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808904", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 204, 
                    "text": "The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808904", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 425, 
                    "offsetInEndSection": 823, 
                    "text": "Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18997733", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 229, 
                    "text": "Patients with advanced pulmonary adenocarcinoma exhibiting overexpression or mutation of epidermal growth factor receptor tend to respond better to targeted therapy with tyrosine kinase inhibitors such as gefitinib and erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730855", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 496, 
                    "text": "Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-small-cell lung cancer (NSCLC), especially in patients with adenocarcinoma and never smokers. Some common somatic mutations in EGFR, including deletion mutations in exon 19 and leucine-to-arginine substitution at amino acid position 858 (L858R) in exon 21, have been examined for their ability to predict sensitivity to gefitinib or erlotinib, which are selective EGFR tyrosine kinase inhibitors (EGFR-TKIs)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16705038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 249, 
                    "text": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16049312", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 196, 
                    "text": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15737014", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 716, 
                    "text": "Somatic gain-of-function mutations in exons encoding the epidermal growth factor receptor (EGFR) tyrosine kinase domain are found in about 10% of non-small cell lung cancers (NSCLCs) from the United States [1,2,3], with higher percentages observed in east Asia [2,4,5,6]. Some 90% of NSCLC-associated mutations occur as either multi-nucleotide in-frame deletions in exon 19, involving elimination of four amino acids, Leu-Arg-Glu-Ala, or as a single nucleotide substitution at nucleotide 2573 (T\u2192G) in exon 21, resulting in substitution of arginine for leucine at position 858 (L858R). Both of these mutations are associated with sensitivity to the small-molecule kinase inhibitors gefitinib or erlotinib"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23507588", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 325, 
                    "offsetInEndSection": 523, 
                    "text": "Epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)(such as gefitinib or erlotinib)treatment of lung cancer harboring EGFR gene mutation is one of the prototypes of such therapies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806307", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 380, 
                    "offsetInEndSection": 630, 
                    "text": "patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647703", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 491, 
                    "offsetInEndSection": 707, 
                    "text": "The evidence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) such as gefitinib and erlotinib was first confirmed as the second-line treatment for non-selective patients with advanced NSCLC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647703", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 927, 
                    "offsetInEndSection": 1402, 
                    "text": "patients with EGFR-mutated advanced NSCLC, the first-line treatment with gefitinib had achieved a significant prolongation of progression-free survival compared with standard platinum doublet chemotherapy in a few phase III trials, and became a new standard of care. Gefitinib is highly effective for patients with advanced NSCLC with EGFR mutation even if their performance status is poor, although one should always pay careful attention to fatal interstitial lung disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512075", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 187, 
                    "text": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19063875", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 226, 
                    "text": "Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the responses to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with non-small-cell lung cancer (NSCLC)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799900", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1051, 
                    "offsetInEndSection": 1393, 
                    "text": "EGFR tyrosine kinase inhibitors (gefitinib, erlotinib), which are molecularly targeted drugs, and it has now become possible to select treatment methods by choosing from a number of anticancer drugs. EGFR tyrosine kinase inhibitors have been demonstrated to have a very high cytoreductive effect on lung cancers that have EGFR gene mutations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726117", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 224, 
                    "offsetInEndSection": 385, 
                    "text": "EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 214, 
                    "offsetInEndSection": 386, 
                    "text": "responsive patients can relapse as a result of selection for EGFR gene mutations that confer resistance to ATP competitive EGFR inhibitors, such as erlotinib and gefitinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145836", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 28, 
                    "offsetInEndSection": 254, 
                    "text": "the epidermal growth factor receptor (EGFR) was a therapeutic target in non-small cell lung cancer (NSCLC) and other cancers led to development of the small-molecule receptor tyrosine kinase inhibitors gefitinib and erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145836", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1387, 
                    "offsetInEndSection": 1501, 
                    "text": "There was a significant correlation between EGFR gene copy number, EGFR gene mutations, and gefitinib sensitivity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199108", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 170, 
                    "text": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16009451", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 262, 
                    "text": "Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329413", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 204, 
                    "text": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329413", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1567, 
                    "offsetInEndSection": 1689, 
                    "text": "frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity."
                }
            ], 
            "triples": [
                {
                    "o": "Gene Mutation", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7647895"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A7850263", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0596611"
                }, 
                {
                    "o": "Gene Mutation", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7850263"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Is the microRNA 132 (miR-132) involved in brain pathologies?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001927", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010336", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001921", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0007420", 
                "http://www.disease-ontology.org/api/metadata/DOID:936", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002545", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002534", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001928"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23144617", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22315408", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21945804", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21813326", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21807765", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20010955", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19557767", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19458943", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21136867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17314675"
            ], 
            "id": "5156be5ed24251bc05000087", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22315408", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1562, 
                    "offsetInEndSection": 1740, 
                    "text": "miR-132 dysregulation and subsequent abnormal expression of miR-132 target genes contribute to the neurodevelopmental and neuromorphological pathologies present in schizophrenia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17314675", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 430, 
                    "offsetInEndSection": 889, 
                    "text": "micro-RNAs encoding miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 are abundantly represented in fetal hippocampus, are differentially regulated in aged brain, and an alteration in specific micro-RNA complexity occurs in Alzheimer hippocampus. These data are consistent with the idea that altered micro-RNA-mediated processing of messenger RNA populations may contribute to atypical mRNA abundance and neural dysfunction in Alzheimer's disease brain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1097, 
                    "offsetInEndSection": 1576, 
                    "text": "Levels of several microRNA (miR-10a, -10b, -212, -132, -495) were significantly altered. One of them (miR-132) has been reported to be highly inducible by growth factors and to be a key regulator of neurite outgrowth. Moreover, miR-132-recognition sequences were detected in the mRNA transcripts of two differentially expressed proteins. MicroRNA may thus represent novel biomarkers for neuronal malfunction and potential therapeutic targets for human neurodegenerative diseases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458943", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 627, 
                    "offsetInEndSection": 769, 
                    "text": "Expression of key neuronal microRNAs-including mir-9/9*, mir-124 and mir-132-is repressed in the brains of human HD patients and mouse models."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19557767", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 224, 
                    "offsetInEndSection": 372, 
                    "text": "To determine if production of miR-132 is regulated by neuronal activity its expression in mouse brain was monitored by quantitative RT-PCR (RT-qPCR)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19557767", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 923, 
                    "offsetInEndSection": 1208, 
                    "text": "Expression levels of primary and mature-miR-132 increased significantly between postnatal Days 10 and 24. We conclude that miR-132 is an activity-dependent microRNA in vivo, and may contribute to the long-lasting proteomic changes required for experience-dependent neuronal plasticity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21945804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 384, 
                    "offsetInEndSection": 529, 
                    "text": "We investigated how prior seizure preconditioning affects the miRNA response to status epilepticus evoked by intra-amygdalar kainic acid in mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21945804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 955, 
                    "offsetInEndSection": 1553, 
                    "text": "Increased miR-132 levels were matched with increased binding to Argonaute-2, a constituent of the RNA-induced silencing complex. In tolerant animals, expression responses of >40% of the injury-group-detected miRNAs differed, being either unchanged relative to control or down-regulated, and this included miR-132. In vivo microinjection of locked nucleic acid-modified oligonucleotides (antagomirs) against miR-132 depleted hippocampal miR-132 levels and reduced seizure-induced neuronal death. Thus, our data strongly suggest that miRNAs are important regulators of seizure-induced neuronal death."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010955", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 204, 
                    "text": "Preconditioning describes the ischemic stimulus that triggers an endogenous, neuroprotective response that protects the brain during a subsequent severe ischemic injury, a phenomenon known as 'tolerance'."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010955", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1135, 
                    "offsetInEndSection": 1542, 
                    "text": "Downregulation of miR-132 is consistent with our finding that preconditioning ischemia induces a rapid increase in MeCP2 protein, but not mRNA, in mouse cortex. These studies reveal that ischemic preconditioning regulates expression of miRNAs and their predicted targets in mouse brain cortex, and further suggest that miRNAs and MeCP2 could serve as effectors of ischemic preconditioning-induced tolerance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 227, 
                    "text": "Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion. MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1117, 
                    "offsetInEndSection": 1302, 
                    "text": "Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1459, 
                    "offsetInEndSection": 1599, 
                    "text": "transgenic HD mice have abnormal miRNA biogenesis. This information should aid in future studies on therapeutic application of miRNAs in HD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21807765", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 976, 
                    "offsetInEndSection": 1630, 
                    "text": "miR-132 directly targets the neuronal splicing factor polypyrimidine tract-binding protein 2 (PTBP2), which protein levels were increased in PSP patients. miR-132 overexpression or PTBP2 knockdown similarly affected endogenous 4R:3R-tau ratios in neuronal cells. Finally, we provide evidence that miR-132 is inversely correlated with PTBP2 during post-natal brain development at the time when 4R-tau becomes expressed. Taken together, these results suggest that changes in the miR-132/PTBP2 pathway could contribute to the abnormal splicing of tau exon 10 in the brain, and sheds light into the potential role played by miRNAs in a subset of tauopathies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21813326", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 7, 
                    "offsetInEndSection": 545, 
                    "text": "reports of microRNA (miR) modulators of both neuronal and immune processes (here termed NeurimmiRs) predict therapeutic potential for manipulating NeurimmiR levels in diseases affecting both the immune system and higher brain functions, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS) and anxiety-related disorders. In our opinion, NeurimmiRs that function within both the nervous and the immune systems, such as miR-132 and miR-124, may act as 'negotiators' between these two interacting compartments."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 467, 
                    "offsetInEndSection": 888, 
                    "text": "of using pairs of brain-enriched plasma microRNA (miRNA), at least one of which is enriched in synapses and neurites, as biomarkers that could differentiate patients with MCI from age-matched controls. The identified biomarker pairs fall into two sets: the \"miR-132 family\" (miR-128/miR-491-5p, miR-132/miR-491-5p and mir-874/miR-491-5p) and the \"miR-134 family\" (miR-134/miR-370, miR-323-3p/miR-370 and miR-382/miR-370)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1040, 
                    "offsetInEndSection": 1096, 
                    "text": "sensitivity and specificity at 79%-100% (miR-132 family)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1174, 
                    "offsetInEndSection": 1410, 
                    "text": "the identified miRNA biomarker pairs successfully detected MCI in majority of patients at asymptomatic stage 1-5 years prior to clinical diagnosis. The reported biomarker pairs also appear useful for detecting age-related brain changes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144617", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1141, 
                    "offsetInEndSection": 1474, 
                    "text": "genes involved in neuronal projection and dendrite development were also altered throughout the disease, culminating in a general decline of gene expression for synaptic proteins. Similarly, deregulated miRNAs such as miR-132-3p, miR-124a-3p, miR-16-5p, miR-26a-5p, miR-29a-3p and miR-140-5p follow concomitant patterns of expression"
                }
            ], 
            "triples": [
                {
                    "o": "Brain", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/citations/10071047"
                }, 
                {
                    "o": "Brain", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/pubmed/10430839"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/12566285", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/citations/12566285"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17397784", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2745360"
                }, 
                {
                    "o": "mmu-mir-132", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17397784"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016246", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=1900370", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=1900368", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011387", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005057", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056890"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23439366", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21441598", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19945378", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20109154", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19706170", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18971321", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17537822", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16545108"
            ], 
            "id": "5157539ed24251bc0500008a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23439366", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 304, 
                    "text": "he CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945378", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 60, 
                    "text": "RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945378", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 127, 
                    "text": "Compelling evidence indicates that the CRISPR-Cas system protects prokaryotes from viruses and other potential genome invaders."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 76, 
                    "text": "RNA in defense: CRISPRs protect prokaryotes against mobile genetic elements."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 588, 
                    "offsetInEndSection": 777, 
                    "text": "n this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20109154", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 503, 
                    "text": "Bacteria have developed several defense mechanisms against bacteriophages over evolutionary time, but the concept of prokaryotic RNA interference mediated defense mechanism against phages and other invading genetic elements has emerged only recently. Clustered regularly interspaced short palindromic repeats (CRISPR) together with closely associated genes (cas genes) constitute the CASS system that is believed to provide a RNAi-like defense mechanism against bacteriophages within the host bacterium."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706170", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3059, 
                    "offsetInEndSection": 3263, 
                    "text": "The recently discovered major prokaryotic phage/plasmid defense system, the CRISPR associated system (CASS) [[22,23], Waters, 2009 #566], also relies on guide RNA that apparently targets invader DNA [24]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706170", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3934, 
                    "offsetInEndSection": 4102, 
                    "text": "Despite general functional analogies, the molecular mechanisms of CASS and eukaryotic RNAi are distinct, and the protein components of the two systems are not homologou"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971321", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 231, 
                    "text": "In many prokaryotes, noncoding RNAs that arise from the clustered regularly interspaced short palindromic repeat (CRISPR) loci are now thought to mediate defense against viruses and other molecular invaders by an RNAi-like pathway."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17537822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 908, 
                    "offsetInEndSection": 1138, 
                    "text": "In a genome, a single CRISPR is generally associated with a family of genes called cas for CRISPR-associated (8,12), encoding proteins showing functional similarity with components of the eukaryotic RNA interference (RNAi) systems"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17537822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1394, 
                    "offsetInEndSection": 1575, 
                    "text": "These observations and the viral origin of spacers have led to the hypothesis that the CRISPR-associated system (CASS) is a prokaryotic defence mechanism against genetic aggressions"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16545108", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 206, 
                    "text": "A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16545108", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2414, 
                    "offsetInEndSection": 2727, 
                    "text": "In contrast, counterparts to the eukaryotic siRNA mechanism so far have not been described in prokaryotes. Here, we apply comparative genomics and in-depth computational analysis of protein and RNA sequences and structures to predict a distinct prokaryotic siRNA-like system and the associated enzymatic apparatus"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16545108", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3460, 
                    "offsetInEndSection": 3867, 
                    "text": ".Independently and almost simultaneously, Jansen and coworkers found [25] that at least several genes from this gene neighborhood were tightly associated with the so-called Clustered Regularly Interspaced Short Palindrome Repeats (CRISPR); the acronym cas (for CRISPR-associated) genes was thus coined. The CRISPR are a distinct class of repetitive elements that are present in numerous prokaryotic genomes."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Is it feasible to determine the complete proteome of yeast?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015003"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23438854", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23334424", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16784548", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15768030", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14730684", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12912986"
            ], 
            "id": "5157fce5d24251bc0500008c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438854", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 101, 
                    "offsetInEndSection": 191, 
                    "text": "or model organisms like yeast, we can now quantify complete proteomes in just a few hours."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334424", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 95, 
                    "text": "A complete mass-spectrometric map of the yeast proteome applied to quantitative trait analysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334424", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 488, 
                    "offsetInEndSection": 806, 
                    "text": "So far, attempts to generate such maps for any proteome have failed to reach complete proteome coverage. Here we use a strategy based on high-throughput peptide synthesis and mass spectrometry to generate an almost complete reference map (97% of the genome-predicted proteins) of the Saccharomyces cerevisiae proteome."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which enzyme is involved in the maintenance of DNA (cytosine-5-)-methylation?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23029374", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22967183", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22898819", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22633409", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22538524", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7638194", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22413869", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22323818", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22284370", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22278882", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22088914", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22072770", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22064703", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22048250", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21913078", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22704242", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21625467", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21559294", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21553025", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21532572", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21518897", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21268065", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20940144", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20864525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20364115", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20139415", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20071334", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20035856", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22073356", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19966177", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19932585", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19789556", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19468253", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19450230", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19417133", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19282482", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19173286", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18922972", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19016755", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18536530", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18302924", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18297739", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17965600", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17929180", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17312023", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16963560", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17033890", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16807237"
            ], 
            "id": "51585b28d24251bc0500008d", 
            "snippets": [
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23029374", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3992, 
                    "offsetInEndSection": 4189, 
                    "text": "Because Dnmt1 is a maintenance DNA methyltransferase, DNA demethylation that is dependent on DNA replication should occur owing to the failure of DNA methylation maintenance in the knockdown cells."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23029374", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 5038, 
                    "offsetInEndSection": 5320, 
                    "text": "In cases of replication-dependent demethylation, a maintenance DNA methyltransferase, Dnmt1, is transiently downregulated in, at least a portion of PGCs at the time of PGC fate determination (E7.25); Dnmt1 is subsequently re-expressed by the time of PGC migration (E8.25) [4], [52]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22967183", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 969, 
                    "offsetInEndSection": 1198, 
                    "text": "his defect does not appear in mouse models with mutations in Dnmt3a and Mthfr genes and, therefore, it is specific for the Dnmt1 gene and is suggestive of a role of DNMT1 in imprint resetting or maintenance in the male germ line."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 667, 
                    "offsetInEndSection": 1261, 
                    "text": "For these elements, the maintenance of DNA methylation during development and aging is important for transcriptional silencing and genome stability [6], [7].The establishment and maintenance of methylation patterns at palindromic CpG sequences (CpG dyads) is performed by three catalytically active DNA methyltransferases (Dnmts). In vitro experiments suggest that Dnmt1 prefers hemimethylated CpG (hemi-mCpG) dyads and maintains the methylation pattern on the newly synthesized strand after replication (maintenance methylation). In vitro, Dnmt1 shows a low activity on unmethylated CpG dyads."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4255, 
                    "offsetInEndSection": 4403, 
                    "text": "Since it is believed that the maintenance of methylation is very stable and occurs semi-conservative, hemimethylated sites should occur very rarely."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22633409", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "Specificity of Dnmt1 for methylation of hemimethylated CpG sites resides in its catalytic domain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1617, 
                    "offsetInEndSection": 1825, 
                    "text": "During DNA replication, the so-called maintenance methyltransferase DNMT1 methylates hemimethylated DNA by copying methylation marks from the parental DNA strand to the newly synthesized daughter strand [10]."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 7132, 
                    "offsetInEndSection": 7304, 
                    "text": "Once the hypermethylation phenotype is established, the maintenance methyltransferase activity of DNMT1 seems to be sufficient to maintain the aberrant methylation pattern."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 5044, 
                    "offsetInEndSection": 5326, 
                    "text": "The observed resistance to demethylation at these loci could be explained by redundant activities in the establishment and maintenance of DNA methylation by DNMT3A and DNMT1, respectively, being capable of activity compensating for the loss of DNMT3B in human cancer cells in vitro."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7638194", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 827, 
                    "offsetInEndSection": 1110, 
                    "text": "We obtained evidence that some 5-methylcytosine residues in these single-stranded DNAs can stimulate de novo methylation of adjacent sites by murine DNA 5-cytosine methyltransferase as effectively as 5-methylcytosine residues in double-stranded DNA stimulate maintenance methylation."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23029374", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3992, 
                    "offsetInEndSection": 4189, 
                    "text": "Because Dnmt1 is a maintenance DNA methyltransferase, DNA demethylation that is dependent on DNA replication should occur owing to the failure of DNA methylation maintenance in the knockdown cells."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23029374", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 5038, 
                    "offsetInEndSection": 5320, 
                    "text": "In cases of replication-dependent demethylation, a maintenance DNA methyltransferase, Dnmt1, is transiently downregulated in, at least a portion of PGCs at the time of PGC fate determination (E7.25); Dnmt1 is subsequently re-expressed by the time of PGC migration (E8.25) [4], [52]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898819", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 249, 
                    "offsetInEndSection": 434, 
                    "text": "We present in vitro evidence that the mammalian de novo DNA methyltransferases DNMT3A and DNMT3B, but not the maintenance enzyme DNMT1, are also redox-dependent DNA dehydroxymethylases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 667, 
                    "offsetInEndSection": 1261, 
                    "text": "For these elements, the maintenance of DNA methylation during development and aging is important for transcriptional silencing and genome stability [6], [7].The establishment and maintenance of methylation patterns at palindromic CpG sequences (CpG dyads) is performed by three catalytically active DNA methyltransferases (Dnmts). In vitro experiments suggest that Dnmt1 prefers hemimethylated CpG (hemi-mCpG) dyads and maintains the methylation pattern on the newly synthesized strand after replication (maintenance methylation). In vitro, Dnmt1 shows a low activity on unmethylated CpG dyads."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1518, 
                    "offsetInEndSection": 1734, 
                    "text": "n vitro analyses furthermore suggest that methylation by Dnmt3b and the maintenance function of Dnmt1 mostly occur in a processive manner, whereas Dnmt3a and the \u201cde novo function\u201d of Dnmt1 are distributive [9]\u2013[12]."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4255, 
                    "offsetInEndSection": 4403, 
                    "text": "Since it is believed that the maintenance of methylation is very stable and occurs semi-conservative, hemimethylated sites should occur very rarely."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 691, 
                    "offsetInEndSection": 807, 
                    "text": "The imprinted genes (Snrpn and H19 (data not shown)), which exclusively depend on Dnmt1 for maintenance methylation."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4550, 
                    "offsetInEndSection": 4629, 
                    "text": "For Dnmt3a and Dnmt3b, we found significant \u201cmaintenance\u201d methylation activity."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761581", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4896, 
                    "offsetInEndSection": 5219, 
                    "text": "Since in vitro Dnmt3a and 3b appear to methylate independent of the methylation status of the CpG dyad, the high contribution of Dnmt3a and 3b to maintain full methylation at CpG dyads following replication might be attributed to targeted and enhanced de novo activity stimulated by the presence of CpG methylation density."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1617, 
                    "offsetInEndSection": 1825, 
                    "text": "During DNA replication, the so-called maintenance methyltransferase DNMT1 methylates hemimethylated DNA by copying methylation marks from the parental DNA strand to the newly synthesized daughter strand [10]."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 17895, 
                    "offsetInEndSection": 18069, 
                    "text": "Once the hypermethylation phenotype is established, the methylation pattern is maintained by the maintenance methyltransferase DNMT1 and becomes independent of DNMT3 enzymes."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 5044, 
                    "offsetInEndSection": 5326, 
                    "text": "The observed resistance to demethylation at these loci could be explained by redundant activities in the establishment and maintenance of DNA methylation by DNMT3A and DNMT1, respectively, being capable of activity compensating for the loss of DNMT3B in human cancer cells in vitro."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563479", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 7132, 
                    "offsetInEndSection": 7304, 
                    "text": "Once the hypermethylation phenotype is established, the maintenance methyltransferase activity of DNMT1 seems to be sufficient to maintain the aberrant methylation pattern."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22538524", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 903, 
                    "offsetInEndSection": 1035, 
                    "text": "Direct comparison to met1 plants, deficient in maintenance methyltransferase MET1, showed higher sensitivity of ddm1 plants to NaCl."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7638194", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 827, 
                    "offsetInEndSection": 1110, 
                    "text": "We obtained evidence that some 5-methylcytosine residues in these single-stranded DNAs can stimulate de novo methylation of adjacent sites by murine DNA 5-cytosine methyltransferase as effectively as 5-methylcytosine residues in double-stranded DNA stimulate maintenance methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22413869", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1358, 
                    "offsetInEndSection": 1872, 
                    "text": "De novo methylation and maintenance methylation are distinct processes that are required for the establishment and inheritance of tissue-specific methylation patterns, especially during implantation. Three main DNA methyltransferase enzymes (DNMT) including DNMT1, DNMT3A and DNMT3B have been characterized [10]. DNMT1, with its high affinity for hemimethylated DNA in vitro, predominantly catalyzes maintenance methylation via binding to proliferating cell nuclear antigen in replication foci during S phase [11]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323818", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 147, 
                    "text": "DNMT1, the major maintenance DNA methyltransferase in animals, helps to regulate gene expression, genome imprinting, and X-chromosome inactivation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22284370", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 456, 
                    "offsetInEndSection": 959, 
                    "text": "Failure in proper maintenance of methylation patterns can result in development of disease states such as cancer [2,3]. Thus, it is essential to faithfully maintain DNA methylation patterns in differentiated cells through somatic divisions.In mammals, the de novo DNA methytransferases, DNMT3A/3B, primarily establish the methylation patterns during embryonic development [4] and later maintain them in differentiated tissues through cooperation with the maintenenace DNA methyltransferase, DNMT1 [5-7]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22284370", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1132, 
                    "offsetInEndSection": 1580, 
                    "text": "While DNMT1 transiently interacts with the chromatin and primarily performs its maintenance activity in association with the replication fork, DNMT3A/3B remain preferentially bound to nucleosomes in chromatin regions containing methylated repeats and CpG islands, which stabilizes these proteins and assists in faithful propagation of DNA methylation within the methylated domains through cooperative activity of DNMT3A/3B and DNMT1 enzymes [9-11]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22278882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 14, 
                    "offsetInEndSection": 200, 
                    "text": "A methyltransferase1 (DNMT1) has been characterized as a maintenance DNA methyltransferase enzyme able to catalyze the addition of a methyl group to cytosines adjacent to guanines (1,2)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088914", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 634, 
                    "offsetInEndSection": 805, 
                    "text": "Correct establishment and maintenance of methylation patterns at imprinted genes has been associated with placental function and regulation of embryonic/fetal development."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22072770", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 107, 
                    "text": "Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22072770", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1191, 
                    "offsetInEndSection": 1301, 
                    "text": "Thus, differential expression of CTCF and DNMT1 and -3B is not critical for maintenance of restricted latency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22064703", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 220, 
                    "text": "Recent studies demonstrate that UHRF1 is required for DNA methylation maintenance by targeting DNMT1 to DNA replication foci, presumably through its unique hemi-methylated DNA-binding activity and interaction with DNMT1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22048250", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 134, 
                    "offsetInEndSection": 476, 
                    "text": "It is generally accepted that DNA methyltransferases carry out specific and non-overlapping functions, Dnmt3a and Dnmt3b being responsible for the establishment of methylation around the time of implantation and Dnmt1 ensuring that methylation is faithfully copied to daughter cells via what has come to be known as \"maintenance methylation.\""
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22048250", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 622, 
                    "offsetInEndSection": 768, 
                    "text": "A new model is emerging that takes into account a contribution of the de novo enzymes Dnmt3a and Dnmt3b in the maintenance of the DNA methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22048250", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1089, 
                    "offsetInEndSection": 1270, 
                    "text": "We propose here observations in support of the hypothesis that the maintenance of methylation and subsequent silencing of a handful of germ line genes requires Dnmt3b but not Dnmt1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913078", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 162, 
                    "offsetInEndSection": 407, 
                    "text": "DNA methyltransferase 1 (Dnmt1) is the enzyme responsible for maintaining the methylation marks through cell division. However, the de novo methyltransferases, Dnmt3a and Dnmt3b, can also contribute to the maintenance of the methylation pattern."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704242", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 569, 
                    "offsetInEndSection": 780, 
                    "text": "These new data support the notion that de novo DNMTs also have an important role in the maintenance of DNA methylation and suggest that, in addition to acting as oncogenes, they also behave as tumor suppressors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625467", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2306, 
                    "offsetInEndSection": 2624, 
                    "text": "Although the role of Dnmt1 in the maintenance of methylation at imprinted genes in post-implantation embryos and somatic cells is well established [20], there have been conflicting and puzzling results related to how these imprints are maintained in cleavage-stage preimplantation embryos [21], [22], [23], [24], [25]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625467", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2835, 
                    "offsetInEndSection": 2985, 
                    "text": "This seemed to exclude the possibility that Dnmt1 could be an imprinting maintenance enzyme functioning during preimplantation development [21], [22]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559294", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 967, 
                    "offsetInEndSection": 1231, 
                    "text": "DNA methylation occurs via two major classes of enzymatic reaction: maintenance-type methylation and de novo methylation. Maintenance-type methylation activity involves the maintenance of methylation patterns in the daughter strands of every DNA replication cycle."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559294", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1517, 
                    "offsetInEndSection": 1658, 
                    "text": "DNMT1 is a member of the maintenance-type methyltransferase family, which is responsible for the maintenance of DNA methylation patterns [5]."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559294", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2074, 
                    "offsetInEndSection": 2253, 
                    "text": "Our results in this investigation suggest that cDNMT1, cDNMT3A, and cDNMT3B are highly active in early embryos for the maintenance of methylation patterns and de novo methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21553025", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3012, 
                    "offsetInEndSection": 3093, 
                    "text": "Dnmt1 is the maintenance DNA methyltransferase in the mouse (Bestor et al. 1988)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21553025", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7, 
                    "offsetInEndSection": 249, 
                    "text": "Reduced dosage of Dnmt1 does not affect overall telomere length in vivoDnmt1 is a maintenance DNA methyltransferase, and its complete loss has previously been reported to lead to telomere elongation in cultured ES cells (Gonzalo et al. 2006)."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21532572", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 100, 
                    "offsetInEndSection": 253, 
                    "text": "Studies have shown that maintenance of methylation could last past the replication stage with DNMT1 continuously loaded on heterochromatin after S phase."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21532572", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 1017, 
                    "offsetInEndSection": 1384, 
                    "text": "Previous studies showed the replication machinery loading of DNMT1 is not required for the genome methylation maintenance21, suggesting DNMT1 binding to heterochromatin after S phase could be involved in the prolonged methylation maintenance, recruitment of histone deacetylases and chromatin stability preservation in the transcriptionally repressed genome region20."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21518897", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 89, 
                    "text": "Structural insight into maintenance methylation by mouse DNA methyltransferase 1 (Dnmt1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21518897", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 103, 
                    "offsetInEndSection": 367, 
                    "text": "The DNA methyltransferase Dnmt1 is responsible for the propagation of methylation patterns to the next generation via its preferential methylation of hemimethylated CpG sites in the genome; however, how Dnmt1 maintains methylation patterns is not fully understood."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21268065", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "Usp7 and Uhrf1 control ubiquitination and stability of the maintenance DNA methyltransferase Dnmt1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21268065", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 219, 
                    "text": "In mammals Dnmt1 is the DNA methyltransferase chiefly responsible for maintaining genomic methylation patterns through DNA replication cycles, but how its maintenance activity is controlled is still not well understood."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20864525", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 706, 
                    "offsetInEndSection": 863, 
                    "text": "DMAP1 is a potent activator of DNMT1 methylation in vitro, suggesting that DMAP1 is a co-repressor that supports the maintenance and de novo action of DNMT1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20364115", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 173, 
                    "offsetInEndSection": 303, 
                    "text": "A group of enzymes, the DNA methyltransferases (DNMTs) tightly regulate both the initiation and maintenance of these methyl marks."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 203, 
                    "offsetInEndSection": 545, 
                    "text": "Occurring exclusively at cytosine within CpG dinucleotides in mammals, DNA methylation is coordinated by a family of DNA methyltransferases (DNMTs)5 comprising DNMT1, -3A, -3B, and -3L. DNMT1 is the \u201cmaintenance\u201d methyltransferase that ensures faithful transmission of methylation profile from maternal to daughter cells during cell division."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071334", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 900, 
                    "offsetInEndSection": 1099, 
                    "text": "DNMT1 acts as a \u201cmaintenance\u201d methyltransferase, playing an essential role in the faithful propagation of the genomic methylation profile from mother to daughter cells following cell division (30). E"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035856", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 232, 
                    "offsetInEndSection": 408, 
                    "text": "Maintenance of DNA methylation depends on DNA methyltransferase 1 (Dnmt1) and intracellular S-adenosylmethionine (SAM) levels, and is inhibited by S-adenosylhomocysteine (SAH)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 262, 
                    "text": "In mammals, the establishment and maintenance of DNA methylation patterns play an important role in the regulation of gene expression and genomic imprinting, and are crucial for normal embryonic development (reviewed in: Bird, 2002; Li, 2002; Reik et al., 2001)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073356", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 365, 
                    "text": "DNA methyltransferases (Dnmts) are responsible for the establishment and the maintenance of methylation patterns. In contrast to Dnmt3a and 3b, which catalyze de novo methylation of unmethylated DNA, Dnmt1 is a maintenance enzyme that methylates hemi-methylated CpG dinucleotides in the nascent strand of DNA after replication (reviewed in: Bestor, 2000; Li, 2002)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19468253", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 314, 
                    "offsetInEndSection": 416, 
                    "text": "While DNMT3a is mostly involved in de novo methylation, DNMT1 acts as a maintenance methyltransferase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789556", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 252, 
                    "offsetInEndSection": 541, 
                    "text": "We propose a new model that suggests that the maintenance of DNA methylation relies not only on the recognition of hemimethylated DNA by DNA methyltransferase 1 (DNMT1) but also on the localization of the DNMT3A and DNMT3B enzymes to specific chromatin regions that contain methylated DNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19450230", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 130, 
                    "offsetInEndSection": 321, 
                    "text": "The maintenance methylase, DNMT1 (DNA methyltransferase 1), is a prominent enzyme in the process that is linked to DNA replication and drives the heritable nature of epigenetic modifications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417133", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 181, 
                    "offsetInEndSection": 341, 
                    "text": "We have shown previously that these drugs selectively and rapidly induce degradation of the maintenance DNA methyltransferase (DNMT) 1 by a proteasomal pathway."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19282482", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 207, 
                    "text": "Inheritance of epigenetic information encoded by cytosine DNA methylation patterns is crucial for mammalian cell survival, in large part through the activity of the maintenance DNA methyltransferase (DNMT1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20940144", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 295, 
                    "offsetInEndSection": 500, 
                    "text": "We and others have shown that DNA methyltransferase 1 (DNMT1), the maintenance methyltransferase, contributes to the cellular response to DNA damage, yet DNMT1's exact role in this process remains unclear."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20139415", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1969, 
                    "offsetInEndSection": 2264, 
                    "text": "DNMT1 is the most abundant methyltransferase in mammalian cells. It is responsible for the maintenance of methylation patterns in DNA (20) and as such shows a preference for hemimethylated over unmethylated substrates (21,22). DNMT1 has been shown to interact with a wide range of proteins (23)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19173286", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 301, 
                    "offsetInEndSection": 494, 
                    "text": "The maintenance function of Dnmt1 is regulated by its large regulatory N-terminal domain that interacts with other chromatin factors and is essential for the recognition of hemi-methylated DNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922972", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 146, 
                    "offsetInEndSection": 380, 
                    "text": "In the absence of a human pituitary tumor cell line, small interfering RNA-mediated knockdown of the maintenance methyltransferase DNA methyltransferase (cytosine 5)-1 (Dnmt1) was used in the murine pituitary adenoma cell line AtT-20."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19016755", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 806, 
                    "offsetInEndSection": 962, 
                    "text": "We found that DNA methylation was maintained only when exogenous DNA methyltransferase 1 (DNMT1) and S-adenosyl methionine (SAM) were added to the reaction."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18536530", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 357, 
                    "offsetInEndSection": 638, 
                    "text": "We examined the expression of DNMT1 and DNMT3a, representative of a maintenance and de novo methyltransferase respectively, in response to in-vitro depolarization of cortical neurons, using standard techniques such as high potassium (KCl) or the sodium channel agonist veratridine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18302924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 349, 
                    "text": "DNA methyltransferase-1 (DNMT1) has a higher specific activity on hemimethylated DNA than on unmethylated DNA, but this preference is too small to explain the faithful mitotic inheritance of genomic methylation patterns. New genetic studies in plants and mammals have identified a novel factor that increases the fidelity of maintenance methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18297739", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 347, 
                    "offsetInEndSection": 520, 
                    "text": "Dnmt1 is the main maintenance methyltransferase in the mouse and its expression is regulated by a splicing mechanism that dictates the expression of stage-specific isoforms."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965600", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 90, 
                    "text": "Phosphorylation of serine-515 activates the Mammalian maintenance methyltransferase Dnmt1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965600", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 93, 
                    "text": "DNA methyltransferase 1 methylates hemi-methylated CG sites generated during DNA replication."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929180", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 166, 
                    "text": "DNA methylation is catalyzed by a family of DNA methyltransferases (DNMTs) including the maintenance enzyme DNMT 1 and de novo methyltransferases DNMT 3a and DNMT 3b."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17312023", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 123, 
                    "text": "DNMT1 but not its interaction with the replication machinery is required for maintenance of DNA methylation in human cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17312023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 246, 
                    "offsetInEndSection": 757, 
                    "text": "DNA methylation patterns are established and maintained by three major DNA methyltransferases (DNMTs): DNMT1, DNMT3A, and DNMT3B. DNMT1 is the only mammalian DNMT that has a preference for hemimethylated CpG sites (Bestor and Ingram, 1983; Pradhan et al., 1999) and localizes at both replication foci and repair sites because of its interaction with the proliferating cell nuclear antigen (PCNA; Leonhardt et al., 1992; Chuang et al., 1997; Margot et al., 2001; Easwaran et al., 2004; Mortusewicz et al., 2005)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17312023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 757, 
                    "offsetInEndSection": 944, 
                    "text": "As a result of these observations and data from genetic manipulations in the mouse, DNMT1 is thought to be the major enzyme responsible for postreplicative maintenance of DNA methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16963560", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1200, 
                    "offsetInEndSection": 1327, 
                    "text": "Our data suggest that DNMT1 might be essential for maintenance of DNA methylation, proliferation, and survival of cancer cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17033890", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "Maintenance DNA methyltransferase (Met1) and silencing of CpG-methylated foreign DNA in Volvox carteri."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17033890", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 220, 
                    "text": "DNA methylation plays an important role in the gene-silencing network of higher eukaryotes. We have analyzed the 21.5-kb maintenance methyltransferase (M-MTase) gene, met1, of the multicellular green alga Volvox carteri."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807237", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 152, 
                    "text": "DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Does physical activity influence gut hormones?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19737911", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21615652", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21554896", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20061436", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23402716", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23111564", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22619704", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21927572", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19158129", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18987287", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17470516", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11321513", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2888163"
            ], 
            "id": "5158644cd24251bc0500008e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737911", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1052, 
                    "offsetInEndSection": 1259, 
                    "text": "Increases in blood PYY(3-36) levels were dependent on the exercise intensity (effect of session: P<0.001 by two-way ANOVA), whereas those in GLP-1 levels were similar between two different exercise sessions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615652", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1289, 
                    "offsetInEndSection": 1430, 
                    "text": "A decrease in serum leptin levels (-48.4%, p < 0.001) was observed after intervention without changes in total peptide YY and insulin levels."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554896", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1576, 
                    "offsetInEndSection": 1765, 
                    "text": "ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20061436", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1102, 
                    "offsetInEndSection": 1165, 
                    "text": "Hunger and gut hormones remained unchanged during the bed rest."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23402716", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1038, 
                    "offsetInEndSection": 1309, 
                    "text": "weight-bearing exercise has a greater exercise-induced appetite suppressive effect compared with non-weight-bearing exercise, and both forms of exercise lowered acylated ghrelin and increased total PYY, but the changes did not differ significantly between exercise modes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23111564", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 929, 
                    "offsetInEndSection": 1211, 
                    "text": "Appetite (P\u00a0<\u00a00.0005) and acylated ghrelin (P\u00a0<\u00a00.002) were suppressed during exercise but more so during SIE. Peptide YY increased during exercise but most consistently during END (P\u00a0<\u00a00.05). Acylated ghrelin was lowest in the afternoon of SIE (P\u00a0=\u00a00.018) despite elevated appetite"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22619704", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2422, 
                    "offsetInEndSection": 2647, 
                    "text": "he recent discovery of several gut peptides involved in appetite regulation and energy homeostasis provides an attractive mechanism to explain how exercise reduces hunger/appetite in some conditions and increases it in others"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22619704", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2649, 
                    "offsetInEndSection": 2908, 
                    "text": "Alterations in circulating ghrelin, the only known orexigenic gut peptide, along with the anorexigenic gut peptides peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) may work in concert to influence exercise-associated alterations in hunger and food intake"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22619704", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 10363, 
                    "offsetInEndSection": 10457, 
                    "text": "we elected to evaluate the effect of walking and running on appetite and gut hormone responses"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22619704", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 331, 
                    "offsetInEndSection": 523, 
                    "text": "Short-lived increases in circulating concentrations of the anorexogenic peptides and a trend for an increase in ghrelinacyl following exercise were apparent in the runners but not the walkers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21927572", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1298, 
                    "offsetInEndSection": 1791, 
                    "text": "Following the pre-exercise meal, ghrelin was suppressed ~17% and insulin and PYY were elevated ~157 and ~40%, respectively, relative to fasting (day 7). Following exercise, PYY, ghrelin, and GH were significantly (p < 0.0001) increased by ~11, ~16 and ~813%, respectively. The noted disruption in the typical inverse relationship between ghrelin and PYY following exercise suggests that interaction of these peptides may be at least partially responsible for post-exercise appetite suppression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158129", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 810, 
                    "offsetInEndSection": 926, 
                    "text": "Plasma levels of PYY and GLP-1 were increased by exercise, whereas plasma ghrelin levels were unaffected by exercise"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18987287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1370, 
                    "offsetInEndSection": 1457, 
                    "text": "These findings suggest ghrelin and PYY may regulate appetite during and after exercise,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18987287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 913, 
                    "offsetInEndSection": 1125, 
                    "text": "significant (P < 0.05) interaction effects for hunger, acylated ghrelin, and PYY, indicating suppressed hunger and acylated ghrelin during aerobic and resistance exercise and increased PYY during aerobic exercise"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470516", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1682, 
                    "offsetInEndSection": 1774, 
                    "text": "'exercise-induced anorexia' may potentially be linked to increased PYY, GLP-1 and PP levels."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470516", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1271, 
                    "offsetInEndSection": 1393, 
                    "text": "Hunger scores and PYY, GLP-1 and PP levels showed an inverse temporal pattern during the 1-h exercise/control intervention"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470516", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 744, 
                    "offsetInEndSection": 969, 
                    "text": "Exercise significantly increased mean PYY, GLP-1 and PP levels, and this effect was maintained during the post-exercise period for GLP-1 and PP. No significant effect of exercise was observed on postprandial levels of ghrelin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11321513", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2370, 
                    "offsetInEndSection": 2469, 
                    "text": "following blood donation the strenuous exercise resulted in a marked reduction in the plasma leptin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11321513", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1977, 
                    "offsetInEndSection": 2362, 
                    "text": "We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2888163", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 729, 
                    "offsetInEndSection": 811, 
                    "text": "the unrestricted exercise group has a significantly elevated SRIF-LI concentration"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Carbapenemase-producing gram-negative bacteria is a major health concern because their resistance to antibiotics.\nList the most frequent carbapenemases found in Enterobacteriaceae.", 
            "concepts": [
                "http://www.uniprot.org/uniprot/BLAN_ENTCL", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004755", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004756", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004352", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024881", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046677", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000903", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015780"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23114438", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22796889", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22553235", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22383444", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20542902", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20534805", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20237104", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17594211", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18070960", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19386850", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17227206", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20686438", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20960935", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20649801"
            ], 
            "id": "515870cdd24251bc0500008f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23114438", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 513, 
                    "offsetInEndSection": 653, 
                    "text": "The most frequent carbapenemases in Enterobacteriaceae were OXA-48, KPC and VIM-1; in P. aeruginosa it was VIM-2 and in A. baumannii OXA-23."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22796889", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 485, 
                    "offsetInEndSection": 576, 
                    "text": "bla(IMP), bla(VIM), bla(SPM), bla(SIM) and bla(GIM), and of bla(KPC), bla(NDM) and bla(OXA-"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553235", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 147, 
                    "text": "Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by matrix-assisted laser desorption ionization-time of flight mass spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22383444", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 121, 
                    "text": "The Check-MDR CT102 DNA microarray enables detection of the most prevalent carbapenemases (NDM, VIM, KPC, OXA-48 and IMP)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20542902", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 642, 
                    "offsetInEndSection": 706, 
                    "text": "63 KPC producers, 47 MBL producers, and 31 KPC and MBL producers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20534805", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 347, 
                    "offsetInEndSection": 475, 
                    "text": "OXA-48 producers were poorly detected, but all systems reliably detected isolates with KPC and most with metallo-carbapenemases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20237104", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 347, 
                    "offsetInEndSection": 699, 
                    "text": "Producers of IMP-, VIM-, and KPC-type carbapenemases with high levels of resistance to cephalosporins and to carbapenems were detected at 1x10(1) CFU/ml. The OXA-48 producers were not detected on ChromID ESBL medium unless coexpressing ESBLs, whereas carbapenemase-producing isolates with MICs of <4 microg/ml were not detected on CHROMagar KPC medium."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18070960", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 288, 
                    "offsetInEndSection": 641, 
                    "text": "The most frequent carbapenemase was KPC-2 or -3 (73 strains), followed by VIM-1 (14), IMP-1 (11), SME-2 (5), and NMC-A (1). All serine carbapenemases were detected in the United States, while MbetaL-producing strains were isolated in Europe. Carbapenemase-producing Enterobacteriaceae showed high rates of resistance to most antimicrobial agents tested."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19386850", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1672, 
                    "offsetInEndSection": 1848, 
                    "text": "By using this methodology, isolates producing KPC, GES, Sme, IMI, and NMC-A carbapenemases were successfully distinguished from those producing other classes of beta-lactamases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17227206", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 887, 
                    "offsetInEndSection": 975, 
                    "text": "KPC-2 and KPC-3 were the most frequently occurring carbapenemases (24 isolates, 20.2%) i"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20649801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 167, 
                    "offsetInEndSection": 243, 
                    "text": "K. pneumoniae strains with known KPC (n\u2003=\u200331) or VIM (n\ufffd\ufffd\ufffd=\u200320) carbapenemases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960935", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 140, 
                    "text": "Carbapenemases including Klebsiella pneumoniae carbapenemases (KPC) are widespread among clinical isolates in the family Enterobacteriaceae."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20686438", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "Outbreak of vim-1-carbapenemase-producing Enterobacter cloacae in a pediatric intensive care unit."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20686438", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 340, 
                    "offsetInEndSection": 498, 
                    "text": "mergence of pediatric infections caused by carbapenemases-producing Enterobacteriaceae is a critical issue as they are resistant to most \u03b2-lactam antibiotics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17227206", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1147, 
                    "offsetInEndSection": 1531, 
                    "text": "SME-2-producing S. marcescens were isolated in the New York City area, Texas, and Ohio, while NMC-A was found in one E. cloacae strain from New York. In contrast, metallo-beta-lactamases were prevalent in Europe. IMP-1-producing E. cloacae (11 isolates) were detected in Turkey, while VIM-1-producing strains were found in Italy (Enterobacter spp.) and Greece (Klebsiella pneumoniae)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19386850", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 402, 
                    "offsetInEndSection": 553, 
                    "text": "d several simple confirmatory methods that allow the recognition of bacteria producing class A carbapenemases, including KPC, Sme, IMI, NMC-A, and GES,"
                }
            ], 
            "triples": [
                {
                    "o": "Enterobacteriaceae", 
                    "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                    "s": "http://linkedlifedata.com/resource/pubmed/mesh/Enterobacteriaceae"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is factor XI deficient in Hemophilia C?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:2229", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005173", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005172", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006467"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20485963", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18378181", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18160615", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8277060", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1546275"
            ], 
            "id": "51588c1ad24251bc05000094", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485963", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 152, 
                    "text": "Factor XI deficiency is a rare hematologic disorder. Hemophilia C (factor XI deficiency) affects both genders and it is usually asymptomatic,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18378181", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 86, 
                    "text": "Congenital factor XI deficiency (also known as the Rosenthal syndrome or hemophilia C)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18160615", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 21, 
                    "offsetInEndSection": 290, 
                    "text": "rare case of an acute cerebral aneurysm rupture in a patient with a known factor XI deficiency. Aneurysmal subarachnoid hemorrhage (SAH) accounts for a high mortality and morbidity rate. When SAH is associated with an inherited coagulation disorder such as hemophilia C"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8277060", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 127, 
                    "offsetInEndSection": 162, 
                    "text": "Factor XI deficiency (Hemophilia C)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1546275", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 47, 
                    "text": "Factor XI deficiency, also called hemophilia C,"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Have Quantitative Trait Loci affecting splicing (splicing QTLs) been linked to disease?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040641", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019655", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056426", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045292", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008380", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012326", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045291", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000398", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017398", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043484", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022821", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000381", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006376", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000389", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000395"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18962861", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23133393", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22723018", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21846806", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20948966", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19915720", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20707912", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22784570", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21628452", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20856809"
            ], 
            "id": "5158a5b8d24251bc05000097", 
            "snippets": [
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22784570", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 9148, 
                    "offsetInEndSection": 9358, 
                    "text": "Among nine splice variants of TRPM3, splice variants 7 and 8 do not include the three SNPs identified (Figure 5(a)). This observation suggests that SNPs can make different functional effects on splice variants."
                }, 
                {
                    "beginSection": "sections.6", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21846806", 
                    "endSection": "sections.6", 
                    "offsetInBeginSection": 13697, 
                    "offsetInEndSection": 13886, 
                    "text": "Three c3-eQTLs (Acox2, Trak2, and Pex11b) also show sequence variation affecting splice sites, potentially leading to aberrant splicing or altered transcript stability and protein function."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948966", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2824, 
                    "offsetInEndSection": 3475, 
                    "text": "Using computational methods we collected data from publicly available sources to find candidate STEPs in consensus regions of introns and in transcripts displaying alternative splicing around the candidate STEP. We further examined candidate STEPs in silico for splice site recognition using sequences containing each SNP allele and for expressed sequence tag (EST) evidence of intron retention where possible. Presented here are results of this search, along with 21 potential intron retaining or exon extending STEPs where allele population frequency and EST data has shown a disproportionate retention of one STEP allele, as well as a spliced form."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948966", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 558, 
                    "offsetInEndSection": 1536, 
                    "text": "Such pre-mRNA splicing may be tissue-specific and is equivalent between all individuals in a population, but some is individual-specific because the alleles of a polymorphism differentially affect splicing through their presence in or effect on splicing sequence motifs. For example, a branch point SNP, rs17266594 leads to the \u03942 isoform of BANK1 protein which lacks a putative IP3R-binding domain, altering B cell signalling and activity and SLE disease risk [4]. Similarly, SNP rs6897932 in a putative exonic splice enhancer in IL7R seems to affect exon 6 splicing, amounts of soluble versus membrane-bound IL7R and risks of multiple sclerosis [5] and type 1 diabetes [6].In a study of the human insulin gene (INS), we recognised in silico, subsequently confirmed in vitro and in silico [7], and later in vivo by others [8], [9], that polymorphism in a 5\u2032 non-coding intron (separating non-coding exon 1 from coding exon 2) could influence intron retention in the final mRNA."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20856809", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 16747, 
                    "offsetInEndSection": 17531, 
                    "text": "There were no differences in gene-level expression of the candidate genes between strains that reached genome-wide significance. When we investigated exon-level expression of the genes, there were no differences between parental strains. However, exon 4 of ZEB1 had much lower expression compared to all other exons of this gene, indicating alternative splicing (Figure 6A). Interestingly, ZEB1 produces two splice variants, Zfhep1 (NP_037296.1, ENSRNOT00000046013) and Zfhep2 (ZEB1, ENSRNOT00000024336), for which exon 4 (NP_037296.1 exon 1) is specific for the Zfhep1 variant (Figure 6B). The resulting protein differs in the first zinc finger cluster (Figure 6C). This prompted us to investigate if splice-variant specific differences of ZEB1 could be involved in regulation of EAE"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001173", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21677849", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23039946"
            ], 
            "id": "51593dc8d24251bc05000099", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23039946", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 111, 
                    "text": "Complete genome sequence and metabolic potential of the quinaldine-degrading bacterium Arthrobacter sp. Rue61a."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21677849", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 80, 
                    "text": "Complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3)."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21677849", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 214, 
                    "offsetInEndSection": 338, 
                    "text": "The genome project is deposited in the Genome OnLine Database [18] and the complete genome sequence is deposited in GenBank."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Proteomic analyses have revealed proteins associated with the triple-negative breast cancers. List some proposed proteins.", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:0060081", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23436753", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23172894", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22692575", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21630460", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19416831", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22934887", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22178447", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20068102", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20005186", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19485423", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22414580"
            ], 
            "id": "51595fb0d24251bc0500009c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436753", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 839, 
                    "offsetInEndSection": 969, 
                    "text": "Some of these proteins are of outstanding interest in the biology and clinical management of this disease, such as CD44 and PARP1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172894", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1254, 
                    "offsetInEndSection": 1532, 
                    "text": "We present here our results, including a large cumulative database of proteins based on the analysis of 78 TNBCs, and the identification and validation of one specific protein, Mage-A4, which was expressed in a significant fraction of TNBC and Her2-positive/ER negative lesions."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172894", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 216, 
                    "text": "Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22692575", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 912, 
                    "offsetInEndSection": 1334, 
                    "text": "Further, we performed comparative quantitative proteomic and gene array analyses of these cells and identified potential novel markers of breast cancer cells with tumor-initiating features, such as lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14 and mucin 1 (MUC1), as well as a novel 31-gene signature capable of predicting distant metastasis in cohorts of estrogen receptor-negative human breast cancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416831", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1503, 
                    "offsetInEndSection": 1718, 
                    "text": "he results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp90 inhibitor PU-H71 for clinical trials involving patients with TNBC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19485423", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 227, 
                    "offsetInEndSection": 511, 
                    "text": "We obtained differential expression patterns for several glycolytic enzymes (as for example MDH2, PGK1, TKT, Aldolase1), cytokeratins (CK7, 8, 9, 14, 17, 19), further structure proteins (vimentin, fibronectin, L-plastin), for NME1-NME2, lactoferrin, and members of the Annexin family."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20005186", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1689, 
                    "offsetInEndSection": 2085, 
                    "text": "he expression of calreticulin, cellular retinoic acid-binding protein II, chloride intracellular channel protein 1, EF-1-beta, galectin 1, peroxiredoxin-2, platelet-derived endothelial cell growth factor, protein disulfide isomerase and ubiquitin carboxyl-terminal hydrolase 5 were further validated using a tissue microarray containing 70 malignant breast carcinomas of various grades of atypia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 484, 
                    "offsetInEndSection": 554, 
                    "text": "The first is characterized by high expression of Stat1, Mx1, and CD74."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 915, 
                    "offsetInEndSection": 1330, 
                    "text": "This effect was accompanied with a marked increase in the membrane expression of beta-catenin, MUC18, plexins, integrins, and other proteins involved in cell adhesion and cancer metastasis. Taken together, our results show that Stat1/CD74 positive triple-negative tumors are more aggressive and suggest an approach for development of better diagnostics and more targeted therapies for triple negative breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22414580", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1033, 
                    "offsetInEndSection": 1185, 
                    "text": "Proteomic analysis also identified high levels of IDH2 and CRABP2 and low levels of SEC14L2 to be prognostic markers for overall breast cancer survival."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20068102", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 651, 
                    "offsetInEndSection": 796, 
                    "text": "Proteomic and validation immunohistochemical analyses revealed that alpha-defensins (DEFA) were overexpressed in tumors from patients with a pCR."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934887", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 583, 
                    "offsetInEndSection": 913, 
                    "text": "The expression of a selected group of high abundance and/or breast cancer-specific potential biomarkers including thromobospondin 1, galectin-3 binding protein, cathepsin D, vimentin, zinc-\u03b12-glycoprotein, CD44, and EGFR from the breast cancer cell lines and in their culture media were further validated by Western blot analysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21630460", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1179, 
                    "offsetInEndSection": 1354, 
                    "text": "his provided novel evidence for PMA regulation of the enzymes glyceraldehyde-3-phosphate dehydrogenase, nucleolar RNA helicase 2 and Heterogeneous nuclear ribonucleoprotein M."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416831", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1196, 
                    "offsetInEndSection": 1501, 
                    "text": "Among them, we identify downregulation of components of the Ras/Raf/MAPK pathway and G(2)-M phase to contribute to its anti-proliferative effect, degradation of activated Akt and Bcl-xL to induce apoptosis, and inhibition of activated NF-kappaB, Akt, ERK2, Tyk2, and PKC to reduce TNBC invasive potential."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Does strenuous physical activity affect thyroid hormone metabolism?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042404", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042403", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0030375", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006590", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.biosemantics.org/jochem#4250044", 
                "http://www.biosemantics.org/jochem#4250045", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=2000609", 
                "http://www.biosemantics.org/jochem#4275389", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0097066", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070460", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.biosemantics.org/jochem#4275394", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THA_LITCT", 
                "http://www.uniprot.org/uniprot/THA_SPAAU", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_RAT", 
                "http://www.uniprot.org/uniprot/THA_PIG"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18057380", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14637241", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8743723", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8325717", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2807143", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3101339", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7198038", 
                "http://www.ncbi.nlm.nih.gov/pubmed/596247"
            ], 
            "id": "51598b08d24251bc0500009f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18057380", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1207, 
                    "offsetInEndSection": 1517, 
                    "text": "The results of the present study in a unique experimental human model of maximal exposure to altitude and physical exercise demonstrate that extreme HA and strenuous physical exercise are coupled with specific endocrine adaptations. These include increased activity of the GH/IGF-I axis and a low T(3) syndrome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14637241", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 373, 
                    "offsetInEndSection": 585, 
                    "text": "3,5,3'-triiodothyronine (T3) and T4 levels increase during strenuous exercise, and, at the end of the exercise bout, a decrease of T3 and T4 levels, with an increase in TSH during the following 4-5 days, is seen."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8743723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1355, 
                    "offsetInEndSection": 1584, 
                    "text": "the obtained results indicate that in intense exercise, causing the rapid development of fatigue, rapid increases in serum levels of hormones of the pituitary-adrenocortical, pituitary-gonadal and pituitary-thyroid systems occur."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8325717", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 435, 
                    "offsetInEndSection": 616, 
                    "text": "Mean levels of fasting plasma estradiol, luteinizing hormone, follicle-stimulating hormone, free thyroxine and triiodothyronine were significantly lower in AR compared to ER and SE."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2807143", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 565, 
                    "offsetInEndSection": 856, 
                    "text": "Reductions in plasma T4, T3 and T3/T4 ratio are probably due to inhibition of T4 secretion and 5'-monodeiodination with possible conversion of T4 to reverse T3 (rT3). These processes may represent a mechanism for regulation of thyroid hormone metabolism during strenuous and extended flight."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3101339", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1225, 
                    "offsetInEndSection": 1429, 
                    "text": "Strenuous endurance training seems to have minor changes on the function of the thyroid gland. Depressed T4 levels in runners may rather be due to lowered TBG levels than due to direct effect of training."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7198038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1235, 
                    "offsetInEndSection": 1410, 
                    "text": "brief strenuous swimming or moderate bicycle exercise had minor or no effect on thyroid hormone concentrations when consideration was given to the attendant hemoconcentration."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/596247", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 17, 
                    "offsetInEndSection": 154, 
                    "text": "thyroxine were determined in 26 men participating in a 90-km cross-country ski race, before, immediately after, and on the following days"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/596247", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 643, 
                    "offsetInEndSection": 823, 
                    "text": "Total thyroxine and free thyroxine in serum were significantly increased at the end of the race, but had returned to the pre-raced levels during the rest of the observation period."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which compounds exist that are thyroid hormone analogs?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21670063", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21239431", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19903697", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18954857", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17164749", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16384862", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15148346", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10329215", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8301561", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3359982", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3756504", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3707599", 
                "http://www.ncbi.nlm.nih.gov/pubmed/6327972"
            ], 
            "id": "515993f3d24251bc050000a0", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670063", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 397, 
                    "offsetInEndSection": 459, 
                    "text": "naturally occurring iodothyronine, 3,5-diiodo-L-thyronine (T2)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21239431", 
                    "endSection": "title", 
                    "offsetInBeginSection": 24, 
                    "offsetInEndSection": 150, 
                    "text": "thyroid hormone receptor beta- and \u03b1-selective agonists GC-24 and CO23"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21239431", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 511, 
                    "offsetInEndSection": 591, 
                    "text": "two thyroid hormone agonists, the TR\u03b2-selective GC-24 and the TR\u03b1-selective CO23"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 221, 
                    "offsetInEndSection": 303, 
                    "text": "Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 400, 
                    "offsetInEndSection": 422, 
                    "text": "analogs DITPA and GC-1"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1184, 
                    "offsetInEndSection": 1310, 
                    "text": "Tetrac inhibits binding of thyroid hormone analogs to the receptor on alphavbeta3 and lacks thyromimetic activity at this site"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18954857", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 309, 
                    "offsetInEndSection": 344, 
                    "text": "thyroid hormone agonist, called GC1"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18954857", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 525, 
                    "offsetInEndSection": 576, 
                    "text": "Other selective thyromimetic, KB- 2115 and KB - 141"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18954857", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 599, 
                    "offsetInEndSection": 657, 
                    "text": "Another class of thyroid hormone analogs, the thyronamines"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17164749", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 355, 
                    "offsetInEndSection": 399, 
                    "text": "T4-agarose, a formulation of thyroid hormone"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16384862", 
                    "endSection": "title", 
                    "offsetInBeginSection": 27, 
                    "offsetInEndSection": 176, 
                    "text": "he thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16384862", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 855, 
                    "offsetInEndSection": 913, 
                    "text": "The thyroid hormone analogs DITPA, T(4), and T(4)-agarose,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16384862", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 330, 
                    "offsetInEndSection": 392, 
                    "text": ",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15148346", 
                    "endSection": "title", 
                    "offsetInBeginSection": 71, 
                    "offsetInEndSection": 283, 
                    "text": "thyroid hormone analogs 3,5-diiodothyropropionic acid and CGS 23425"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15148346", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 328, 
                    "offsetInEndSection": 408, 
                    "text": "wo thyroid hormone analogs, 3,5-diidodothyropropionic acid (DITPA) and CGS 23425"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10329215", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 156, 
                    "offsetInEndSection": 482, 
                    "text": "several thyroid hormone analogs, including T4(3,3',5,5'-tetraiodo-L-thyronine), rT3(3,3',5'-triiodo-L-thyronine), D-T3(3,3',5-triiodo-D-thyronine), 3,5-T2(3,5-diiodo-L-thyronine), DIT (3,5-diiodo-L-tyrosine), MIT (3-monoiodo-L-tyrosine), tetrac (3,3',5,5'-tetraiodo-thyroacetic acid), triac (3, 3',5-triiodo-thyroacetic acid),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8301561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 440, 
                    "offsetInEndSection": 588, 
                    "text": ",5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) was found to bind specifically to bacterially expressed alpha-1 and beta-1 thyroid hormone receptors"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8301561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1465, 
                    "offsetInEndSection": 1503, 
                    "text": "DIHPA is a novel thyromimetic compound"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8301561", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 133, 
                    "text": "Identification of simple substituted phenols with thyromimetic activity: cardiac effects of 3,5-diiodo-4-hydroxyphenylpropionic acid"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3359982", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1083, 
                    "offsetInEndSection": 1276, 
                    "text": "The relative affinity of the receptor for thyroid hormone analogs was triiodothyroacetic acid = T3 greater than T4 greater than tetraiodothyroacetic acid in oligodendrocyte and astrocyte nuclei"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3756504", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 786, 
                    "offsetInEndSection": 955, 
                    "text": "The relative binding affinity of the receptor for thyroid hormone analogs was in the order TRIAC greater than L-T3 greater than D-T3 greater than L-T4 in both cell lines"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3707599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 127, 
                    "text": "3,5-Dimethyl-3'-isopropyl-L-thyronine (DIMIT) and 3,5-diiodo-3'-isopropylthyroacetic acid (IpTA2), two thyroid hormone analogs,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6327972", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 82, 
                    "offsetInEndSection": 252, 
                    "text": "synthetic thyroid analogs (3,5,3'-L-triiodothyronine, 3,5,3'-D-triiodothyronine, 3,3',5'-L- triiodothyronine , 3,5,3'-L-triiodothyroacetic acid and 3,5-L-diiodothyronine)"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "How does thyroid  hormone  regulate  SR-Ca2+ ATPase  (SERCA) protein in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.uniprot.org/uniprot/AT2A_CHIOP", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006590", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.biosemantics.org/jochem#4275389", 
                "http://www.biosemantics.org/jochem#4250045", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=2000609", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0015349", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THAA_DANRE", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_PIG", 
                "http://www.uniprot.org/uniprot/THA_RAT"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20232113", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22975595", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18658259", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18274800", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17560116", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17317766", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16595628", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15242794", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11577024", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11470472", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11145561", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9312172", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8779840"
            ], 
            "id": "5159a306d24251bc050000a1", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20232113", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 850, 
                    "offsetInEndSection": 1200, 
                    "text": "Furthermore, using specific inhibitors of the TH-activated kinases, we show that the long-term effects of TH on the expression of sarcoplasmic reticulum Ca(2+)-ATPase (SERCA), alpha- and beta-myosin heavy chain (MHC) and cell growth are reverted, implying that what is initiated as a non-genomic action of the hormone interfaces with genomic effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22975595", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 688, 
                    "offsetInEndSection": 850, 
                    "text": "Hypothyroid neonates showed increased cholesterol levels and decreased expression of D1 in liver and of Serca-2 in heart, which were normalized with T3 treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18658259", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 587, 
                    "offsetInEndSection": 891, 
                    "text": "ERCA2 transcript and protein levels were reduced in FOG-2 transgenic hearts, and FOG-2 overexpression impaired T3-mediated SERCA2 expression in cultured cardiomyocytes. FOG-2 physically interacts with thyroid hormone receptor-alpha1 and abrogated even high levels of T3-mediated SERCA2 promoter activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18274800", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1352, 
                    "offsetInEndSection": 1516, 
                    "text": "A marked elevation of the expression of beta-MHC and a reduced ratio of SERCA/Phospholamban were found in viable myocardium of AMI hearts, which was prevented by TH"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560116", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1496, 
                    "offsetInEndSection": 1682, 
                    "text": "After TH treatment, AMI-THYR hearts expressed 71% alpha-MHC and 29% beta-MHC, P<0.05 versus SHAM and AMI and the ratio of SERCA/PLB was increased by 2.0-fold, P<0.05 versus SHAM and AMI."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17317766", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 405, 
                    "offsetInEndSection": 535, 
                    "text": "Because the binding of T(3) occupied receptors to the thyroid response elements in the SERCA promotor can increase gene expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17317766", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1620, 
                    "offsetInEndSection": 1792, 
                    "text": "These results demonstrate that increasing TR expression in the hypertrophied heart is associated with an improvement in contractile function and increased SERCA expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16595628", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 609, 
                    "offsetInEndSection": 933, 
                    "text": "Increased cardiac D2 activity led to elevated cardiac T3 levels and to enhanced myocardial contractility, accompanied by increased Ca(2+) transients and sarcoplasmic reticulum (SR) Ca(2+) uptake. These phenotypic changes were associated with up-regulation of sarco(endo)plasmic reticulum calcium ATPase (SERCA) 2a expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16595628", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1298, 
                    "offsetInEndSection": 1471, 
                    "text": "Our results establish that elevated D2 activity in the heart increases T3 levels and enhances cardiac contractile function while preventing deterioration of cardiac function"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 525, 
                    "text": "Hypothyroid heart displays a phenotype of cardioprotection against ischemia and this study investigated whether administration of dronedarone, an amiodarone-like compound that has been shown to preferentially antagonize thyroid hormone binding to thyroid hormone receptor alpha1 (TRalpha1), results in a similar effect. Dronedarone was given in Wistar rats (90 mg/kg, once daily (od) for 2 weeks) (DRON), while untreated animals served as controls (CONT). Hypothyroidism (HYPO) was induced by propylthiouracil administration."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 830, 
                    "offsetInEndSection": 1050, 
                    "text": "while beta-myosin heavy chain (beta-MHC) and sarcoplasmic reticulum Ca2+ adenosine triphosphatase (ATPase) expression (SERCA) was similar to CONT. In HYPO, alpha-MHC and SERCA were decreased while beta-MHC was increased."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15242794", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 829, 
                    "offsetInEndSection": 1141, 
                    "text": "the postnatal switch from beta- to alpha-myosin heavy chain (beta- and alpha-MHC, respectively) gene expression and the increase of SERCA-2a mRNA expression did not occur in the ventricular myocardium of either the transgenic (thyroid destroyed) or nontransgenic (intact thyroid) offspring of hypothyroid mothers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11577024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1170, 
                    "offsetInEndSection": 1373, 
                    "text": "In addition, TR cotransfection and treatment with the TRbeta1-selective agonist GC-1 suggested different functional coupling of the TR isoforms, TRbeta1 to transcription of beta-MyHC, SERCA, and TRbeta1,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11470472", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1239, 
                    "offsetInEndSection": 1454, 
                    "text": "dditionally, in T3-deprived samples alpha-sarcomeric actinin and SERCA-2 protein levels were reduced to 65.6 +/- 3% (P < 0.0001) and 74.1 +/- 4% (P=0.005), respectively, when compared with the T3-supplemented group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11145561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1055, 
                    "offsetInEndSection": 1277, 
                    "text": "even mild chronic myocardial thyrotoxicosis, such as may occur in human hyperthyroidism, can cause tachycardia and associated changes in high energy phosphate compounds independent of an increase in SERCA II and alpha-MHC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9312172", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 882, 
                    "offsetInEndSection": 1009, 
                    "text": "Myocytes from banded hearts treated with T4 were hypertrophied but had increased concentrations of alpha-MHC and SERCA proteins"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 181, 
                    "text": "Thyroid hormone (T3) increases the transcription of the sarcoplasmic reticulum Ca2+ adenosine triphosphatase (ATPase) gene (SERCA 2) through three thyroid hormone response elements."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 743, 
                    "offsetInEndSection": 1218, 
                    "text": "MEF-2a in combination with either T3R alpha 1 or T3R beta 1 isoforms resulted in a 2.5-fold increase in SERCA 2 transgene expression in the absence of T3. Addition of T3 did not induce any further increase in SERCA 2 expression when T3R alpha 1 and MEF-2a expression vectors were cotransfected. In contrast, in the presence of T3R beta 1 and MEF-2, the addition of T3 increased chlorampenicol acetyltransferase activity by an additional 2.2-fold to a total 5.5-fold increase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1746, 
                    "offsetInEndSection": 1902, 
                    "text": "Our findings point to T3R isoform-specific interactions with a cell type-specific transcription factor (MEF-2) in the regulation of SERCA 2 gene expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8779840", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1154, 
                    "offsetInEndSection": 1305, 
                    "text": "These data are consistent with pretranslational and possibly transcriptional level effect of thyroid hormone on the cardiac SR Ca2+ pump gene (SERCA 2)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8779840", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 955, 
                    "offsetInEndSection": 1153, 
                    "text": "These data demonstrate that T3 increases expression of the cardiac SR Ca2+ pump, that the effect can be localized to the cardiomyocyte, and that the effect is dependent on thyroid hormone receptors."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What are the effects of depleting protein  km23-1 (DYNLRB1)  in a cell?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/DLRB1_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23079622", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22637579", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19711352", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17420258", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15925487", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19571232", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16778097"
            ], 
            "id": "515a7ffdd24251bc050000a5", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23079622", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 797, 
                    "offsetInEndSection": 1156, 
                    "text": "Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22637579", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 650, 
                    "offsetInEndSection": 798, 
                    "text": "Further, knockdown of km23-1 inhibited TGF\u03b2-mediated activation of ERK and JNK, phosphorylation of c-Jun, and transactivation of the c-Jun promoter."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23079622", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 719, 
                    "offsetInEndSection": 795, 
                    "text": "knockdown (KD) of km23-1 decreased RhoA activation in Mv1Lu epithelial cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711352", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 119, 
                    "text": "We have previously reported that the dynein light chain (DLC) km23-1 is required for Smad2-dependent TGFbeta signaling."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420258", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 701, 
                    "offsetInEndSection": 894, 
                    "text": "Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15925487", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 572, 
                    "offsetInEndSection": 741, 
                    "text": "Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19571232", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1236, 
                    "offsetInEndSection": 1446, 
                    "text": "On the other hand, inhibiting the endogenous DYNLRB1 with gene-specific small interfering RNA or pharmacologically with a specific inhibitor (vanadate) led to a significant (P < 0.05) decrease in folate uptake."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778097", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 189, 
                    "offsetInEndSection": 361, 
                    "text": "Functional studies showed that some mutations disrupt km23 function, resulting in aberrant transforming growth factor-beta signaling and presumably enhanced tumorigenicity."
                }
            ], 
            "triples": [
                {
                    "o": "http://linkedlifedata.com/resource/#_41324156523900A", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject", 
                    "s": "http://linkedlifedata.com/resource/#_41324156523900B"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Albumin depletion is a common first step for proteomic analysis of CSF fluid. What is the advantage and disadvantage of this procedure?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005441", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0033326", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000418"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23300121", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21906361", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19327347", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18412540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18288611", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16335978", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15952730", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15822917"
            ], 
            "id": "515a9d86d24251bc050000a7", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 206, 
                    "offsetInEndSection": 436, 
                    "text": "However, albumin binds peptides and proteins, which raises concerns as to how the removal of albumin could impact the outcome of the biomarker study while ignoring the possibility that this could be a biomarker subproteome itself."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21906361", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2352, 
                    "offsetInEndSection": 2492, 
                    "text": "They have also pointed out the potential loss of non-target proteins as a result of non-specific binding to immunodepletion columns [10,12]."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21906361", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 57, 
                    "offsetInEndSection": 100, 
                    "text": "enrichment of low-abundance proteins in CSF"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19327347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1147, 
                    "offsetInEndSection": 1274, 
                    "text": "This study demonstrates that reduction of sample complexity by albumin depletion of CSF can be performed without CV impairment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18288611", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 125, 
                    "offsetInEndSection": 350, 
                    "text": "We have utilized albumin depletion prior to 2D gel electrophoresis to enhance glycoprotein concentration for image analysis as well as structural glycoprotein determination without glycan release using mass spectrometry (MS)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16335978", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 355, 
                    "offsetInEndSection": 543, 
                    "text": "The albumin depletion method is the most suitable as prefractionation method of CSF prior to 2-DE for structural determination of glycoproteins in the study of neurodegenerative disorders."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15952730", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 479, 
                    "text": "A proper sample preparation, in particular, abundant protein removal is crucial in the characterization of low-abundance proteins including those harboring post-translational modifications. In human cerebrospinal fluid (CSF), approximately 80% of proteins originate from serum, and removal of major proteins is necessary to study brain-derived proteins that are present at low concentrations for successful biomarker and therapeutic target discoveries for neurological disorders."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15822917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 221, 
                    "offsetInEndSection": 590, 
                    "text": "The most abundant component in human body fluids, human serum albumin (HSA), is present at concentrations corresponding to approximately 50% of the total protein content in, e.g., plasma and cerebrospinal fluid (CSF). If this component could be selectively removed, then the chances of observing lower-abundance component of clinical interest would be greatly improved."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15822917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1259, 
                    "offsetInEndSection": 1337, 
                    "text": ", and the identification of lower abundant components was clearly facilitated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19327347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 363, 
                    "text": "Two different depletion strategies for removing albumin from human cerebrospinal fluid (CSF), Microcon Centrifugal Filter vs. Montage Albumin Deplete kit, were evaluated for improving protein profiling pattern and reproducibility in SELDI analysis. METHODS: Pooled CSF was divided into 20 aliquots and these aliquots were subjected to SELDI analysis ei"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18412540", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1740, 
                    "offsetInEndSection": 1880, 
                    "text": "Enhanced identification of lower-abundance components was observed in the depleted fraction, in terms of more detected peptides per protein."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "How does thyroid hormone regulate mitochondrial biogenesis in the myocardium?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008929", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006590", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008928", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0002154", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THAA_DANRE", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_CAIMO", 
                "http://www.biosemantics.org/jochem#4250045", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_LITCT"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20100314", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17962579", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15543939", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15893763", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12734114", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12388124", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22109994", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21914860", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21568860", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20515651", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19462004", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19036942", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18575627", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7556180", 
                "http://www.ncbi.nlm.nih.gov/pubmed/6157679", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2773621", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1321044"
            ], 
            "id": "515ac941d24251bc050000ab", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100314", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1083, 
                    "offsetInEndSection": 1364, 
                    "text": "L-T3 significantly increased the expression of factors involved in mitochondrial DNA transcription and biogenesis, such as hypoxic inducible factor-1\u03b1, mitochondrial transcription factor A and peroxisome proliferator activated receptor \u03b3 coactivator-1\u03b1, in the LV peri-infarct zone"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17962579", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1692, 
                    "offsetInEndSection": 1918, 
                    "text": "the T(3)-induced phosphorylation of p38 and AMPK in both slow- and fast-twitch skeletal muscles suggests that these events may be important in mediating hormone-induced increases in mitochondrial biogenesis in skeletal muscle."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15543939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1333, 
                    "offsetInEndSection": 1498, 
                    "text": "Our findings indicate parallel increases in myocardial mitochondrial bioenergetic capacity, oxygen consumption and markers of mitochondrial biogenesis with 15-day T4"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15543939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1589, 
                    "offsetInEndSection": 1751, 
                    "text": "The marked, parallel increases in PPARalpha levels suggest its potential involvement in mediating myocardial-specific remodeling of mitochondria in response to T4"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15893763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1099, 
                    "offsetInEndSection": 1287, 
                    "text": "T3 mediates an early stimulation of enzymes containing mtDNA encoded subunits (e.g. complex IV and V) in contrast to a different regulatory pattern for the entirely nuclear-encoded enzymes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15893763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 386, 
                    "offsetInEndSection": 682, 
                    "text": "Activity of respiratory complexes II, IV, V and citrate synthase (CS), levels of mitochondrial enzyme subunits (e.g. COXI, COXIV) and nuclear-encoded transcription factors, involved in mitochondrial biogenesis (e.g. PGC-1, mtTFA and PPAR-alpha), were significantly elevated with 72 h T3 treatment"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734114", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1085, 
                    "offsetInEndSection": 1209, 
                    "text": "T(3) increased PGC-1alpha content similarly in both fast- and slow-twitch muscle, as well as in the liver, but not in heart."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388124", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 228, 
                    "text": "Thyroid hormone [3,5,3'-triiodo-l-thyronine (T(3))] induces phenotypic alterations in cardiac mitochondria, in part by influencing protein import and the expression of the import motor mitochondrial heat shock protein (mtHsp70)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388124", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1259, 
                    "offsetInEndSection": 1436, 
                    "text": "These findings indicate that import machinery components are differentially regulated in response to stimuli that induce mitochondrial biogenesis, like T(3) and differentiation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109994", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 159, 
                    "offsetInEndSection": 422, 
                    "text": "We have previously identified a mitochondrial triiodothyronine receptor (p43) regulating mitochondrial transcription and mitochondrial biogenesis. When overexpressed in skeletal muscle, it increases mitochondrial DNA content, stimulates mitochondrial respiration,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109994", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 548, 
                    "offsetInEndSection": 679, 
                    "text": "Here we show that a p43 depletion in mice decreases mitochondrial DNA replication and respiratory chain activity in skeletal muscle"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21568860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 692, 
                    "offsetInEndSection": 1147, 
                    "text": "The contribution of TFAM, TFB2M, and helicase Twinkle in thyroid-induced mtDNA biogenesis was assessed. The activation of TFAM and TFB2M expression is shown to be required for the induction of mtDNA biogenesis. The role of helicase Twinkle, the expression induction of which is also observed after triiodothyronine addition, remains unclear. The analysis of factors that activate TFAM and TFB2M expression showed that NRF-1 is the determinative regulator:"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20515651", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 558, 
                    "offsetInEndSection": 730, 
                    "text": "in rat cerebellum show that hypothyroidism causes reduction in expression of nuclear encoded genes controlling mitochondrial biogenesis like PGC-1alpha, NRF-1alpha and Tfam"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20515651", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 957, 
                    "offsetInEndSection": 1108, 
                    "text": "These results thus indicate an integrated nuclear-mitochondrial cross talk in regulation of mitochondrial transcription by TH during brain development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19462004", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 801, 
                    "offsetInEndSection": 1191, 
                    "text": "We have previously identified in mitochondria truncated forms of the nuclear receptor TR\u03b11, with molecular weights of 43 kDa (p43) and 28 Kda [7], [8]. P43 is a mitochondrial T3 receptor which stimulates mitochondrial transcription and protein synthesis in the presence of T3 [9]. In C2C12 cells, its overexpression stimulates mitochondrial activity and potentiates terminal differentiation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19462004", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1204, 
                    "offsetInEndSection": 1509, 
                    "text": "More recently, in in vivo studies, we have shown that p43 overexpression in skeletal muscle increases mitochondrial transcription and mitochondrial biogenesis inducing a stimulation of mitochondrial respiration and changes in metabolic and contractile features of muscle fibers which became more oxidative"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19036942", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1759, 
                    "offsetInEndSection": 1942, 
                    "text": "T(3) acts to reduce cellular oxidative stress, which may help attenuate ROS-mediated damage, along with improving mitochondrial function and energy status in cells with mtDNA defects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18575627", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1444, 
                    "offsetInEndSection": 1723, 
                    "text": "we have identified in mitochondria two N-terminally truncated forms of the nuclear receptor TR\u03b11, with molecular weight of 43 and 28 kDa (p43 and p28) [9], [10]. These proteins are synthesized by the use of internal initiation sites of translation occuring in the TR\u03b11 transcript"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18575627", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1872, 
                    "offsetInEndSection": 2133, 
                    "text": "n gel shift experiments, p43 binds as dimeric complexes involving at least two other truncated forms of nuclear receptors located in mitochondria, mt-RXR and mt-PPAR, to specific sequences of the mitochondrial genome, sharing strong homologies with nuclear T3RE"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18575627", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2166, 
                    "offsetInEndSection": 2278, 
                    "text": "on isolated mitochondria, p43 stimulates mitochondrial transcription and protein synthesis in the presence of T3"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18575627", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2285, 
                    "offsetInEndSection": 2392, 
                    "text": "Lastly, in CV1 cells, p43 overexpression stimulates mitochondrial biogenesis and respiratory chain activity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7556180", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1254, 
                    "offsetInEndSection": 1583, 
                    "text": "These findings suggest the existence of compensatory mechanisms operating at the translational and/or post-translational levels which promote proliferation of mitochondria in the hypothyroid liver. However, when the liver mass was considered, hypothyroidism significantly reduced overall mitochondrial proliferation in rat liver."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6157679", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1333, 
                    "offsetInEndSection": 1595, 
                    "text": "Total liver mitochondrial DNA levels in thyroid-treated animals were greater than age-paired controls by 79% at 7 days but only 67% at 14 days since a small gain occurred in control animals and no further increase occurred in treated rats during the second week."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6157679", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1809, 
                    "offsetInEndSection": 1917, 
                    "text": "thyroid hormone treatment produces hyperplasia and an increase in mitochondrial number and mass in rat liver"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2773621", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1153, 
                    "offsetInEndSection": 1340, 
                    "text": "It is concluded that T3 exerts a direct, rather than permissive, effect on mitochondrial biogenesis, and that high affinity binding sites for GH are not present in rat liver mitochondria."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1321044", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1024, 
                    "offsetInEndSection": 1248, 
                    "text": "These data strengthen the view that thyroid hormone regulates synthesis of specific components within each respiratory-chain complex and that these products apparently play key roles in inner-membrane biogenesis and assembly"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Where can we find the protein lacritin?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/LACRT_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23482462", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23425695", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23422824", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22956620", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22918641", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22871838", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22300579", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21087963", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20375347", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19770725", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19714880", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18334948", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17850790", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16982797", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16923831", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15952718", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14574570", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16488965", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16865190", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11419941"
            ], 
            "id": "515b30d8d24251bc050000b0", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23482462", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 197, 
                    "offsetInEndSection": 258, 
                    "text": "Lacritin, a glycoprotein secreted from lacrimal acinar cells,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425695", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 139, 
                    "offsetInEndSection": 389, 
                    "text": "Essential for the viability of the surface epithelium of the eye and for normal vision is the thin, but protein-rich, tear film in which the small tear glycoprotein lacritin appears to play a prominent prosecretory, cytoprotective, and mitogenic role"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422824", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 140, 
                    "text": "Lacritin is a prosecretory mitogen in tears and, although a tear protein, it promotes basal tearing and lacrimal gland secretion."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11419941", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11419941", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 479, 
                    "offsetInEndSection": 717, 
                    "text": "Lacritin mRNA and protein are highly expressed in human lacrimal gland, moderately in major and minor salivary glands and slightly in thyroid. No lacritin message or protein is detected elsewhere among more than 50 human tissues examined."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16865190", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1155, 
                    "offsetInEndSection": 1198, 
                    "text": "and tear-specific proteins such as lacritin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22918641", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 234, 
                    "offsetInEndSection": 303, 
                    "text": "This study assessed lacritin levels in tears from healthy individuals"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300579", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 866, 
                    "offsetInEndSection": 1109, 
                    "text": "The lipocalin 1, lactotransferrin, lacritin, lysozyme C, lipophilin A and immunoglobulin lambda chain were identified as possible biomarker candidates with significantly higher relative levels in the tear of patients with diabetic retinopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21087963", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 54, 
                    "text": "Lacritin is a novel human tear glycoprotein"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17850790", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1483, 
                    "offsetInEndSection": 1569, 
                    "text": "In primates, lacritin was produced in the lacrimal gland and secreted into tear fluid."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574570", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 708, 
                    "offsetInEndSection": 1069, 
                    "text": "Here we show by quantitative real-time PCR that lacritin is expressed in human breast tumors, breast cancer cell lines, and normal breast. The previously reported restricted expression pattern of lacritin is therefore incorrect. Lacritin transcripts were not detected in peripheral blood which makes lacritin a potential candidate as a breast cancer marker gene"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "A common problem in proteomics is the contamination of samples with exogenous proteins (often from other species). These proteins can be found in specific databases. List some contaminants.", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22954629", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12872232", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12422360", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20641139", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12915006"
            ], 
            "id": "515d7693298dcd4e5100000c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12422360", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 312, 
                    "offsetInEndSection": 355, 
                    "text": "protease autolysis or keratin contaminants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12872232", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 515, 
                    "offsetInEndSection": 598, 
                    "text": "Most of the interfering masses originate from trypsin autolysis and human keratins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20641139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 139, 
                    "offsetInEndSection": 271, 
                    "text": "5-15% FBS. Contamination by bovine proteins is difficult to avoid because of adherence to the plastic vessel and the cultured cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12915006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 221, 
                    "offsetInEndSection": 389, 
                    "text": "The main disadvantage of traditional IP and co-IP is that the conditions used to elute the precipitated antigen also release the antibody thus contaminating the antigen"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22954629", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 71, 
                    "text": "MaConDa: a publicly accessible mass spectrometry contaminants database."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "In what proportion of children with heart failure has Enalapril been shown to be safe and effective?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006333", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004656", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054143", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054144", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002648", 
                "http://www.disease-ontology.org/api/metadata/DOID:6000", 
                "http://www.biosemantics.org/jochem#4176194", 
                "http://www.biosemantics.org/jochem#4249241", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015773", 
                "http://www.disease-ontology.org/api/metadata/DOID:9775", 
                "http://www.disease-ontology.org/api/metadata/DOID:9651", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", 
                "http://www.biosemantics.org/jochem#4175579", 
                "http://www.biosemantics.org/jochem#4250224"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23124387", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14990637", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12530495", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12454107", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9315539", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7576410", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8110005", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8512763", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1318542", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9381720"
            ], 
            "id": "515dd3d5298dcd4e5100001c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23124387", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1407, 
                    "offsetInEndSection": 1609, 
                    "text": "The responses to IV KCl were attenuated by concomitant furosemide (p\u00a0=\u00a00.01), amphotericin B (p\u00a0<\u00a00.01), and KCl in parenteral nutrition (p\u00a0<\u00a00.01). The responses were augmented by concomitant enalapril"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14990637", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 306, 
                    "text": "To determine whether an angiotensin-converting enzyme (ACE) inhibitor, enalapril, prevents cardiac function deterioration (defined using maximal cardiac index [MCI] on exercise testing or increase in left ventricular end-systolic wall stress [LVESWS]) in long-term survivors of pediatric cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14990637", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1342, 
                    "offsetInEndSection": 1441, 
                    "text": "Enalapril treatment did not influence exercise performance, but did reduce LVESWS in the first year"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530495", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 233, 
                    "text": "Patients with intraatrial baffle procedure for transposition of the great arteries (TGA) have diastolic dysfunction, decreased exercise capacity, stroke volume response and elevated systemic vascular resistance (SVR) during exercise."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530495", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1713, 
                    "offsetInEndSection": 1887, 
                    "text": "We conclude that short-term (<1 year) use of enalapril does not improve exercise performance in patients with TGA in whom the intraatrial baffle procedure has been performed."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12454107", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 428, 
                    "text": "A common late effect of doxorubicin therapy for childhood cancer is reduced left-ventricular (LV) wall thickness resulting in elevated LV afterload and depressed LV function. Many children are given angiotensin-converting enzyme inhibitors, which have been studied primarily in adults. We document the long-term effects of angiotensin-converting enzyme inhibitors in doxorubicin-treated survivors of childhood cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12454107", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1375, 
                    "offsetInEndSection": 1676, 
                    "text": "In doxorubicin-treated long-term survivors of childhood cancer, enalapril-induced improvement in LV structure and function is transient. The primary defect, which is LV wall thinning, continues to deteriorate, and thus the short-term improvement was mostly related to lowered diastolic blood pressure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315539", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 208, 
                    "offsetInEndSection": 417, 
                    "text": "Patients who have undergone the Fontan procedure have decreased cardiac output, increased systemic vascular resistance, abnormal diastolic function, and decreased exercise capacity compared with normal people."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315539", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1884, 
                    "offsetInEndSection": 2107, 
                    "text": "We conclude that enalapril administration for 10 weeks does not alter abnormal systemic vascular resistance, resting cardiac index, diastolic function, or exercise capacity in patients who have undergone a Fontan procedure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9381720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 642, 
                    "text": "Angiotensin convertase inhibitor (Enalapril) was used in 51 children aged 4 days up to 18 years (mean 4.3 +/- 5.5, years). As many as 27 subjects were newborns (4) and infants (23). The patients suffered from circulatory insufficiency due to congestive cardiomyopathy (13 cases). 6 treated subjects suffered from circulatory insufficiency due to congenital heart malformations before cardiac surgery and 22 after it (including complex malformations operated according to Fontan method). 10 children were treated because of arterial hypertension. 4 subjects suffered form life-threatening arrhythmias coexisting with circulatory insufficiency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9381720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 850, 
                    "offsetInEndSection": 1233, 
                    "text": "4 patients (8%) died during treatment but their deaths can not be related to angiotensin convertase inhibitor therapy. In the other children (82%) the beneficial influence of angiotensin convertase inhibitor use was found (improvement in comparison with the state before convertase inhibitor introduction). In 10% of subjects enalapril did not show any significant therapeutic effect"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7576410", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1183, 
                    "offsetInEndSection": 1385, 
                    "text": "We conclude that the combination of ACE inhibitor and beta-blocker deserves further exploration for inclusion in any management regimen for the treatment of muscular dystrophy-associated cardiomyopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7576410", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 943, 
                    "offsetInEndSection": 1182, 
                    "text": "Addition of these medications, never before attempted in the management of cardiomyopathy associated with generalized myopathic disease, complemented each other in relieving symptoms and reversing signs of congestive heart failure and DCM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8110005", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 864, 
                    "offsetInEndSection": 1098, 
                    "text": "Enalapril was clinically safe and effective for children with cardiac failure secondary to ventricular impairment, valvar regurgitation, or after cardiac surgery. Renal failure was a problem in young infants with left-to-right shunts."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8110005", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 694, 
                    "text": "In a tertiary referral centre 63 patients underwent 67 treatment periods with enalapril. The median age was 5.4 months. All children had signs of heart failure: congestive cardiac failure with breathlessness at rest was present in 88%. Haemodynamic groups were left-to-right shunt (n = 15), impaired ventricular function (n = 14), after cardiac surgery (n = 23), valvar regurgitation (n = 12), and hypertension (n = 3). Serial clinical, radiological, and laboratory data were used to judge outcome. The mean (SD) maximal dose was 0.30 (0.21) mg/kg/day. Thirty nine (58%) patients improved, 20 (30%) showed no improvement, and eight (12%) had side effects requiring discontinuation of enalapril."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8512763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 225, 
                    "text": "We studied the inhibition of angiotensin converting enzyme (ACE) in eight infants with congestive heart failure (CHF) poorly controlled with digoxin and diuretics, treated orally with 0.25 mg kg-1 enalapril maleate once a day"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8512763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 584, 
                    "offsetInEndSection": 680, 
                    "text": "In infants with CHF, mean baseline ACE activity was significantly higher than in control infants"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1318542", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1240, 
                    "offsetInEndSection": 1397, 
                    "text": "Converting enzyme inhibitors may benefit \"heart failure\" associated with large ventricular septal defects and normal or mildly elevated pulmonary resistance."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What is the lay name of the treatment for CCSVI (chronic cerebro-spinal venous insufficiency)  in multiple sclerosis.", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", 
                "http://www.disease-ontology.org/api/metadata/DOID:2377"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23523158", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23402260", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23380649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23354606", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23301864", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23202144", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23034121", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22951366", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22687168", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22648477", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22640501", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22155803", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22088659", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21856578", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21839654", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21838669", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21803799", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21755134", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21679067", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21136256", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21107001", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20373339", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20351675", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21687341", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19958985"
            ], 
            "id": "515df199298dcd4e5100002a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523158", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 130, 
                    "offsetInEndSection": 366, 
                    "text": "patients with relapsing-remitting (RR) multiple sclerosis (MS) receiving standard medical treatment who had been diagnosed with chronic cerebrospinal venous insufficiency (CCSVI) and underwent percutaneous transluminal angioplasty (PTA)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23402260", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 218, 
                    "text": "In 2009, Dr. Paolo Zamboni proposed chronic cerebrospinal venous insufficiency (CCSVI) as a possible cause of multiple sclerosis (MS). Although his theory and the associated treatment (\"liberation therapy\")"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 194, 
                    "text": "Although it is debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients undergo endovascular treatment (ET) of CCSVI"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23354606", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "Endovascular treatment of CCSVI in patients with multiple sclerosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23354606", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 203, 
                    "text": "Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23301864", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 21, 
                    "offsetInEndSection": 282, 
                    "text": "Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) has been proposed to be associated with Multiple Sclerosis (MS). Zamboni et\u00a0al reported significant improvement in neurological outcomes in MS patients who underwent Percutaneous Transluminal Angioplasty (PTA)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23202144", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 243, 
                    "offsetInEndSection": 434, 
                    "text": "Our open-label study included 94 MS patients who fulfilled ultrasound sonographic criteria required for CCSVI. The internal jugular and/or azygous veins by a catheter venography were dilated."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23202144", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 179, 
                    "text": "Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: possible improvement by venous angioplasty. Results of a prospective study."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034121", 
                    "endSection": "title", 
                    "offsetInBeginSection": 23, 
                    "offsetInEndSection": 245, 
                    "text": "venous angioplasty of the extracranial veins for multiple sclerosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 379, 
                    "offsetInEndSection": 646, 
                    "text": "Despite a wide variability among studies, it has been found to be associated with MS. Data from a few small case series suggest possible improvement of the clinical course and quality of life by performing percutaneous balloon angioplasty (PTA) of the stenotic veins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22951366", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 73, 
                    "text": "Clinical improvement after extracranial venoplasty in multiple sclerosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22951366", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 218, 
                    "text": "This study proposed to prospectively evaluate safety and clinical changes in outpatient endovascular treatment in patients with multiple sclerosis (MS) and chronic cerebrospinal venous insufficiency (CCSVI)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22687168", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 204, 
                    "offsetInEndSection": 359, 
                    "text": "Twenty-nine patients with clinically definite relapsing-remitting MS underwent percutaneous transluminal angioplasty for CCSVI, outside a clinical relapse."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22648477", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1192, 
                    "offsetInEndSection": 1495, 
                    "text": "The European Society of Neurosonology and Cerebral Hemodynamics (ESNCH) has considerable concerns regarding the accuracy of the proposed criteria for CCSVI in MS. Therefore, any potentially harmful interventional treatment such as transluminal angioplasty and/or stenting should be strongly discouraged."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22640501", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 93, 
                    "text": "Catheter venography and endovascular treatment of chronic cerebrospinal venous insufficiency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22640501", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 898, 
                    "offsetInEndSection": 1103, 
                    "text": "The work of Dr. Zamboni, et al, who reported that treating the venous stenoses causing CCSVI with angioplasty resulting in significant improvement in the symptoms and quality of life of patients with MS (2"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155803", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 106, 
                    "text": "Endovascular treatment of patients with chronic cerebrospinal venous insufficiency and multiple sclerosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155803", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 478, 
                    "offsetInEndSection": 639, 
                    "text": "Endovascular treatment (percutaneous transluminal angioplasty (PTA) with or without stenting) of CCSVI was reported to be feasible with a minor complication rate"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088659", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 129, 
                    "text": "Safety of endovascular treatment of chronic cerebrospinal venous insufficiency:"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088659", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 699, 
                    "offsetInEndSection": 933, 
                    "text": "For patients treated primarily, 87% (208 of 239) had angioplasty, and 11% (26 of 239) had stent placement; 5 patients were not treated. Of patients with restenosis, 50% (9 of 18) had angioplasty, and 50% (9 of 18) had stent placement."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 132, 
                    "text": "An endovascular treatment of Chronic Cerebro-Spinal Venous Insufficiency in multiple sclerosis patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 223, 
                    "text": "In this study, the mid-term results (6 month follow-up) of the endovascular treatment in patients with Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) and multiple sclerosis (MS) were prospectively evaluated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 233, 
                    "offsetInEndSection": 407, 
                    "text": "Thirty-six patients with confirmed MS and CCSVI underwent endovascular treatment by the means of the uni- or bilateral jugular vein angioplasty with optional stent placement."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876515", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1004, 
                    "offsetInEndSection": 1045, 
                    "text": "stent implantation into the jugular vein,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856578", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1161, 
                    "offsetInEndSection": 1351, 
                    "text": "As the debate about CCSVI and its relationship to MS continues, the complications and risks associated with venous stenting and angioplasty in jugular and azygous veins are becoming clearer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839654", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 274, 
                    "text": "Chronic cerebrospinal venous insufficiency (CCSVI) is associated with multiple sclerosis (MS). The objective of the study was to see if percutaneous transluminal angioplasty (PTA) of duplex-detected lesions, of the internal jugular and/or azygous veins, was safe,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21838669", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 434, 
                    "offsetInEndSection": 602, 
                    "text": "CCSVI theory has generated a scientific and mass media debate with a great hope for the miracle of a new possible endovascular treatment of MS (\"liberation procedure\")."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 90, 
                    "text": "Endovascular therapy for chronic cerebrospinal venous insufficiency in multiple sclerosis."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 709, 
                    "offsetInEndSection": 902, 
                    "text": "The proposed treatment for CCSVI is percutaneous transluminal angioplasty (PTA) as described by Zamboni et al. (2009b) in a subsequent series of endovascular treatment for CCSVI in MS patients."
                }, 
                {
                    "beginSection": "sections.7", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
                    "endSection": "sections.7", 
                    "offsetInBeginSection": 183, 
                    "offsetInEndSection": 332, 
                    "text": "In the prospective endovascular treatment pilot trial by Zamboni et al. (2009a) PTA was performed on 65 patients and 18-month follow-up was described"
                }, 
                {
                    "beginSection": "sections.7", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808631", 
                    "endSection": "sections.7", 
                    "offsetInBeginSection": 1779, 
                    "offsetInEndSection": 2343, 
                    "text": "The long-term effects of endoluminal scaffold implantation with stents in the venous system is not as well understood and will need further investigation of host response, such as endothelialization, and the appropriate subsequent antithrombotic regimen. Stent design will also likely be important in achieving safety, durability, and efficacy, however this will only follow a better understanding of the lesion pathology. Although endovascular technique and device technology are available to implement invasive treatment, data on safety and efficacy are lacking."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803799", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 91, 
                    "text": "Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21755134", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 900, 
                    "offsetInEndSection": 990, 
                    "text": "The treatment based on the CCSVI theory has appealingly been called \"liberation treatment\""
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21679067", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 184, 
                    "offsetInEndSection": 330, 
                    "text": "MS patients (261 women; mean age 45.4 years, range 21-79) with CCSVI underwent endovascular treatment of 1012 venous lesions during 495 procedures"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21679067", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 360, 
                    "offsetInEndSection": 495, 
                    "text": "While balloon angioplasty was preferred, 98 stents were implanted in 76 patients for lesion recoil, restenosis, or suboptimal dilation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4811, 
                    "offsetInEndSection": 4996, 
                    "text": "we believe that until real scientific data are available for CCSVI and balloon dilatation, this treatment should not be offered to MS patients outside of a well-designed clinical trial."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21107001", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 138, 
                    "text": "The aim of this report is to assess the safety of endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21107001", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 323, 
                    "offsetInEndSection": 422, 
                    "text": "A total of 564 endovascular procedures (balloon angioplasty or, if this procedure failed, stenting)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373339", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 341, 
                    "offsetInEndSection": 522, 
                    "text": "A potential shift in the treatment paradigm of MS involving endovascular balloon angioplasty or venous stent placement has been proposed as well as conducted in small patient series"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20351675", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 730, 
                    "offsetInEndSection": 845, 
                    "text": "She underwent percutaneous balloon angioplasty of the associated chronic cerebrospinal venous insufficiency (CCSVI)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687341", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "Endovascular treatment for multiple sclerosis:"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687341", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 467, 
                    "offsetInEndSection": 516, 
                    "text": "whether to fund endovascular treatment for CCSVI,"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958985", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958985", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 584, 
                    "offsetInEndSection": 830, 
                    "text": "Sixty-five consecutive patients with CCSVI, subdivided by MS clinical course into 35 with relapsing remitting (RR), 20 with secondary progressive (SP), and 10 with primary progressive (PP) MS, underwent percutaneous transluminal angioplasty (PTA)"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Do selenoproteins and selenium play a role in prostate cancer prevention?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:10283", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051140"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19074884", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17160069", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16690748", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23133653", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22072582", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20852007", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20424130", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19690186", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19299660", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15875088"
            ], 
            "id": "515ed87c298dcd4e51000032", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690748", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1115, 
                    "offsetInEndSection": 1402, 
                    "text": "The selenoprotein-deficient mice exhibited accelerated development of lesions associated with prostate cancer progression, implicating selenoproteins in cancer risk and development and raising the possibility that selenium prevents cancer by modulating the levels of these selenoproteins"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160069", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1293, 
                    "offsetInEndSection": 1564, 
                    "text": "Notably and in contrast to previous studies, RWPE-1 cells were significantly more sensitive to selenite than either of the prostate cancer cell lines. These results demonstrate that selenoproteins and selenium metabolism are regulated at multiple levels in prostate cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074884", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1783, 
                    "offsetInEndSection": 2110, 
                    "text": "In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133653", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 838, 
                    "offsetInEndSection": 1345, 
                    "text": "Risk of high-grade or advanced stage prostate cancer was modified by interactions between serum markers of Se status and genotypes for rs9880056 in SELK, rs9605030 and rs9605031 in TXNRD2, and rs7310505 in TXNRD1. No significant effects of SNPs on prostate cancer risk were observed when grade or Se status was not taken into account. In conclusion, the risk of high-grade or advanced-stage prostate cancer is significantly altered by a combination of genotype for SNPs in selenoprotein genes and Se status."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20852007", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1417, 
                    "offsetInEndSection": 1566, 
                    "text": "Our results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20424130", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1470, 
                    "offsetInEndSection": 1767, 
                    "text": "This study provides evidence that SEP15 genetic variation may influence PCa mortality. Additionally, the association of selenium with PCa mortality was modified by a variant, suggesting the possibility that some men with PCa may benefit more from selenium than others, depending on their genotype."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690186", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1619, 
                    "offsetInEndSection": 1752, 
                    "text": "We conclude that decreased SEPP concentration in serum might represent an additional valuable marker for prostate cancer diagnostics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299660", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 289, 
                    "text": "The recently completed Selenium and Vitamin E Cancer Prevention Trial (SELECT) was one of the largest human cancer prevention trials ever undertaken. Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15875088", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 325, 
                    "offsetInEndSection": 928, 
                    "text": "We studied Se levels in whole blood, plasma and prostate of 32 PC and 40 benign prostate hyperplasia (BPH) patients and in the control group composed of 39 healthy subjects. The selenoenzyme glutathione peroxidase (GSH-Px) was also measured in the patients' red cells, plasma and prostate tissue. Se concentration in whole blood and plasma in both groups of patients was lower as compared with controls, while in prostate gland it was significantly higher in PC than in BPH patients and controls. Red cell GSH-Px activity was the same in PC patients and controls but significantly lower in BPH patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22072582", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1352, 
                    "offsetInEndSection": 1553, 
                    "text": "Of particular interest was the positive correlation between tissue GPx activity and Gleason score, with this relationship achieving statistical significance among African-Americans (r\u2009=\u20090.67, P\u2009=\u20090.02)"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What is the effect of TRH on myocardial contractility?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009200", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008437", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003285", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", 
                "http://www.biosemantics.org/jochem#4254151", 
                "http://www.uniprot.org/uniprot/TRFR_CHICK", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013973", 
                "http://www.uniprot.org/uniprot/TRFR_HUMAN", 
                "http://www.uniprot.org/uniprot/TRFR_MOUSE", 
                "http://www.uniprot.org/uniprot/TRFR_SHEEP", 
                "http://www.uniprot.org/uniprot/TRFR_RAT", 
                "http://www.uniprot.org/uniprot/TRFR_BOVIN", 
                "http://www.disease-ontology.org/api/metadata/DOID:114", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006331"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15096458", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9225129", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9088928", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1611701", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1979356", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2848686"
            ], 
            "id": "5160193d298dcd4e51000039", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15096458", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 876, 
                    "offsetInEndSection": 1078, 
                    "text": "Acute intravenous administration of TRH to rats with ischemic cardiomyopathy caused a significant increase in heart rate, mean arterial pressure, cardiac output, stroke volume, and cardiac contractility"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9225129", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 92, 
                    "offsetInEndSection": 144, 
                    "text": "TRH can enhance cardiomyocyte contractility in vivo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9088928", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 257, 
                    "text": "TRH in the range of 0.1-10 mumol/l was found to exert a positive inotropic effect on cardiac contractility"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1611701", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 139, 
                    "text": "Thyrotropin-releasing hormone (TRH) improved mean arterial pressure (MAP) and myocardial contractility (dp/dtmax, -dp/dtmax, Vpm, and Vmax)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1611701", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1124, 
                    "offsetInEndSection": 1192, 
                    "text": "TRH improves cardiac contractility, cardiac output, and hemodynamics"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1979356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 142, 
                    "text": "Thyrotropin-releasing hormone (TRH) could improve mean arterial pressure (MAP), myocardial contractile parameters (+/- dp/dtmax, Vpm and Vmax)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2848686", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 170, 
                    "offsetInEndSection": 281, 
                    "text": "TRH increased the contractile force of muscles dose-dependently without changing the time course of contraction"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2848686", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 522, 
                    "offsetInEndSection": 619, 
                    "text": "TRH potentiated the response of contractile force to increasing extracellular Ca2+ concentration."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2848686", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 857, 
                    "offsetInEndSection": 959, 
                    "text": "TRH has a positive inotropic effect at least partly due to an increase in the slow inward Ca2+ current"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Have germline variants been associated to colorectal cancer?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017422", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059014"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23263490", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22431159", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22020387", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21918173", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21791631", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21351276", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18091433", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17604324", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17524638"
            ], 
            "id": "5161cfa3298dcd4e5100003d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431159", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 288, 
                    "offsetInEndSection": 766, 
                    "text": "Overall, we identified aberrant transcripts in 8% of the patients (familial cases 30%; early-onset manifestation 21%). In eight of them, two different out-of-frame pseudoexons were found consisting of a 167-bp insertion from intron 4 in five families with a shared founder haplotype and a 83-bp insertion from intron 10 in three patients. The pseudoexon formation was caused by three different heterozygous germline mutations, which are supposed to activate cryptic splice sites"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22020387", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 270, 
                    "offsetInEndSection": 717, 
                    "text": "We apply OS-Seq to resequence the exons of either 10 or 344 cancer genes from human DNA samples. In our assessment of capture performance, >87% of the captured sequence originated from the intended target region with sequencing coverage falling within a tenfold range for a majority of all targets. Single nucleotide variants (SNVs) called from OS-Seq data agreed with >95% of variants obtained from whole-genome sequencing of the same individual."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21918173", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 912, 
                    "offsetInEndSection": 1545, 
                    "text": "The minor alleles of CD44 rs8193 C>T, ALCAM rs1157 G>A, and LGR5 rs17109924 T>C were significantly associated with increased TTR (9.4 vs. 5.4 years; HR, 0.51; 95% CI: 0.35-0.93; P = 0.022; 11.3 vs. 5.7 years; HR, 0.56; 95% CI: 0.33-0.94; P = 0.024, and 10.7 vs. 5.7 years; HR, 0.33; 95% CI: 0.12-0.90; P = 0.023, respectively) and remained significant in the multivariate analysis stratified by ethnicity. In recursive partitioning, a specific gene variant profile including LGR5 rs17109924, CD44 rs8193, and ALDH1A1 rs1342024 represented a high-risk subgroup with a median TTR of 1.7 years (HR, 6.71, 95% CI: 2.71-16.63, P < 0.001)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21791631", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1432, 
                    "offsetInEndSection": 1677, 
                    "text": "In this study, we identified common germline variants in VEGF-dependent and -independent angiogenesis genes predicting clinical outcome and tumor response in patients with mCRC receiving first-line bevacizumab and oxaliplatin-based chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351276", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 979, 
                    "offsetInEndSection": 1354, 
                    "text": "We identified 22 nonsynonymous somatic mutations of which the majority was of missense type. In germline, three novel nonsynonymous variants were identified in the following genes: CSMD3, EPHB6 and C10orf137, and none of the variants were present in 890 population-matched healthy controls. It is possible that the identified germline variants modulate predisposition to CRC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18091433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 863, 
                    "offsetInEndSection": 1246, 
                    "text": "One patient proved to carry an APC whole-gene deletion; 4 of 25 (16%) patients showed biallelic and 3 of 25 (12%) monoallelic MUTYH mutations. In the three heterozygous subjects no pathogenetic variants were found in OGG1, MTH1, APE1, MSH2, and MSH6 genes. Frequency assessment of MUTYH mutations in healthy subjects showed that only Y165C and G382D reach a subpolymorphic frequency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17604324", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 872, 
                    "offsetInEndSection": 1355, 
                    "text": "Scrutinizing the molecular genetic results and family data of 242 index patients with pathogenic APC mutations led to the identification of 10 mosaic cases (4%). C>T transitions were observed in CGA sites in four of the 10 cases with somatic mosaicism, which is significantly more than 26 of the 232 non-mosaic cases (p = 0.02). Phenotypes of patients with somatic mosaicism ranged from an attenuated form of polyposis coli to florid polyposis with major extracolonic manifestations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17524638", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 494, 
                    "offsetInEndSection": 936, 
                    "text": "Altogether 12 previously reported changes and four novel genetic alterations, mostly in intronic sequences, were identified. The results revealed the presence of biallelic germline MYH mutations in two patients. These patients were compound heterozygotes for two of the most common germline mutations c.494 A>G (p.Y165C); c.1,145 G>A (p.G382D). These variants are established to be associated with adenomatous polyposis and colorectal cancer."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010748", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045163"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23485197", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22906719", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22499769", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22499768", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22369663", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22345495", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21822884", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20927383", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20340162", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17372656"
            ], 
            "id": "516281e6298dcd4e51000040", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23485197", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 156, 
                    "offsetInEndSection": 383, 
                    "text": "Phosphopeptide enrichment by SCX and TiO2 lead to the identification of a total of 10,096 phosphorylation sites on 2,551 protein groups, and quantified the ratios of 8,275 phosphorylation sites between the two lifecycle stages."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22906719", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 113, 
                    "text": "TiSH--a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22906719", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 429, 
                    "offsetInEndSection": 740, 
                    "text": "An initial TiO(2) phosphopeptide pre-enrichment step is followed by post-fractionation using sequential elution from IMAC (SIMAC) to separate multi- and mono-phosphorylated peptides, and hydrophilic interaction liquid chromatography (HILIC) of the mono-phosphorylated peptides (collectively abbreviated \"TiSH\")."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22499769", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 618, 
                    "offsetInEndSection": 729, 
                    "text": "After enrichment by anti-phosphotyrosine antibodies, we identified 29 potential novel c-Src substrate proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22499768", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 579, 
                    "offsetInEndSection": 845, 
                    "text": "Combining immunoprecipitation with an antiphosphotyrosine antibody, titanium dioxide phosphopeptide enrichment, isobaric tag for the relative and absolute quantitation methodology, and strong cation exchange separation, we were able to identify 2814 phosphopeptides."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22369663", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 443, 
                    "offsetInEndSection": 710, 
                    "text": "Phosphopeptide fractionation by strong cation exchange chromatography combined with immobilized metal affinity chromatography (IMAC) enrichment enabled quantification of more than 8000 distinct phosphorylation sites in Ppt1 wild-type versus Ppt1-deficient yeast cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22345495", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 710, 
                    "offsetInEndSection": 868, 
                    "text": "By employing titanium dioxide in addition to antiphosphotyrosine antibodies as enrichment methods, we identified 4164 phosphopeptides on 1670 phosphoproteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21822884", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 676, 
                    "offsetInEndSection": 942, 
                    "text": "Our method combines the use of strong cation exchange (SCX) and titanium dioxide (TiO(2)) for phosphopeptide enrichment, high-resolution MS for peptide and protein identification, and stable isotope labeling by amino acids in cell culture (SILAC) for quantification."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20927383", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2637, 
                    "offsetInEndSection": 2920, 
                    "text": "By coupling with a phosphoprotein or phosphopeptide enrichment method, such as titanium dioxide (TiO2) [17], strong cation exchange (SCX) [18], or the two in combination [19], SILAC has been widely applied to profile dynamic phosphorylation changes in signal transduction [20], [21]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17372656", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1007, 
                    "offsetInEndSection": 1136, 
                    "text": "Phosphopeptides were isolated with high specificity through a simple derivatization procedure based on phosphoramidate chemistry."
                }
            ], 
            "triples": [
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A0319731", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0031684"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is the role of deadenylases in the cell?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/CNOT6_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23496118", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23388391", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23019593", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21984185", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22614729", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22955276", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19307292", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19111172", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18625844", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18334997", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18056425", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17090538", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15247430", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14970390", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12590136"
            ], 
            "id": "5162af0f298dcd4e51000045", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496118", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 9, 
                    "offsetInEndSection": 149, 
                    "text": "Deadenylation of eukaryotic mRNA is a mechanism critical for mRNA function by influencing mRNA turnover and efficiency of protein synthesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496118", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 516, 
                    "offsetInEndSection": 696, 
                    "text": "In short, PARN is a divalent metal-ion dependent poly(A)-specific, processive and cap-interacting 3'-5' exoribonuclease that efficiently degrades poly(A) tails of eukaryotic mRNAs."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388391", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 110, 
                    "text": "Distinct roles of the R3H and RRM domains in poly(A)-specific ribonuclease structural integrity and catalysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388391", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 378, 
                    "text": "Deadenylases specifically catalyze the degradation of eukaryotic mRNA poly(A) tail in the 3'- to 5'-end direction with the release of 5'-AMP as the product. Among the deadenylase family, poly(A)-specific ribonuclease (PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and the RRM domain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1671, 
                    "offsetInEndSection": 2034, 
                    "text": "DEDD-type nucleases, such as PARN, PAN2 and Pop2p, are RNA-specific and contain a number of conserved catalytic aspartate and glutamate residues in the active site required for catalysis, while EEP nucleases, such as Ccr4p, belong to a much broader class of enzymes capable of degrading both RNA and DNA via both exonucleolytic and endonucleolytic mechanisms (1)."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 271, 
                    "offsetInEndSection": 435, 
                    "text": "In particular, Mn2+ appears to alter the rate of catalysis and specificity of the enzyme in a subtle way removing some of the specificity of the enzyme (Figure 1C)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 441, 
                    "offsetInEndSection": 574, 
                    "text": "Deadenylation is thus the first and rate-limiting step of mRNA turnover, making it an important control point during gene expression."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21984185", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 111, 
                    "text": "miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614729", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 130, 
                    "offsetInEndSection": 224, 
                    "text": "The rate-limiting step of mRNA degradation is the removal of the poly(A) tail by deadenylases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955276", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 668, 
                    "offsetInEndSection": 819, 
                    "text": "Purified PUM complexes were found to contain subunits of the CCR4-NOT (CNOT) complex, which contains multiple enzymes that catalyze mRNA deadenylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955276", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1192, 
                    "offsetInEndSection": 1381, 
                    "text": "These findings demonstrate a conserved mechanism of PUF-mediated repression via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational inhibition and mRNA degradation."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19307292", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 121, 
                    "text": "The activity and selectivity of fission yeast Pop2p are affected by a high affinity for Zn2+ and Mn2+ in the active site."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19307292", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 233, 
                    "text": "In eukaryotic organisms, initiation of mRNA turnover is controlled by progressive shortening of the poly-A tail, a process involving the mega-Dalton Ccr4-Not complex and its two associated 3'-5' exonucleases, Ccr4p and Pop2p (Caf1p)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19307292", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 421, 
                    "offsetInEndSection": 698, 
                    "text": "Here, we show biochemically and structurally that fission yeast (Schizosaccharomyces pombe) Pop2p prefers Mn(2+) and Zn(2+) over Mg(2+) at the concentrations of the ions found inside cells and that the identity of the ions in the active site affects the activity of the enzyme."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19111172", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 205, 
                    "text": "The 3'-poly(A) tail, found on virtually all mRNAs, is enzymatically shortened by a process referred to as \"deadenylation.\" Deadenylation is a widespread means of controlling mRNA stability and translation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18625844", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 800, 
                    "offsetInEndSection": 1013, 
                    "text": "Poly(A) tails are first shortened to \u223c110 nt by Pan2 in association with Pan3. In the second phase of deadenylation, a complex composed of Ccr4 and Caf1 catalyze further shortening of the poly(A) tail to oligo(A)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334997", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "Dynamic changes of the lengths of mRNA poly(A) tails are catalysed by diverse deadenylase enzymes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056425", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 241, 
                    "text": "In eukaryotes, shortening of the 3'-poly(A) tail is the rate-limiting step in the degradation of most mRNAs, and two major mRNA deadenylase complexes--Caf1-Ccr4 and Pan2-Pan3--play central roles in this process, referred to as deadenylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056425", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 317, 
                    "offsetInEndSection": 471, 
                    "text": "Previously, we demonstrated that eukaryotic releasing factor eRF3 mediates deadenylation and decay of mRNA in a manner coupled to translation termination."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17090538", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 57, 
                    "text": "PUF protein-mediated deadenylation is catalyzed by Ccr4p."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15247430", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 342, 
                    "text": "Deadenylation of mRNA is often the first and rate-limiting step in mRNA decay. PARN, a poly(A)-specific 3' --> 5' ribonuclease which is conserved in many eukaryotes, has been proposed to be primarily responsible for such a reaction, yet the importance of the PARN function at the whole-organism level has not been demonstrated in any species."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14970390", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 586, 
                    "offsetInEndSection": 776, 
                    "text": "The trypanosomal deadenylase activity is a 3'-->5' exonuclease specific for adenylate residues, generates 5'-AMP as a product, is magnesium dependent, and is inhibited by neomycin B sulfate."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12590136", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 83, 
                    "text": "Identification of multiple RNA features that influence CCR4 deadenylation activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12590136", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 115, 
                    "text": "The CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA."
                }
            ], 
            "triples": [
                {
                    "o": "mRNA deadenylase", 
                    "p": "http://purl.uniprot.org/core/fullName", 
                    "s": "http://linkedlifedata.com/resource/#_443256444B36007"
                }, 
                {
                    "o": "Cytoplasmic deadenylase", 
                    "p": "http://purl.uniprot.org/core/fullName", 
                    "s": "http://linkedlifedata.com/resource/#_503331333834001E"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What are the functions of sorting nexin 27?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058305", 
                "http://www.uniprot.org/uniprot/SNX27_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23536889", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23524343", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22411990", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21926430", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21602791", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18690037", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21303929", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21300787", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20733053", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17828261", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17644068", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17577583", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17351151", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15466885"
            ], 
            "id": "5162da97298dcd4e51000048", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23524343", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 107, 
                    "text": "Sorting nexin 27 (SNX27), a brain-enriched PDZ domain protein, regulates endocytic sorting and trafficking."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23524343", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 262, 
                    "offsetInEndSection": 320, 
                    "text": "we found defects in synaptic function, learning and memory"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22411990", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 808, 
                    "offsetInEndSection": 1027, 
                    "text": "Knockdown of SNX27 by siRNA in HEK293 cells raised MRP4 expression on the plasma membrane, increased the extrusion of 6-[(14)C]mercaptopurine, an MRP4 substrate, and conferred resistance against 6-[(14)C]mercaptopurine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926430", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 156, 
                    "text": "Sorting nexin 27 (SNX27) is a 62-kDa protein localized to early endosomes and known to regulate the intracellular trafficking of ion channels and receptors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926430", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1028, 
                    "offsetInEndSection": 1315, 
                    "text": "Finally, migration assays revealed that depletion of SNX27 from HeLa and mouse principal kidney cortical collecting duct cells significantly decreases cell motility. We propose a model by which SNX27 regulates trafficking of \u03b2-Pix to focal adhesions and thereby influences cell motility."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15466885", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1237, 
                    "offsetInEndSection": 1306, 
                    "text": "We found that SNX27a redirected part of 5-HT4(a)R to early endosomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17351151", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 688, 
                    "offsetInEndSection": 800, 
                    "text": "sorting nexin 27 (SNX27), a recently described member of a protein family involved in intracellular trafficking,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17351151", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1199, 
                    "offsetInEndSection": 1323, 
                    "text": "SNX27 co-localized with transferrin receptor-positive vesicles, pointing to its participation in T cell endocytic recycling."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17577583", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 631, 
                    "offsetInEndSection": 783, 
                    "text": "This protein is a unique member of the sorting nexin family of proteins, a group generally involved in the endocytic and intracellular sorting machinery"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644068", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 815, 
                    "offsetInEndSection": 954, 
                    "text": "These previously unreported results indicate that SNX27 is a participant in NK cell polarization, as a mediator or target of the mechanism."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17828261", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 271, 
                    "offsetInEndSection": 480, 
                    "text": "Like most sorting nexins, SNX27 possesses a functional PX domain that selectively binds the membrane phospholipid phosphatidylinositol-3-phosphate (PI3P) and is important for trafficking to the early endosome."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20733053", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 24067, 
                    "offsetInEndSection": 24328, 
                    "text": "We believe that the present study, by establishing SNX27 as a mediator of PDZ motif\u2013directed recycling from the early endosome membrane, significantly extends the concept of molecular sorting in the recycling pathway and supports its physiological significance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300787", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 902, 
                    "offsetInEndSection": 1130, 
                    "text": "This is consistent with a role of SNX27 as a general regulator for sorting of membrane proteins containing a PDZ-binding motif, and its absence may alter the trafficking of these proteins, leading to growth and survival defects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303929", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 295, 
                    "text": "Sorting nexin 27 (SNX27) belongs to the sorting nexin family of proteins, which participate in vesicular and protein trafficking. Similarly to all sorting nexin proteins, SNX27 has a functional PX domain that is important for endosome binding, but it is the only sorting nexin with a PDZ domain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303929", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1186, 
                    "offsetInEndSection": 1424, 
                    "text": "These results identify SNX27 as a PDZ-containing component of the T cell immunological synapse, and demonstrate a role for this protein in the regulation of the Ras-ERK pathway, suggesting a functional relationship between SNX27 and DGK\u03b6."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18690037", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 406, 
                    "offsetInEndSection": 500, 
                    "text": "Sorting nexins have been implicated in trafficking of proteins through endosomal compartments."
                }, 
                {
                    "beginSection": "sections.14", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602791", 
                    "endSection": "sections.14", 
                    "offsetInBeginSection": 456, 
                    "offsetInEndSection": 668, 
                    "text": "SNX27 contains a PDZ domain that binds the \u03b22AR tail, and has recently been shown to be essential for PDZ-directed recycling of the \u03b22AR30. Verifying this, knockdown of SNX27 robustly inhibited recycling of \u03b22ARs"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/NEP_RABIT", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015260", 
                "http://www.uniprot.org/uniprot/NEP_HUMAN", 
                "http://www.disease-ontology.org/api/metadata/DOID:10652", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023582", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016503", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018014"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22751177", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21304989", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17760499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19469700", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23503602", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23378928", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22114052", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20817034"
            ], 
            "id": "5162e44f298dcd4e5100004a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21304989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1523, 
                    "offsetInEndSection": 1738, 
                    "text": "We and other groups have shown that overexpression of NEP by gene transfer with viral vectors[12], [13], [14], transgenesis[15], or induction[16], [17], [18], [19], [20] resulted in a reduction in amyloid pathology."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21304989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2137, 
                    "offsetInEndSection": 2446, 
                    "text": "a novel approach was developed for delivering therapeutic proteins to neurons of the CNS by targeting passage across the BBB[21]. Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein allows active transport of the protein across the BBB to the CNS."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17760499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1203, 
                    "offsetInEndSection": 1464, 
                    "text": "Supporting a therapeutic function for A\u03b2-degrading proteases, both transgenic overexpression [15] and direct viral vector injection [14,16,17] of these enzymes have been shown to potently lower A\u03b2 levels and plaque burden and reduce A\u03b2-associated neuropathology"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17760499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1604, 
                    "offsetInEndSection": 1765, 
                    "text": "In ex vivo gene therapy, cells are taken from a patient, genetically modified in vitro, then implanted back into the patient to exert their new salutary effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17760499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3204, 
                    "offsetInEndSection": 3568, 
                    "text": "we replaced the transmembrane domain of NEP with a signal peptide, which produced a soluble and secreted form of NEP, termed sNEP. We then used ex vivo gene delivery utilizing syngenic primary fibroblasts to introduce sNEP into the brains of APP transgenic mice that had advanced plaque deposition and studied the effect of this protein on brain amyloid pathology."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23503602", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 510, 
                    "offsetInEndSection": 602, 
                    "text": "A single intracardiac administration of the vector carrying neprilysin gene in AD-model mice"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114052", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 641, 
                    "offsetInEndSection": 816, 
                    "text": "he novel, syringe-focused US device was used to introduce purified plasmid DNA encoding human neprilysin (hNEP) into mouse hindlimb skeletal muscle concurrent with US protocol"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20817034", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1494, 
                    "offsetInEndSection": 1673, 
                    "text": "This technique provides a safe and efficient non-viral method for in vivo gene delivery with potential applications in both basic research and in gene therapy of neuronal disease."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20817034", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 78, 
                    "text": "A novel system for in vivo neprilysin gene delivery using a syringe electrode."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22751177", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 97, 
                    "offsetInEndSection": 257, 
                    "text": "Previous studies have demonstrated the therapeutic potential of viral vector-mediated neprilysin (NEP) gene therapy in mouse models of Alzheimer's disease (AD)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22751177", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 93, 
                    "text": "Convection-enhanced delivery of neprilysin: a novel amyloid-\u03b2-degrading therapeutic strategy."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17760499", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 139, 
                    "text": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378928", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 235, 
                    "offsetInEndSection": 561, 
                    "text": "Thus, researchers have explored virus-mediated NEP gene delivery. However, such strategies may entail unexpected risks, and thus exploration of a new possibility for NEP delivery is also required. Here, we show that human adipose tissue-derived mesenchymal stem cells (ADSCs) secrete exosomes carrying enzymatically active NEP"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378928", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 968, 
                    "offsetInEndSection": 1037, 
                    "text": "suggesting the therapeutic relevance of ADSC-derived exosomes for AD."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378928", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What are the advantages of the top down mass spectrometric analysis of histones?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013058", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053719", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013057", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016339", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019032", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D021241", 
                "http://www.biosemantics.org/jochem#4278518", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042421"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23466885", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23034525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22647927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21898261", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21249157", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20879039", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20848673", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20707390", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20486121", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20202861", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18381279", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18302345", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17967882", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17652096", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17569892", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16457589", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16457588", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16457587", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15025441", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14976258"
            ], 
            "id": "51630226298dcd4e5100004d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034525", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 358, 
                    "offsetInEndSection": 449, 
                    "text": "high-throughput and sensitive characterization of histone PTMs at the intact protein level."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21898261", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 648, 
                    "offsetInEndSection": 996, 
                    "text": "recent advances in MS technology, such as high-field Fourier transform ion cyclotron resonance (FTICR)-mass spectrometry, have permitted the study of intact proteins and their modifications. On-line and off-line protein separation instruments coupled to FTICR-MS allow the characterization of PTMs previously undetectable with bottom-up approaches."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879039", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 252, 
                    "offsetInEndSection": 465, 
                    "text": "With just \u223c24\u2009\u03bcg on-column of core histones (H4, H2B, H2A, and H3) purified from human fibroblasts, 41 H4 isoforms were identified, with the type and location of PTMs unambiguously mapped for 20 of these variants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466885", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 917, 
                    "offsetInEndSection": 1305, 
                    "text": "This synopsis emphasizes how the advances in high resolution MS, from \"Bottom Up\" to \"Top Down\" analysis, together with the uptake of quantitative proteomics methods by chromatin biologists, have made MS a well-established method in the epigenetics field, enabling the acquisition of original information, highly complementary to that offered by more conventional, antibody-based, assays."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 714, 
                    "offsetInEndSection": 881, 
                    "text": "Our results indicated that dH1 is extensively modified by phosphorylation, methylation, acetylation and ubiquitination, with most PTMs falling in the N-terminal domain"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249157", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4786, 
                    "offsetInEndSection": 4979, 
                    "text": "More recently, advances in MS have led to the development of the top-down approach as a complementary method to bottom-up analysis as a highly useful means by which to identify PTMs on histones"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20848673", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 615, 
                    "offsetInEndSection": 890, 
                    "text": "Optimized for the intricacies of whole proteins, new software modules visualize proteome-scale data based on the LC retention time and intensity of intact masses and enable selective detection of PTMs to automatically screen for acetylation, phosphorylation, and methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707390", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1252, 
                    "offsetInEndSection": 1396, 
                    "text": "our UHPLC-MS approach for histone profiling offers a sensitive and reproducible tool that will be of great value for exploring PTMs and variants"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20486121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1105, 
                    "offsetInEndSection": 1285, 
                    "text": "This work demonstrates the power of top-down MS for a detailed structural confirmation of recombinant proteins, even without prior information on aa substitutions or modifications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20202861", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1079, 
                    "offsetInEndSection": 1187, 
                    "text": "Top and Middle Down MS were utilized to identify the most commonly occurring combinatorially modified forms."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18302345", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 321, 
                    "offsetInEndSection": 533, 
                    "text": "In this paper we investigate the application of spectral alignment to the problem of identifying protein forms in top-down mass spectra (i.e., identifying the modifications, mutations, insertions, and deletions)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18381279", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1351, 
                    "offsetInEndSection": 1464, 
                    "text": "This work represents the most comprehensive analysis of histone H4 forms present in human cells reported to date."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17967882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 280, 
                    "offsetInEndSection": 510, 
                    "text": "Metabolic labeling and top-down mass spectrometry reveal that newly synthesized H4 is progressively methylated at K20 during the G(2), M, and G(1) phases of the cell cycle in a process that is largely inescapable and irreversible."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652096", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 370, 
                    "offsetInEndSection": 505, 
                    "text": "The \"top down\" mass spectrometry approach detected dramatic decreases in acetylation on H3 and H2B in gcn5Delta cells versus wild type."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652096", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1207, 
                    "offsetInEndSection": 1451, 
                    "text": "In sum, we have defined the \"basis set\" of histone forms present in yeast chromatin using a current mass spectrometric approach that both quickly profiles global changes and directly probes the connectivity of modifications on the same histone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569892", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 329, 
                    "text": "Recent developments in top down mass spectrometry have enabled closely related histone variants and their modified forms to be identified and quantitated with unprecedented precision, facilitating efforts to better understand how histones contribute to the epigenetic regulation of gene transcription and other nuclear processes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16457589", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 347, 
                    "offsetInEndSection": 524, 
                    "text": "This unequivocal identification of H2A forms illustrates the advantages of Top Down Mass Spectrometry and provides a global perspective of H2A regulation through the cell cycle."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16457588", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 96, 
                    "text": "The modification of H3 in asynchronous HeLa cells was profiled using Top Down Mass Spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16457587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 126, 
                    "text": "The basis set of protein forms expressed by human cells from the H2B gene family was determined by Top Down Mass Spectrometry."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15025441", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 176, 
                    "offsetInEndSection": 458, 
                    "text": "To help crack this code more efficiently, we demonstrate a new strategy for protein characterization wherein complete PTM descriptions are obtained by database retrieval instead of manual interpretation of information-rich data from high-resolution tandem mass spectrometry (MS/MS)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14976258", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "Targeted analysis and discovery of posttranslational modifications in proteins from methanogenic archaea by top-down MS."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14976258", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1268, 
                    "offsetInEndSection": 1429, 
                    "text": "This study illustrates a significant evolutionary step for the MS tools available for characterization of WT proteins from complex proteomes without proteolysis."
                }
            ], 
            "triples": [
                {
                    "o": "Mass Spectrometry Mass Spectrometry", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10908479"
                }, 
                {
                    "o": "histone", 
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/chebi/id/CHEBI:15358"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is the use of MammaPrint and Oncotype DX?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045506"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23573359", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23462680", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23411384", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23337633", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22359236", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21998967", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21501481", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20587405", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23495982", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19585214", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19101988"
            ], 
            "id": "5167d47e298dcd4e5100005e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23573359", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 122, 
                    "offsetInEndSection": 599, 
                    "text": "Molecular tests such as the 21 gene expression test (Oncotype DX(TM)) and 70 gene microarray test (MammaPrint(\u00ae)) have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, HER2 targeted therapy or endocrine therapy or the combination of the therapies for patients with particular genetic expressions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462680", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 697, 
                    "text": "Gene expression profiling tests are used in an attempt to determine the right treatment for the right person with early-stage breast cancer that may have spread to nearby lymph nodes but not to distant parts of the body. These new diagnostic approaches are designed to spare people who do not need additional treatment (adjuvant therapy) the side effects of unnecessary treatment, and allow people who may benefit from adjuvant therapy to receive it. In the present review we discuss in detail the major diagnostic tests available such as MammaPrint dx, Oncotype dx, PAM50, Mammostrat, IHC4, MapQuant DX, Theros-Breast Cancer Gene Expression Ratio Assay, and their potential clinical applications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411384", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 185, 
                    "text": "Oncotype DX, PAM50, and MammaPrint are multigene tests that are being used clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23337633", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 504, 
                    "text": "We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit. METHODS: Independent evaluation of six genomic tests [Oncotype Dx\u2122, MammaPrint(\u00ae), Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP criteria. PANEL"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22359236", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 526, 
                    "text": "Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph node-negative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the cost effectiveness of recurrence score-guided treatment using 2 commercially available GEP tests, Oncotype DX (Genomic Health, Redwood City, Calif) and MammaPrint (Agendia Inc., Irvine, Calif), from a third-party payer's perspective."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998967", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 128, 
                    "offsetInEndSection": 686, 
                    "text": "genomic tumor signatures that predict a patient's risk of breast cancer recurrence and response to chemotherapy. The paper builds on empirical evidence from the two trials to explore the emergence of diverse regulatory-scientific hybrids; that is, the paper discusses configurations of genomic practice and bioclinical work that depend on linkages between technical, commercial, patient, clinical, and legal interests and institutions. The development of the genomic signatures for each trial--Oncotype DX and MammaPrint--has followed quite different routes."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501481", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4538, 
                    "offsetInEndSection": 4978, 
                    "text": "In addition to examining the relationship between the molecular subtypes of breast cancer identified in this study and various clinical parameters, our classifier genes were also applied to the other two published independent breast cancer datasets for confirmation [10,24]. In addition, we used the reported genes of the OncotypeDX [8] and MammaPrint [3] predictors to assess the risk of distant recurrence for cases in all three datasets."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1350, 
                    "offsetInEndSection": 1694, 
                    "text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587405", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 476, 
                    "offsetInEndSection": 903, 
                    "text": "We will review the primary tools in clinical use: Adjuvant!, Oncotype DX, and MammaPrint as well as intrinsic subtypes and the plans for their further assessment in the clinical trial setting. The expected benefit from these models are that treatment recommendations for women with early-stage breast cancer will become more individualized and thereby appropriate by combining standard clinicopathologic and molecular features."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23495982", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 559, 
                    "offsetInEndSection": 914, 
                    "text": "newer prognostic markers with a focus on the 21-gene recurrence score (Oncotype DX(\u2122)), 70-gene prognosis profile (Mammaprint(\u00ae)), and Adjuvant! Online. Conclusion: These techniques differ in their execution and application and have been demonstrated to provide further data on risk stratification as compared with conventional breast-cancer-risk factors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19585214", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 18, 
                    "offsetInEndSection": 496, 
                    "text": "diagnostic tools such as MammaPrint and oncotype-DX are beginning to have impact on clinical practice of breast cancer. They are based on gene expression profiling, i.e., gene expression analysis of a large number of genes. Their unique characteristic is the use of a score calculated from expression values of a number of genes, for which the Food and Drug Administration (FDA) created a new diagnostic category entitled \"in vitro diagnostic multivariate index assay (IVDMIA).\""
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 699, 
                    "offsetInEndSection": 970, 
                    "text": "the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples."
                }
            ], 
            "triples": [
                {
                    "o": "MammaPrint", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17680439"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17680439", 
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2827401"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10812803"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A10812803", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1709318"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Does Serca2a bind PLN in the heart?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/PPLA_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053498"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22693651", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22659291", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22129433", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20484118", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17515962", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17241641", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11854448", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12424227", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12589804", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12610310", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12763867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9603928", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9182523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8702967"
            ], 
            "id": "51680b05298dcd4e51000064", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 110, 
                    "text": "The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1259, 
                    "offsetInEndSection": 1338, 
                    "text": "Moreover, PLN-R14Del did not co-immunoprecipitate with SERCA2a (as did WT-PLN),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22129433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 441, 
                    "offsetInEndSection": 695, 
                    "text": "n this review, we attempted to highlight the functional significance of PLN in vertebrate cardiac physiology. We will refer to the huge literature on mammals in order to describe the molecular characteristics of this protein, its interaction with SERCA2a"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8702967", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 189, 
                    "text": "There is clear evidence for direct regulatory protein-protein interactions between phospholamban (PLN) and the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) in cytoplasmic domains"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8702967", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1216, 
                    "offsetInEndSection": 1447, 
                    "text": "These results suggest that PLN modulates the apparent Ca2+ affinity of SERCA2a through intramembrane interactions, which are disrupted at long range and in concert with disruption of the well characterized cytoplasmic interactions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9182523", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 183, 
                    "text": "Phospholamban (PLN), a homopentameric, integral membrane protein, reversibly inhibits cardiac sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity through intramembrane interactions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9182523", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1247, 
                    "offsetInEndSection": 1493, 
                    "text": "The concentration of this inhibited complex is determined by the dissociation constant for the PLN pentamer (which is mutation-sensitive) and by the dissociation constant for the PLN/SERCA2a heterodimer (which is likely to be mutation-sensitive)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603928", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1439, 
                    "offsetInEndSection": 1634, 
                    "text": "These results support the proposal that PLN inhibition of SERCA2a involves, first, depolymerization of PLN and, second, the formation of inhibitory interactions between monomeric PLN and SERCA2a."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12763867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 979, 
                    "offsetInEndSection": 1162, 
                    "text": "SLN and PLN appear to bind to the same regulatory site in SERCA. However, in a ternary complex, PLN occupies the regulatory site and SLN binds to the exposed side of PLN and to SERCA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610310", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 595, 
                    "offsetInEndSection": 707, 
                    "text": "Cellular and biochemical studies revealed that, unlike wild-type PLN, PLN(R9C) did not directly inhibit SERCA2a."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12589804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 789, 
                    "offsetInEndSection": 997, 
                    "text": ". Conversely, using anti-SERCA2a antibody, both PLN and acylphosphatase were co-immunoprecipitated with SERCA2a, and the PLN amount in the precipitate decreased with increasing acylphosphatase concentrations."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11854448", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "Reconstitution of the cytoplasmic interaction between phospholamban and Ca(2+)-ATPase of cardiac sarcoplasmic reticulum."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11854448", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 235, 
                    "text": "Phospholamban (PLN) reversibly inhibits the Ca(2+)-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) through a direct protein-protein interaction, playing a pivotal role in the regulation of intracellular Ca(2+) in heart muscle cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 258, 
                    "text": "Phospholamban (PLN) is a key regulator of Ca(2+) homeostasis and contractility in the heart. Its regulatory effects are mediated through its interaction with the sarcoplasmic reticulum Ca(2+)-ATPase, (SERCA2a), resulting in alterations of its Ca(2+)-affinity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20484118", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1138, 
                    "offsetInEndSection": 1284, 
                    "text": "In a co-immunoprecipitation of PLN with SERCA2a, the physical interaction between the two proteins was increased in PUGNAc-treated cardiomyocytes."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is the UGT1A1*28 polymorphism associated with irinotecan response in Caucasians?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/UD11_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011110", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020641", 
                "http://www.biosemantics.org/jochem#4260100", 
                "http://www.biosemantics.org/jochem#4231334", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044465"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23529007", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23516488", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22866151", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22077505", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18832463", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18633245", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17762398", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15286088"
            ], 
            "id": "51680b0e298dcd4e51000065", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23529007", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 578, 
                    "offsetInEndSection": 888, 
                    "text": "UGT1A1*28/*28 genotype was associated with more than fourfold (odds ratio (OR)=4.79, 95% confidence intervals (CI): 3.28-7.01; P<0.00001) and threefold (OR=3.44, 95% CI: 2.45-4.82; P<0.00001) increases in the risk of neutropenia when compared with wild type and with at least one UGT1A1*1 allele, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23516488", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 868, 
                    "offsetInEndSection": 1133, 
                    "text": "Differences in TR, PFS and OS for any genotype comparison, UGT1A1*28/*28 versus (vs) UGT1A1*1/*1 (homozygous model), UGT1A1*1/*28 vs UGT1A1*1/*1 (heterozygous model), and UGT1A1*28/*28 vs all others (recessive model, only for TR) were not statistically significant."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23516488", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1698, 
                    "offsetInEndSection": 1945, 
                    "text": "UGT1A1*28 polymorphism cannot be considered as a reliable predictor of TR and PFS in CRC patients treated with IRI-based chemotherapy. The OS relationship with UGT1A1*28 in the patients with lower-dose IRI chemotherapy requires further validation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22077505", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 912, 
                    "offsetInEndSection": 980, 
                    "text": "These variants are associated with greater risk of serious toxicity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18832463", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 384, 
                    "offsetInEndSection": 507, 
                    "text": "Homozygous carriers of UGT1A1*28 as well as those with additional UGT1A variants can suffer from severe irinotecan toxicity"
                }
            ], 
            "triples": [
                {
                    "o": "http://purl.uniprot.org/core/Gene", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/#_5136543545370015"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/drugs", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00762"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What is the mode of inheritance of nemaline myopathy?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3191", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017696", 
                "http://www.disease-ontology.org/api/metadata/DOID:423", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020914", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020512"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17846275", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15336686", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2213842"
            ], 
            "id": "516be1d6298dcd4e5100006a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17846275", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 879, 
                    "offsetInEndSection": 1010, 
                    "text": "The results indicate that mutations in TPM2 may cause nemaline myopathy as well as cap disease with a dominant mode of inheritance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15336686", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 346, 
                    "offsetInEndSection": 435, 
                    "text": "Autosomal recessive inheritance had been verified or appeared likely in all nebulin cases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15336686", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 664, 
                    "offsetInEndSection": 850, 
                    "text": "Most cases were sporadic, but in addition there were instances of both autosomal dominant and autosomal recessive inheritance, while two families showed mosaicism for dominant mutations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15336686", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1046, 
                    "offsetInEndSection": 1114, 
                    "text": "Finding the causative mutation(s) determines the mode of inheritance"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2213842", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 751, 
                    "offsetInEndSection": 967, 
                    "text": "We conclude that in the Finnish CNM patients, the mode of inheritance appears to be recessive. Apart from a few instances of dominant inheritance, most cases published also seem compatible with recessive inheritance."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What is the gene frequently mutated in Multiple endocrine neoplasia 2 (MEN2) and Hisrchsprung disease?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006627", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018813"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23210566", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22199277", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21678021", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21542403", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21422799", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20152359", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19826964", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19177457", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18062802", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17525482", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16712668", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15991157", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9745455", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7641404"
            ], 
            "id": "5171438a8ed59a060a000007", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23210566", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2064, 
                    "offsetInEndSection": 2196, 
                    "text": "Our results further substantiate that gene scanning of all relevant RET exons is a powerful tool in the management of MEN2 patients,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22199277", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 871, 
                    "offsetInEndSection": 1274, 
                    "text": "We identified RET mutations in seven of 13 MTCs: five RET-positive cases revealed a mutation in exon 16 (M918T) and two a mutation in exon 10 (C618S and C620S). In four of the RET-positive cases, the mutation was inherited, out of which three were reportedly associated with a multiple endocrine neoplasia type 2 (MEN2) syndrome, i.e. MEN2A (C618S), MEN2A/familial MTC (FMTC) (C620S), and MEN2B (M918T)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21542403", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2243, 
                    "offsetInEndSection": 2328, 
                    "text": "RET gene mutation carries a risk of MEN2 and MTC in all ethnic groups in South Africa"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422799", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1258, 
                    "offsetInEndSection": 1361, 
                    "text": "Mutational screening of the RET gene identified a common mutation (C618R) in all 8 (7 FMTC and 1 MEN2A)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20152359", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1197, 
                    "offsetInEndSection": 1330, 
                    "text": "Gene mutation in the RET-620 position carries significant risk and may be part of a targeted investigation of high-risk areas in HSCR"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826964", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 730, 
                    "text": "Activating germline RET mutations are presented in patients with familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia (MEN) types 2A and 2B, whereas inactivating germline mutations in patients with Hirschsprung's disease (HSCR). The aim of this study was to evaluate genotype-phenotype correlations of the frequently discussed Tyr791Phe mutation in exon 13 of the RET proto-oncogene. Screening of three groups of patients was performed (276 families with medullary thyroid carcinoma (MTC), 122 families with HSCR, and 29 patients with pheochromocytoma). We found this mutation in 3 families with apparently sporadic MTC, 3 families with FMTC/MEN2, 1 patient with pheochromocytoma, and 3 families with HSCR."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19177457", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 256, 
                    "text": "Multiple endocrine neoplasia type 2 (MEN2) is an inherited, autosomal-dominant disorder caused by deleterious mutations within the RET protooncogene. MEN2 RET mutations are mainly heterozygous, missense sequence changes found in RET exons 10, 11, and 13-16"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16712668", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 316, 
                    "text": "Medullary thyroid carcinoma (MTC) occurs both sporadically and in the context of autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN2) syndromes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC), which are caused by activating germline mutations in the RET proto-oncogene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15991157", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 967, 
                    "offsetInEndSection": 1261, 
                    "text": "The germline mutation was detected because of the systematic genetic screening of the RET proto-oncogene, which is useful for genetic counseling of potential risk of HSCR and MTC in other family members. This family could be added to the small worldwide cohort of families with MEN2A/FMTC-HSCR."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9745455", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 123, 
                    "offsetInEndSection": 462, 
                    "text": "Germline mutations of the ret protooncogene are the underlying cause of the MEN2 syndromes and a proportion of cases of HSCR. In this report, we describe a new kindred in which the MEN2 and HSCR phenotypes are associated with a single C620S point mutation at one of the cysteine codons of the extracellular domain of the ret protooncogene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7641404", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 376, 
                    "text": "Medullary thyroid carcinoma (MTC) occurs both sporadically and in the autosomal dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes. The distinction between true sporadic MTC and a new mutation familial case is important for future clinical management of both the patient and family. The susceptibility gene for MEN 2 is the RET proto-oncogene."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What is the correlation between SPARC expression and growth inhibition in human cancer?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045926", 
                "http://www.uniprot.org/uniprot/SPRC_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23321672", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22863973", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22206672", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21799470", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21098700", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20955243", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20215880", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20100207", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20087345", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19920824", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19830689", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19236378", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16424866", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15958556", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12500936", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12414657"
            ], 
            "id": "517151f28ed59a060a000008", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321672", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 264, 
                    "offsetInEndSection": 535, 
                    "text": "Using a chemical carcinogenesis model in Sparc-deficient mice and their wild-type littermates, we found that loss of SPARC accelerated the development of urothelial preneoplasia (atypia and dysplasia), neoplasia, and metastasis and was associated with decreased survival."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863973", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 683, 
                    "offsetInEndSection": 1003, 
                    "text": "Our studies showed that inhibition of HDAC decreased NB proliferation, and induced caspase activity and G1 growth arrest. Expression patterns of cancer-related genes were modulated by VPA. The expression of THBS1, CASP8, SPARC, CDKN1A, HIC1, CDKN1B, and HIN1 was upregulated, and that of MYCN and TIG1 was downregulated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206672", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 325, 
                    "offsetInEndSection": 424, 
                    "text": "In this study, we demonstrate that expression of SPARC inhibits medulloblastoma cell proliferation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21799470", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1208, 
                    "offsetInEndSection": 1437, 
                    "text": "Concomitantly, SPARC was upregulated in all ccRCC cells, suggesting that Ukrain could also affect cell proliferation by cell cycle inhibition, as supported by the cell cycle analysis, as SPARC also acts as a cell cycle inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21098700", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 470, 
                    "offsetInEndSection": 770, 
                    "text": "SPARC silencing in IM-R cells restored imatinib sensitivity, whereas enforced SPARC expression in imatinib-sensitive cells promoted viability as well as protection against imatinib-mediated apoptosis. Notably, we found that the protective effect of SPARC required intracellular retention inside cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20955243", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 455, 
                    "offsetInEndSection": 667, 
                    "text": "We found that depletion of SPARC induces G2/M cell cycle arrest and tumor growth inhibition with activation of p53 and induction of p21(Cip1/Waf1) acting as a checkpoint, preventing efficient mitotic progression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20215880", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1020, 
                    "offsetInEndSection": 1413, 
                    "text": "Knockdown of SPARC expression in H322 and A549 cells led to suppression of cell invasion, comparable to that observed in KLF4-transfected cells. Moreover, retrovirus-mediated restoration of SPARC expression in KLF4-transfected cells abrogated KLF4-induced anti-invasion activity. Together, our results indicate that KLF4 inhibits lung cancer cell invasion by suppressing SPARC gene expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100207", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 256, 
                    "offsetInEndSection": 953, 
                    "text": "To validate the potential of SPARC as a therapeutic target, we examined the effect of the knockdown of SPARC with SPARC-specific siRNA on the growth of human melanoma cell lines. SPARC siRNAs exerted a potent knockdown effect. Silencing of SPARC resulted in growth inhibition with G(1) arrest accompanied by accumulation of p21, a G(1) cyclin-dependent kinase inhibitor, in MeWo and CRL1579 cells. Moreover, the induction of p53 was observed in MeWo cells, but not in CRL1579 cells. Conditioned media containing SPARC from MeWo cells could not restore the growth of SPARC-silenced MeWo cells. This result suggests that intracellular SPARC, but not secreted SPARC, is involved in cell proliferation"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20087345", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 496, 
                    "offsetInEndSection": 756, 
                    "text": "The SPARC expression reduced xenograft growth with reduced vascularity in an orthotopic medulloblastoma model. We also demonstrated that SPARC expression inhibits VEGF-mediated angiogenesis by altering MMP-9 expression, thereby leading to reduced angiogenesis."
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920824", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 4830, 
                    "offsetInEndSection": 5235, 
                    "text": "In summary, we showed that inhibition of endogenous SPARC enhances the malignant phenotype of PDAC cells and showed that endogenous SPARC expression is regulated by FGFR1 domain III isoform expression. On the basis of these observations, we conclude that endogenous SPARC levels can contribute to the reversion of the malignant phenotype and may, therefore, act as a tumour suppressor in human PDAC cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830689", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1424, 
                    "offsetInEndSection": 1791, 
                    "text": "In vivo experiments revealed that SPARC overexpression in HCC cells inhibited their tumorigenic capacity and increased animal survival through a mechanism that partially involves host macrophages. Our data suggest that SPARC overexpression in HCC cells results in a reduced tumorigenicity partially through the induction of mesenchymal-to-epithelial transition (MET)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19236378", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1201, 
                    "offsetInEndSection": 1345, 
                    "text": "Finally, we demonstrated that SPARC, which has been previously associated with meningioma invasiveness, was increased in aggressive meningiomas."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16424866", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 291, 
                    "offsetInEndSection": 824, 
                    "text": "We found that the leukemic cells of AML patients with MLL gene rearrangements express low to undetectable amounts of SPARC whereas normal hematopoietic progenitors and most AML patients express this gene. SPARC RNA and protein levels were also low or undetectable in AML cell lines with MLL translocations. Consistent with its tumor suppressive effects in various solid tumor models, exogenous SPARC protein selectively reduced the growth of cell lines with MLL rearrangements by inhibiting cell cycle progression from G1 to S phase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15958556", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1102, 
                    "offsetInEndSection": 1252, 
                    "text": "These data indicate that SPARC plays an essential role in tumor evasion from immune surveillance through the inhibition of the antitumor PMN activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12500936", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1437, 
                    "offsetInEndSection": 1801, 
                    "text": "We conclude that SPARC is inhibitory to human breast cancer cell proliferation, and does not stimulate migration, in contrast to its stimulatory effects reported for melanoma (proliferation and migration) and glioma (migration) cells. Similar growth repression by SPARC has been reported for ovarian cancer cells, and this may be a common feature among carcinomas."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12414657", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2345, 
                    "offsetInEndSection": 2508, 
                    "text": "Furthermore, SPARC delayed but did not inhibit tumor growth. The patterns of invasion and the extent of growth delay correlated with the level of SPARC expression."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the mechanism of microRNA deregulation in carcinogenesis?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23276969", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23175432", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23125218", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23087084", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23071542", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23064433", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23016435", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22616882", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22583478", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22548175", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22392644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22056881", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21962230", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22469780", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21903334", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19521961", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22898998", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21971665"
            ], 
            "id": "51718fbc8ed59a060a000010", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276969", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 239, 
                    "offsetInEndSection": 537, 
                    "text": "MicroRNAs are a class of small non-coding RNAs that negatively regulate gene expression by interacting with the 3'UTR of protein-coding mRNA. MicroRNAs are implicated in nearly all major biological and cellular events, and recent findings further link microRNA deregulation to human carcinogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175432", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 130, 
                    "text": "MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-\u03baB pathways."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125218", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 195, 
                    "offsetInEndSection": 312, 
                    "text": "MicroRNAs (miRNAs), which are small non-coding RNAs, are involved in diverse biological functions and carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23087084", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 924, 
                    "offsetInEndSection": 1063, 
                    "text": "Moreover, we demonstrated that miR-106b downregulates APC expression by directly targeting the 3'-untranslated region of APC messenger RNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071542", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 54, 
                    "offsetInEndSection": 887, 
                    "text": "MicroRNAs (miRNAs) are endogenous 19\u201325 nucleotide non-coding single-stranded RNAs that regulate gene expression by blocking the translation or decreasing the stability of mRNAs [1]. In fact, almost one-third of the protein-coding genes are susceptible to miRNA regulation [2]. Therefore, many miRNAs seem to play pivotal roles in many biological processes, including cellular proliferation, differentiation and apoptosis [3]. In recent years, accumulating evidence indicates that dysregulation of miRNAs is associated with the initiation and progression of cancer. Several studies have shown that unique miRNA expression profiles are present in lots of cancers, such as breast, lung, oesophageal, prostate and pancreatic cancer, gastric cancer and colon cancer, suggesting that miRNAs may act as oncogenes or cancer suppressors [4]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 287, 
                    "offsetInEndSection": 657, 
                    "text": "Furthermore, miRNAs present a mechanism by which genes with diverse functions on multiple pathways can be simultaneously regulated at the post-transcriptional level. However, little is known about the cancer-related pathways through which cancer-associated miRNAs (CA-miRNAs) regulate these processes representing either positive or negative functions in carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016435", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 41, 
                    "offsetInEndSection": 602, 
                    "text": "MicroRNAs, known as small noncoding MiRNAs, 19 to 24 nt in length, are important gene regulators and recognized as key players in carcinogenesis. The mechanism lies in that the MiRNAs can conjugate with their targeted mRNA and then lead to the targeted mRNA degradation or repress their translation. Bioinformatic analysis indicates that each MiRNA can regulate hundreds of gene targets and could serve functionally as \"oncogenes\" or \"tumor suppressor genes\", and therefore regulate multiple cellular processes relevant to carcinogenesis and cancer progression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 395, 
                    "offsetInEndSection": 1041, 
                    "text": "miRNAs are a class of noncoding RNAs 18 to 25 nucleotides long that negatively regulate gene expression by binding to the 3'-UTR of target messenger mRNAs, causing translational repression or degradation. Deregulation of miRNAs has been demonstrated to play roles in the pathogenesis of human diseases, including malignancy [1,2]. Some miRNAs have been identified from cancers and appear to play crucial roles in proliferation, differentiation, and apoptosis [3-5]. One of these, microRNA-21 (miR-21), is a key player. As an anti-apoptosis factor, aberrantly expressed miR-21 compromises tumor suppressor-mediated apoptosis of cancer cells [6,7]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21971665", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 106, 
                    "text": "microRNAs (miRs) are endogenous small non-coding RNAs that are aberrantly expressed in various carcinomas."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898998", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 89, 
                    "offsetInEndSection": 253, 
                    "text": "While deregulated miRNA expression levels have been detected in many tumors, whether miRNA functional impairment is also involved in carcinogenesis remains unknown."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19521961", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 263, 
                    "text": "In the last years, microRNAs (miRNA) have emerged as new molecular players involved in carcinogenesis. Deregulation of miRNAs expression has been shown in different human cancer but the molecular mechanism underlying the alteration of miRNA expression is unknown."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 269, 
                    "offsetInEndSection": 730, 
                    "text": "These are microRNAs (miRNAs), a class of noncoding RNAs, 20-23 nucleotides in length, that can up or downregulate gene expression of downstream gene targets (including transcription factors, oncogenes, and tumour suppressor genes) at the post-transcriptional level. Some members of this new class of genes seem to have the potential to act simultaneously either as oncogenes or as tumour suppressor genes depending on the molecular microenvironment of the cell."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22469780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 240, 
                    "text": "MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 77, 
                    "text": "Mechanisms and role of microRNA deregulation in cancer onset and progression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 42, 
                    "offsetInEndSection": 172, 
                    "text": "MicroRNAs (miRNAs) are a group of small RNAs, with around 19 to 25 nucleotides, resulting from cleavage of larger non-coding RNAs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1351, 
                    "offsetInEndSection": 1886, 
                    "text": "Recent studies have emphasized the importance of understanding the mechanism of mRNA regulation by studying changes in miRNA expression in a variety of human pathological conditions, including cancers (Vanderboom et al., 2008). Given their importance in development, it was to be expected that miRNAs would also have a significant role in tumorigenesis. Since their discovery close to 3000 publications, including over 700 reviews, documented associations between miRNAs and cancer, (Garofalo and Croce, 2010; Medina and Slack, 2008).T"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 855, 
                    "offsetInEndSection": 1383, 
                    "text": "It is now recognized that miRNA also have a primary role in cancer onset and progression. Oncomir is the term used to describe an miRNA involved in cancer. Such miRNAs were initially linked to tumorigenesis due to their proximity to chromosomal breakpoints (Calin et al., 2004b) and their dysregulated expression levels in many malignancies (Calin et al., 2004a). Abnormal gene expression by miRNAs has been correlated with several types of tumors, and such genes may function as oncogenes or tumor-suppressing genes (Figure 2)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 1384, 
                    "offsetInEndSection": 1506, 
                    "text": "In humans, 50% of the miRNA genes are located at genomic sites associated with cancer-specific chromosomal rearrangements."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 2888, 
                    "offsetInEndSection": 3107, 
                    "text": "The strongest evidence for an association between miRNAs and cancer was demonstrated by a sequence of three concurrent studies published in Nature in June 2005 (He et al., 2005; Lu et al., 2005; O\u2019Donnell et al., 2005)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3779, 
                    "offsetInEndSection": 4507, 
                    "text": "Several classes of deregulated miRNAs have also been shown to be differentially expressed in breast cancer, compared with healthy breast tissue (Volinia et al., 2006). Moreover, the expression signatures of informative miRNA subsets have enabled better molecular classification than mRNA expression profiles in several types of human cancer (Lu et al., 2005).Among the miRNAs differentially expressed in breast cancer, miR-10b, miR-125, miR-145, miR-21 and miR-155 have consistently presented the highest degree of deregulation. Downregulation of miR-10b, miR-125b and miR-145 and upregulation of miR-21 and miR-155 suggest that these miRNAs may play an important role as tumor-suppressors or oncogenes (Blenkiron et al., 2007)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931505", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 5828, 
                    "offsetInEndSection": 6039, 
                    "text": "In line with this, novel molecular classifications of tumors based on their miRNA expression, have provided a wealth of new resources for predictive and prognostic biomarkers for clinical applications in cancer."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276969", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 48, 
                    "text": "Regulation of hepatocarcinogenesis by microRNAs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276969", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 381, 
                    "offsetInEndSection": 537, 
                    "text": "MicroRNAs are implicated in nearly all major biological and cellular events, and recent findings further link microRNA deregulation to human carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125218", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 195, 
                    "offsetInEndSection": 312, 
                    "text": "MicroRNAs (miRNAs), which are small non-coding RNAs, are involved in diverse biological functions and carcinogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23087084", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 116, 
                    "text": "miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071542", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 74, 
                    "text": "MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 453, 
                    "offsetInEndSection": 657, 
                    "text": "However, little is known about the cancer-related pathways through which cancer-associated miRNAs (CA-miRNAs) regulate these processes representing either positive or negative functions in carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1406, 
                    "offsetInEndSection": 1681, 
                    "text": "Combined with previous cancer studies, the analysis of the relevance between functions of CA-miRNAs and cancer-related pathways exploring different internal carcinogenesis stimuli also revealed the potential of the top five pathways to regulate core carcinogenesis processes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016435", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 41, 
                    "offsetInEndSection": 186, 
                    "text": "MicroRNAs, known as small noncoding MiRNAs, 19 to 24 nt in length, are important gene regulators and recognized as key players in carcinogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616882", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 151, 
                    "text": "MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 914, 
                    "offsetInEndSection": 1041, 
                    "text": "As an anti-apoptosis factor, aberrantly expressed miR-21 compromises tumor suppressor-mediated apoptosis of cancer cells [6,7]."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583478", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 130, 
                    "text": "Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583478", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5535, 
                    "offsetInEndSection": 5889, 
                    "text": "Despite the undeniable role of progestins in breast cancer progression, progestin-mediated regulation of miRNAs has only recently been explored [49]. Bearing in mind the importance of progestins in breast cancer growth, we hypothesized that progestins may also govern a set of miRNAs that regulate the expression of genes relevant to breast cancer growth"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548175", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 87, 
                    "text": "Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by Epigenetics."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548175", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 174, 
                    "offsetInEndSection": 340, 
                    "text": "miRNAs have been found to be downregulated by methylation of DNA in various cancers, and these miRNAs are referred to as tumor suppressor miRNAs (TS-miRNAs) [25, 26]."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392644", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 177, 
                    "text": "Deregulation of microRNAs (miRNAs) is common in advanced human hepatocellular carcinoma (HCC); however, the ones involved in early carcinogenesis have not yet been investigated."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21962230", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21962230", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2759, 
                    "offsetInEndSection": 2948, 
                    "text": "However, whether and how miR-185 could regulate DNMT1 expression and affect the genomic DNA methylation, contributing to the development of human glioma, has not been systemically explored."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21962230", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3797, 
                    "offsetInEndSection": 4024, 
                    "text": "More importantly, our findings indicate that miR-185 can directly target DNMT1, thereby leading to a reduction in global DNA methylation (GDM) and regulating the expression of the promoter-hypermethylated genes in glioma cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056881", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 116, 
                    "text": "MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056881", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 236, 
                    "text": "MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Name the major classes of small  non coding RNAs in mammalians?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19908360"
            ], 
            "id": "517295c18ed59a060a000016", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 317, 
                    "offsetInEndSection": 632, 
                    "text": "For instance, they are used to determine expression profiles of miRNAs, 20\u201324 nt long RNA molecules, that have emerged in recent years as important post-transcriptional regulators in all known multicellular organisms and that are known to play roles in development, tumorigenesis and viral infection (Bartel, 2004)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 633, 
                    "offsetInEndSection": 819, 
                    "text": "Besides miRNAs other small non-coding RNA (ncRNA) classes such as piRNAs (Aravin et al., 2001), snoRNAs (Bachellerie et al., 2002) or scaRNAs (Gerard et al., 2010) have been investigated"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1419, 
                    "offsetInEndSection": 1619, 
                    "text": "Most ncRNAs have very specific structural properties that have been used to classify them (Will et al., 2007), e.g. tRNAs possess a cloverleaf structure, whereas miRNA precursors form stable hairpins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5034, 
                    "offsetInEndSection": 5177, 
                    "text": "Distance information also helps to distinguish miRNAs from degradation products of other abundant RNA species such as tRNAs or snRNAs (Fig. 1)."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 5461, 
                    "offsetInEndSection": 5575, 
                    "text": "Since there are only very few unique snRNAs, snoRNAs and rRNAs, we only considered miRNAs and tRNAs for evaluation"
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20823303", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 322, 
                    "offsetInEndSection": 448, 
                    "text": "egulatory RNAs such as miRNAs, piRNAs or siRNAs are believed to recognize their targets by a short complementary region (seed)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19908360", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 292, 
                    "offsetInEndSection": 429, 
                    "text": "Some of these RNA classes, in particular microRNAs and snoRNAs, undergo maturation processes that lead to the production of shorter RNAs."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which genes are regulated by MEF-2 in the heart?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21812548", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21244855", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20075332", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19893013", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17938175", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17518763", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16049055", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15491989", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15040454", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12805933", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11770083", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9043061", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8674419", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7982978", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8035789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8366095", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8321243", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8449897", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1532229", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1328854"
            ], 
            "id": "517539af8ed59a060a000026", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21244855", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1560, 
                    "offsetInEndSection": 1654, 
                    "text": "Inhibition of MEF2A using siRNA attenuated HB-EGF-induced COX-2, ANF expression and cell size."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19893013", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 913, 
                    "offsetInEndSection": 1078, 
                    "text": "This genetic reprogramming coincides with a pronounced increase in expression of the estrogen receptor (ER)alpha gene, which we show to be a direct MEF2 target gene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17938175", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 120, 
                    "offsetInEndSection": 154, 
                    "text": "cardiac calsequestrin gene (casq2)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17938175", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1423, 
                    "offsetInEndSection": 1732, 
                    "text": "Functional studies demonstrated that site-directed mutagenesis of the proximal MEF-2 and CArG box sites significantly decreased the transcription of the gene in cardiac and skeletal muscle cells, indicating that they are important to drive cardiac and skeletal muscle-specific transcription of the casq2 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16049055", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 885, 
                    "offsetInEndSection": 1025, 
                    "text": "DTEF-1 also interacts with MEF- 2 by coimmunoprecipitation and independently or cooperatively (with MEF-2) trans-activates the cTnT promoter"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15491989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 432, 
                    "offsetInEndSection": 822, 
                    "text": "An 85-bp region within the enhancer is highly conserved between human and mouse and contains a central AT-rich site, which is essential for enhancer activity. This site binds myocyte enhancer factor (MEF)2 factors, principally MEF2D and MEF2A in cardiocyte nuclear extracts. These results are discussed in the context of MEF2 activity and of the regulation of the alpha-cardiac actin locus."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15040454", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 261, 
                    "offsetInEndSection": 424, 
                    "text": "The cis-acting elements, MEF-2, E boxes and A/T rich elements present in the enhancer region of the mouse MCK gene are known to regulate the expression of the gene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12805933", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 253, 
                    "text": "The sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs) belong to a family of active calcium transport enzymes encoded by the SERCA1, 2, and 3 genes. In this study, we describe the complete structure of the human SERCA2 gene and its 5 -regulatory region."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12805933", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 972, 
                    "offsetInEndSection": 1252, 
                    "text": "Among the DNA cis-elements present in these two regulatory regions there are potential binding sites for: GATA-4, -5, -6, Nkx-2.5/Csx, OTF-1, USF, MEF-2, SRF, PPAR/RXR, AP-2, and TREs. Upstream from position -1.5 kb, there is no significant homology among the SERCA2 genes cloned."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11770083", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 554, 
                    "offsetInEndSection": 890, 
                    "text": "The cardiac calsequestrin gene consists of 11 exons and its 5' flanking region is characterized by the presence of a TATA-like box, muscle specific promoter elements such as 7 E-boxes, 1 MEF-2, 1 MCBF and 1 Repeat (musS) motifs, as well as several muscle non-specific transcriptional elements (AP-2A, NRE1, NRE2, p53, Spel and TFI-IIA)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9043061", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 336, 
                    "offsetInEndSection": 516, 
                    "text": "our laboratory identified a 28 bp HF-la/MEF-2 element in the MLC-2v promoter region, which confers cardiac ventricular chamber-specific gene expression during murine cardiogenesis,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 501, 
                    "offsetInEndSection": 742, 
                    "text": "In this study, we investigated T3R alpha 1-vs. T3R beta 1-specific interactions with the myocyte enhancer-specific factor-2 (MEF-2) on the expression of the SERCA 2 gene in transient transfection assays in embryonal heart-derived H9c2 cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977381", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1759, 
                    "offsetInEndSection": 1902, 
                    "text": "point to T3R isoform-specific interactions with a cell type-specific transcription factor (MEF-2) in the regulation of SERCA 2 gene expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8674419", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 519, 
                    "offsetInEndSection": 874, 
                    "text": "In multiple independent transgenic mouse lines, we found that both a 250 base pair myosin light chain-2 ventricular promoter fragment, as well as a dimerized 28 bp sub-element (HF-1) containing binding sites for HF1a and HF1b/MEF2 factors, directed ventricular-specific reporter expression from as early as the endogenous gene, at day 7.5-8.0 post coitum."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8366095", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 129, 
                    "text": "Myocyte-specific enhancer-binding factor (MEF-2) regulates alpha-cardiac myosin heavy chain gene expression in vitro and in vivo"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8321243", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 153, 
                    "offsetInEndSection": 288, 
                    "text": "In the MLC-2 gene, an AT-rich element (HF-1b) which contains a consensus MEF-2 site is required for cardiac tissue-specific expression."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8449897", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 132, 
                    "text": "Role of myocyte-specific enhancer-binding factor (MEF-2) in transcriptional regulation of the alpha-cardiac myosin heavy chain gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1328854", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 199, 
                    "text": "In order to analyze the transcriptional regulation of the muscle-specific subunit of the human phosphoglycerate mutase (PGAM-M) gene, chimeric genes composed of the upstream region of the PGAM-M gene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1328854", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1483, 
                    "offsetInEndSection": 1650, 
                    "text": "These observations define the PGAM-M enhancer as the only cardiac- and skeletal-muscle-specific enhancer characterized thus far that is mainly activated through MEF-2."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "List some ways to reverse Tau hyperphosphorylation in Tauopathies?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016875", 
                "http://www.uniprot.org/uniprot/TAU_HUMAN", 
                "http://www.uniprot.org/uniprot/TAU_MOUSE", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016310", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010766", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042327"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20471717", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18755209", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16806196", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16687499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12212772"
            ], 
            "id": "517775c78ed59a060a000033", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20471717", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 529, 
                    "offsetInEndSection": 617, 
                    "text": "tau hyperphosphorylation were dramatically reduced in hUCB-MSC transplanted APP/PS1 mice"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18755209", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1110, 
                    "offsetInEndSection": 1384, 
                    "text": "Administration of 7-nitroindazole to CMS-exposed old rats significantly (p=0.002) increased GAD activity, decreased glutamate levels (7.19+/-3.19 vs. 763.9+/-91 micromol/g tissue protein; p=0.0005), and decreased phosphorylation of tau proteins compared to CMS exposed rats."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18755209", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 221, 
                    "text": "Changes in glutamate decarboxylase enzyme activity and tau-protein phosphorylation in the hippocampus of old rats exposed to chronic mild stress: reversal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806196", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 96, 
                    "text": "Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16687499", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 131, 
                    "text": "Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16687499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1590, 
                    "offsetInEndSection": 1854, 
                    "text": "Here, we show that transgene shutdown in symptomatic mice leads to normal GSK-3 activity, normal phospho-tau levels, diminished neuronal death, and suppression of the cognitive deficit, thus further supporting the potential of GSK-3 inhibitors for AD therapeutics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12212772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 524, 
                    "offsetInEndSection": 795, 
                    "text": "These effects can be combined with the beneficial effects of these compounds on some other major hallmarks of Alzheimer's disease (AD) (e.g. tau hyperphosphorylation and paired helical filaments [PHF]; and loss of cholinergic function conducive to cognitive impairments.)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12212772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 522, 
                    "text": "The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren's Syndrome), AF150(S) and AF267B--1) are neurotrophic and synergistic with neurotrophins such as nerve growth factor and epidermal growth factor; 2) elevate the non-amyloidogenic amyloid precursor protein (alpha-APPs) in vitro and decrease beta-amyloid (A beta) levels in vitro and in vivo; and 3) inhibit A beta- and oxidative-stress-induced cell death and apoptosis in PC12 cells transfected with the M1 muscarinic receptor"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What are the effects of ILK ablation?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/ILK_MOUSE", 
                "http://www.uniprot.org/uniprot/ILK_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055011"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22658851", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20980390", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20564195", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19920070", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19575460", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19349584", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18846549", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16951252", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16837631"
            ], 
            "id": "5179602c8ed59a060a00003d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658851", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 450, 
                    "offsetInEndSection": 544, 
                    "text": "ILK knockdown had no effect on the viability or survival pathway activity pattern of MM cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658851", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 768, 
                    "offsetInEndSection": 869, 
                    "text": "We conclude that ILK does not play a prominent role in the promotion or sustenance of established MM."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20980390", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 152, 
                    "text": "Defective granulation tissue formation in mice with specific ablation of integrin-linked kinase in fibroblasts"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20980390", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 311, 
                    "offsetInEndSection": 558, 
                    "text": "Here, we show that fibroblast-restricted inactivation of ILK in mice leads to impaired healing due to a severe reduction in the number of myofibroblasts, whereas inflammatory infiltrate and vascularization of the granulation tissue are unaffected."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20980390", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1006, 
                    "offsetInEndSection": 1152, 
                    "text": "in fibroblasts, ILK is crucial for limiting RhoA activity, thus promoting TGF\u03b21 production, which is essential for dermal repair following injury."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20564195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1429, 
                    "offsetInEndSection": 1530, 
                    "text": "Our results show that ILK is important for the function, but not the differentiation, of osteoclasts."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20564195", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 94, 
                    "text": "Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920070", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1448, 
                    "offsetInEndSection": 1622, 
                    "text": "ack of ILK in the hepatocytes imparts prolonged proliferative response not only to stimuli related to liver regeneration but also to xenobiotic chemical mitogens, such as PB."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920070", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 163, 
                    "text": "Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19575460", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16837631", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 794, 
                    "offsetInEndSection": 966, 
                    "text": "ILK deficiency caused an aberrant distribution of nephrin and alpha-actinin-4 in podocytes, whereas the localization of podocin and synaptopodin remained relatively intact."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16951252", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 111, 
                    "text": "Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16951252", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 155, 
                    "offsetInEndSection": 309, 
                    "text": "Here we show that targeted ablation of the integrin-linked kinase (ILK) expression results in spontaneous cardiomyopathy and heart failure by 6 wk of age."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16951252", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 637, 
                    "offsetInEndSection": 768, 
                    "text": "Together, these results suggest that ILK plays a central role in protecting the mammalian heart against cardiomyopathy and failure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18846549", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1653, 
                    "offsetInEndSection": 1810, 
                    "text": "Our results show for the first time in vivo the significance of ILK and hepatic ECM-signaling for regulation of hepatocyte proliferation and differentiation."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18846549", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 135, 
                    "text": "Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19349584", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 127, 
                    "text": "Integrin-linked kinase is required for radial sorting of axons and Schwann cell remyelination in the peripheral nervous system."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which deiodinase is known to be present in liver?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15072569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9389494", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9709961", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9794474", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8550759", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7629231"
            ], 
            "id": "517a8b768ed59a060a00003f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072569", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 168, 
                    "text": "Iodothyronine deiodinase in vitro activity studies in the chicken showed the presence of type I and type III iodothyronine deiodinase activity in both liver and kidney."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9389494", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "In embryonic chicken liver (ECL) two types of iodothyronine deiodinases are expressed: D1 and D3."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9709961", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1140, 
                    "offsetInEndSection": 1666, 
                    "text": "In liver homogenates, D1 activity was not correlated with age, whereas D3 activity showed a strong negative correlation with age (r -0.84), with high D3 activities in preterm infants and (except in 1 infant of 35 weeks) absent D3 activity in full-term infants. In microsomes, D1 activities amounted to 4.3-60 pmol/min/mg protein in fetal livers and to 170-313 pmol/min/mg protein in adult livers, whereas microsomal D3 activities were 0.15-1.45 pmol/min/mg protein in fetuses and <0.1 pmol/min/mg protein in all but one adult."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9709961", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1822, 
                    "offsetInEndSection": 1935, 
                    "text": "high D1 and D3 activities in fetal human liver, and high D1 and mostly absent D3 activities in adult human liver."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which dediodinases are present in kidney?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15072569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9794474", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7768329", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3197644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3595535"
            ], 
            "id": "517a8c238ed59a060a000042", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072569", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 168, 
                    "text": "Iodothyronine deiodinase in vitro activity studies in the chicken showed the presence of type I and type III iodothyronine deiodinase activity in both liver and kidney."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072569", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 977, 
                    "offsetInEndSection": 1039, 
                    "text": "Co-expression of the deiodinases was also found in the kidney."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7768329", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 437, 
                    "offsetInEndSection": 485, 
                    "text": "high ID-I activities were found in liver, kidney"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3595535", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1347, 
                    "offsetInEndSection": 1392, 
                    "text": "the kidney microsome 5'-deiodinase is type I."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is the treatment of amiodarone-induced thyrotoxicosis?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22130792", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22386340", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22865896", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21225109", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21865355", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20583541", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19675515", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19622616", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19105148", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19109209", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18595575", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18421194", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18410546"
            ], 
            "id": "518cb513310faafe08000007", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22130792", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1746, 
                    "offsetInEndSection": 1902, 
                    "text": "Prednisone remains the preferred treatment modality of AIT type 2, because perchlorate given alone or in combination with prednisone had no better outcomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22865896", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1924, 
                    "offsetInEndSection": 2085, 
                    "text": "Total thyroidectomy, by rapidly restoring euthyroidism, may improve cardiac function and reduce the risk of mortality in AIT patients with severe LV dysfunction."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21865355", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1641, 
                    "offsetInEndSection": 1957, 
                    "text": "Prednisone restores euthyroidism in most type 2 AIT patients, irrespective of amiodarone continuation or withdrawal. However, continuing amiodarone increases the recurrence rate of thyrotoxicosis, causing a delay in the stable restoration of euthyroidism and a longer exposure of the heart to thyroid hormone excess."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583541", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 714, 
                    "offsetInEndSection": 912, 
                    "text": "Steroid therapy should be started when findings indicate type II or mixed-type AIT. Beta blockers may prevent heart thyrotoxicosis and recurrence of primary arrhythmia if amiodarone is discontinued."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19622616", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1668, 
                    "offsetInEndSection": 1793, 
                    "text": "Glucocorticoids are the first-line treatment in type 2 AIT, whereas thionamides play no role in this destructive thyroiditis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19105148", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 948, 
                    "offsetInEndSection": 1065, 
                    "text": "iopanoic can be used to rapidly lower FT(3) levels and to treat symptoms of thyrotoxicosis in a preoperative setting."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19105148", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 633, 
                    "offsetInEndSection": 752, 
                    "text": "The patient responded to iopanoic acid with a rapid decrease in his FT(3) level and slight increase in his FT(4) level."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18595575", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1791, 
                    "offsetInEndSection": 1890, 
                    "text": "In patients with type-2 AIT, RAI treatment may be the therapy of choice for thyroid gland ablation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18410546", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1582, 
                    "offsetInEndSection": 1687, 
                    "text": "In type 1 AIT thionamides represent the treatment of choice for North Americans as well as for Europeans,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18410546", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1876, 
                    "offsetInEndSection": 2008, 
                    "text": "Glucocorticoids are the selected treatment for type 2 AIT, alone (62%vs. 46% in Europe, P < 0.05) or in association with thionamides"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18410546", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2041, 
                    "offsetInEndSection": 2200, 
                    "text": "After restoration of euthyroidism, thyroid ablation in the absence of recurrent thyrotoxicosis is recommended in type 1 AIT less frequently by North Americans."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which microRNAs are involved in exercise adaptation?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015444", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005081", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000222", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000220"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23242657", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23047984", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21690193", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21311168", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20724368", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19440340"
            ], 
            "id": "518cca6f310faafe0800000a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242657", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 345, 
                    "offsetInEndSection": 614, 
                    "text": "Some miRNAs as miR-1, miR-133 and miR-208a are highly expressed in the heart and strongly associated with the development of cardiac hypertrophy. Recent data indicate that these miRNAs as well as miR-206 change their expression quickly in response to physical activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23047984", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 909, 
                    "offsetInEndSection": 1253, 
                    "text": "the miR-494 content significantly decreased after endurance exercise in C57BL/6J mice, accompanied by an increase in expression of mtTFA and Foxj3 proteins. These results suggest that miR-494 regulates mitochondrial biogenesis by downregulating mtTFA and Foxj3 during myocyte differentiation and skeletal muscle adaptation to physical exercise."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21690193", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1003, 
                    "offsetInEndSection": 1268, 
                    "text": "1) c-miRNA up-regulated by acute exercise before and after sustained training (miR-146a and miR-222), (2) c-miRNA responsive to acute exercise before but not after sustained training (miR-21 and miR-221), (3) c-miRNA responsive only to sustained training (miR-20a),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21311168", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1255, 
                    "offsetInEndSection": 1416, 
                    "text": "MicroRNA 1 expression was decreased independent of the training modality, and was paralleled by an increased expression of IGF-1 representing a potential target."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20724368", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 169, 
                    "offsetInEndSection": 476, 
                    "text": "we investigated the expression of these myomiRs, including miR-1, miR-133a, miR-133b and miR-206 in muscle biopsies from vastus lateralis of healthy young males (n = 10) in relation to a hyperinsulinaemic\u2013euglycaemic clamp as well as acute endurance exercise before and after 12 weeks of endurance training."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20724368", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 824, 
                    "offsetInEndSection": 934, 
                    "text": "In resting biopsies, endurance training for 12 weeks decreased basal expression of all four myomiRs (P < 0.05)"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19440340", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 246, 
                    "text": "In this study, we found that down-regulation of miR-23 is associated with a significant increase in PGC-1\u03b1 mRNA expression and protein content in quadriceps of C57Bl/6J male mice three hours following an acute bout of endurance exercise"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19440340", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 403, 
                    "offsetInEndSection": 541, 
                    "text": "In addition, we report a significant induction in miR- 107, 1 and 181 in the skeletal muscle of male mice subjected to endurance exercise."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is intense physical activity associated with longevity?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008136", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015444", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005081"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21618162", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22587716", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23449779", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10670554", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7707624", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2279154"
            ], 
            "id": "518ccac0310faafe0800000b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21618162", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1345, 
                    "offsetInEndSection": 1451, 
                    "text": "Our major finding is that repeated very intense exercise prolongs life span in well trained practitioners."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22587716", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1331, 
                    "offsetInEndSection": 1690, 
                    "text": "Death rates declined with increased levels of total activity (estimated in kilocalories), and declined also with increased intensity of effort measured as from none, to light, to moderately vigorous or vigorous sports play. Death rates at any given quantity of physical exercise were lower for men playing moderately intense sports than for less vigorous men."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23449779", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 168, 
                    "offsetInEndSection": 318, 
                    "text": "he purpose of this study was to investigate if jogging, which can be very vigorous, is associated with increased all-cause mortality in men and women."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23449779", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1056, 
                    "offsetInEndSection": 1230, 
                    "text": "This long-term study of joggers showed that jogging was associated with significantly lower all-cause mortality and a substantial increase in survival for both men and women."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10670554", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 470, 
                    "offsetInEndSection": 776, 
                    "text": "Light activities (<4 multiples of resting metabolic rate (METs)) were not associated with reduced mortality rates, moderate activities (4-<6 METs) appeared somewhat beneficial, and vigorous activities (> or =6 METs) clearly predicted lower mortality rates (p, trend = 0.72, 0.07, and <0.001, respectively)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7707624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1732, 
                    "offsetInEndSection": 1927, 
                    "text": "These data demonstrate a graded inverse relationship between total physical activity and mortality. Furthermore, vigorous activities but not nonvigorous activities were associated with longevity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2279154", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 902, 
                    "offsetInEndSection": 1042, 
                    "text": "The capacity for prolonged and vigorous physical exercise, particularly if the exercise is recreational, is a strong indicator of longevity."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006914", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0072321", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0038024", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008565", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004872", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001343", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018832"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23404999", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23070014", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22809326", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22426402", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22363588", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22331875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22227450", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21966475", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21514572", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19433452", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18927485", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18644871", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18635949", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18550537", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17284523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16585521", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15331765", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12505983", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11208145", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11082038", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10806201"
            ], 
            "id": "51bdd9c2047fa84d1d000002", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 149, 
                    "offsetInEndSection": 346, 
                    "text": "These proteins are targeted by chaperones and delivered to lysosomes where they are translocated into the lysosomal lumen and degraded via the lysosome-associated membrane protein type 2A (LAMP-2A)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23070014", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1165, 
                    "offsetInEndSection": 1432, 
                    "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22809326", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 8373, 
                    "offsetInEndSection": 8887, 
                    "text": "Chaperone-mediated autophagy (CMA) is a lysosomal pathway for selective removal of damaged cytosolic proteins (reviewed in [27]). CMA effects direct transmembrane import of cytosolic proteins into the endolysosomal system. The LAMP-2 isoform LAMP-2A functions as a receptor for cytosolic proteins and also as essential component of the CMA translocation complex [28]. Cytosolic substrate proteins bind to monomers of LAMP-2A, which then multimerizes to form the complex required for substrate transmembrane import."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426402", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 671, 
                    "offsetInEndSection": 756, 
                    "text": "CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363588", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4124, 
                    "offsetInEndSection": 4400, 
                    "text": "Mammalian LAMP2, which is localized in the lysosomal membrane, consists of three splicing isoforms (LAMP2A, B, C) that are alternatively spliced in their carboxyl termini [23]. Among the isoforms, only LAMP2A is involved in CMA as a lysosomal receptor for CMA substrates [24]."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363588", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7, 
                    "offsetInEndSection": 458, 
                    "text": "Single-cell monitoring of CMA activity by visualizing lysosomal accumulation of a CMA substrate using the HaloTag systemIn the process of CMA, cytosolic substrate proteins for CMA are recognized by heat shock cognate protein 70 (Hsc70), a molecular chaperone. The substrates are then transferred to the lysosome, where they are translocated through lysosome-associated membrane protein type 2A (LAMP2A) and subsequently degraded by lysosomal proteases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22331875", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 747, 
                    "offsetInEndSection": 900, 
                    "text": "Lysosomes from livers of lipid-challenged mice had a marked decrease in the levels of the CMA receptor, the lysosome-associated membrane protein type 2A,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227450", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 994, 
                    "offsetInEndSection": 1171, 
                    "text": "We report that Bcl-2-related early rod apoptosis was associated with the upregulation of autophagy markers including chaperone-mediated autophagy (CMA) substrate receptor LAMP-2"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21966475", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 13890, 
                    "offsetInEndSection": 14065, 
                    "text": "Once delivered to the lysosomal membrane by Hsc70, the misfolded cargo proteins are translocated to the lysosomal cavity with the help of Lamp2A, a rate limiting factor of CMA"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514572", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 617, 
                    "offsetInEndSection": 710, 
                    "text": "we examined gene expression levels of lysosome-associated membrane 2 (LAMP-2), a CMA receptor"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19433452", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1439, 
                    "offsetInEndSection": 1678, 
                    "text": "In chaperone-mediated autophagy (CMA), substrates are recognized by a chaperone complex containing Hsc70 (heat shock cognate of 70 kD) and delivered into lysosomes through interactions with LAMP-2A (lysosome-associated membrane protein 2A)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18927485", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 110, 
                    "offsetInEndSection": 236, 
                    "text": "The lysosomal-membrane protein type 2A (LAMP-2A) acts as the receptor for the substrates of chaperone-mediated autophagy (CMA)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18644871", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 373, 
                    "text": "Chaperone-mediated autophagy (CMA) is a selective type of autophagy by which specific cytosolic proteins are sent to lysosomes for degradation. Substrate proteins bind to the lysosomal membrane through the lysosome-associated membrane protein type 2A (LAMP-2A), one of the three splice variants of the lamp2 gene, and this binding is limiting for their degradation via CMA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18644871", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 662, 
                    "offsetInEndSection": 837, 
                    "text": "Substrate proteins only bind to monomeric LAMP-2A, while the efficient translocation of substrates requires the formation of a particular high-molecular-weight LAMP-2A complex"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18635949", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 266, 
                    "offsetInEndSection": 394, 
                    "text": "We recently reported that UCH-L1 physically interacts with LAMP-2A, the lysosomal receptor for chaperone-mediated autophagy (CMA"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550537", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 460, 
                    "offsetInEndSection": 562, 
                    "text": "In this study, we found that UCH-L1 physically interacts with LAMP-2A, the lysosomal receptor for CMA,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17284523", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 113, 
                    "offsetInEndSection": 406, 
                    "text": "We have previously described an age-related decline in chaperone-mediated autophagy (CMA), a selective form of autophagy, by which particular cytosolic proteins are delivered to lysosomes after binding to the lysosome-associated membrane protein type 2A (LAMP-2A), a receptor for this pathway."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16585521", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 266, 
                    "text": "Chaperone-mediated autophagy (CMA) is a selective pathway for the degradation of cytosolic proteins in lysosomes. CMA declines with age because of a decrease in the levels of lysosome-associated membrane protein (LAMP) type 2A, a lysosomal receptor for this pathway."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15331765", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 543, 
                    "offsetInEndSection": 853, 
                    "text": "Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12505983", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 112, 
                    "offsetInEndSection": 296, 
                    "text": "We now demonstrate that this protease activity triggers the degradation of the lysosome-associated membrane protein type 2a (lamp2a), a receptor for chaperone-mediated autophagy (CMA)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11208145", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 185, 
                    "offsetInEndSection": 289, 
                    "text": "We have previously identified this receptor as the lysosome-associated membrane protein type 2a (lamp2a)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11082038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 107, 
                    "text": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11082038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1007, 
                    "offsetInEndSection": 1111, 
                    "text": "These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10806201", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 603, 
                    "offsetInEndSection": 760, 
                    "text": "A progressive age-related decrease in the levels of the lysosome-associated membrane protein type 2a that acts as a receptor for chaperone-mediated autophagy"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which are currently available software tools for detecting rare codon clusters in coding sequences?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22467916", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22199385", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20167116", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18923675", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10689191"
            ], 
            "id": "51be411b047fa84d1d000006", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22467916", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 631, 
                    "offsetInEndSection": 755, 
                    "text": "Our program Sherlocc, detects statistically relevant conserved rare codon clusters and produces a user-friendly HTML output."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22199385", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 77, 
                    "text": "LaTcOm: a web server for visualizing rare codon clusters in coding sequences"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22199385", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 133, 
                    "text": "We present LaTcOm, a new web tool, which offers several alternative methods for 'rare codon cluster' (RCC) identification"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22199385", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 209, 
                    "offsetInEndSection": 485, 
                    "text": "three RCC detection schemes are implemented: the recently described %MinMax algorithm and a simplified sliding window approach, along with a novel modification of a linear-time algorithm for the detection of maximally scoring subsequences tailored to the RCC detection problem"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167116", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7, 
                    "offsetInEndSection": 132, 
                    "text": "To quantify the relative rareness of codons used across an entire ORFeome, we used the previously developed %MinMax algorithm"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167116", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 1020, 
                    "offsetInEndSection": 1283, 
                    "text": "To evaluate the relative rareness of any given mRNA sequence, the %MinMax algorithm compares the codon usage frequency of the sequence to the usage frequency for theoretical sequences encoding the same amino acid sequence using the most common or most rare codons"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167116", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3125, 
                    "offsetInEndSection": 3335, 
                    "text": "The %MinMax algorithm identified significant enrichment of %Min windows relative to a random distribution of codons, indicating significant clustering of rare codons throughout the ORFeomes of several organisms"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167116", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3537, 
                    "offsetInEndSection": 3649, 
                    "text": "The rare codon clusters identified with %MinMax correlate with experimentally determined translation pause sites"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167116", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3654, 
                    "offsetInEndSection": 3788, 
                    "text": "Here, we used %MinMax to examine the locations of rare codon clusters within the primary structure of genes across the E. coli ORFeome"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923675", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 22, 
                    "offsetInEndSection": 421, 
                    "text": "In order to determine the relative rareness of the codons used to encode a particular amino acid sequence, we developed the %MinMax algorithm. %MinMax defines the relationship between a given mRNA sequence and hypothetical sequences encoding the same protein using the most rare (minimum) or most common (maximum) codons, as a function of the arithmetic mean of all possible codon usage frequencies."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923675", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 581, 
                    "offsetInEndSection": 810, 
                    "text": "A sliding window of %MinMax output along an mRNA sequence produces a plot in which clusters of predominantly common codons appear as positive (%Max) peaks, and clusters of predominantly rare codons appear as negative (%Min) peaks"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10689191", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 403, 
                    "text": "The PAUSE software has been developed as a new tool to study translational control over protein targeting. This makes it possible to correlate the position of clusters of rare codons in a gene, predicted to cause a translational pause, with the position of hydrophobic stretches in the encoded protein, predicted to span a membrane or to act as a cleavable signal for targeting to the secretory pathway."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is macroautophagy a selective degradation process?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016236", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0035459", 
                "http://www.uniprot.org/uniprot/ATG7_PICPA", 
                "http://www.uniprot.org/uniprot/ATG1_PICPA", 
                "http://www.uniprot.org/uniprot/ATG11_PICPA"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21839922", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21383079", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20498061", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20417604", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11309418", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23295856", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23064313", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23046644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22977244", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22561104", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22017874", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21913110", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21681022", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21431350", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20798600", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20703094", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20659474", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20543572", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20364111", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19793921", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19717456", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19619495", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18539900", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17622797", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17351330", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17204848", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16874038", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12960228", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11739783", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9296392"
            ], 
            "id": "51bedaac3148fdcc22da7188", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839922", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 109, 
                    "text": "Selective autophagy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839922", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 128, 
                    "text": "Macroautophagy (autophagy) is a bulk degradation system for cytoplasmic components and is ubiquitously found in eukaryotic cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839922", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 505, 
                    "offsetInEndSection": 574, 
                    "text": "Here we show that selective autophagy downregulates Ty1 transposition"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839922", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 723, 
                    "offsetInEndSection": 908, 
                    "text": "We propose that selective autophagy safeguards genome integrity against excessive insertional mutagenesis caused during nutrient starvation by transposable elements in eukaryotic cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21383079", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2013, 
                    "offsetInEndSection": 2097, 
                    "text": "Another function of Atg8 homologues is as an adapter for selective autophagy because"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21383079", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 10100, 
                    "offsetInEndSection": 10227, 
                    "text": "Because two Atg8 homologue\u2013binding proteins, p62 and NBR1, have been shown to be degraded in the process of selective autophagy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20498061", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 438, 
                    "offsetInEndSection": 577, 
                    "text": "Moreover, it is becoming apparent that proteins, organelles, and pathogens can be targeted for autophagic clearance by selective mechanisms"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20498061", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1003, 
                    "offsetInEndSection": 1154, 
                    "text": "Cell spreading required ref(2)P, the Drosophila p62 multiadaptor, implicating selective autophagy as a novel mechanism for modulating cortical dynamics"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417604", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 104, 
                    "text": "The selective macroautophagic degradation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417604", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 182, 
                    "text": "There is growing evidence that macroautophagic cargo is not limited to bulk cytosol in response to starvation and can occur selectively for substrates, including aggregated proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417604", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 183, 
                    "offsetInEndSection": 468, 
                    "text": "<a class=\"btn btn-mini annotationText\" href=\"#\" data-id=\"10\" rel=\"tooltip\" title=\"Remove annotation\"><i class=\"icon-remove\"></i></a> It remains unclear, however, whether starvation-induced and selective macroautophagy share identical adaptor molecules to capture their cargo. Here, we report that Alfy, a phosphatidylinositol 3-phosphate-binding protein, is central to the selective elimination of aggregated proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417604", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 933, 
                    "offsetInEndSection": 1071, 
                    "text": "We propose that Alfy plays a key role in selective macroautophagy by bridging cargo to the molecular machinery that builds autophagosomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11309418", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5689, 
                    "offsetInEndSection": 5823, 
                    "text": "macroautophagy machinery is essential for the selective delivery of excess peroxisomes to the vacuole by the related pexophagy pathway"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295856", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 920, 
                    "offsetInEndSection": 1032, 
                    "text": "Thus, cytoplasmic NBR1 might be important to maintain basal levels of selective macroautophagy in these neurons."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064313", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1048, 
                    "offsetInEndSection": 1181, 
                    "text": "we could show that Smatg8 and Smatg4 are not only required for nonselective macroautophagy, but for selective macropexophagy as well."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 186, 
                    "offsetInEndSection": 311, 
                    "text": "The latter is performed by proteasome-mediated degradation, chaperone-mediated autophagy (CMA), and selective macroautophagy,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977244", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 429, 
                    "offsetInEndSection": 558, 
                    "text": "Here we demonstrate a role for PtdIns 4-kinases and PtdIns4P 5-kinases in selective and nonselective types of autophagy in yeast."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977244", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 151, 
                    "text": "Macroautophagy (hereafter autophagy) is a degradative cellular pathway that protects eukaryotic cells from stress, starvation, and microbial infection."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561104", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 150, 
                    "offsetInEndSection": 351, 
                    "text": "Previously, we showed that macroautophagy is necessary for conidiation in the rice-blast fungus Magnaporthe oryzae. Here, we analyzed the physiological function(s) of selective autophagy in Magnaporthe"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22017874", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 108, 
                    "text": "Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22017874", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 229, 
                    "text": "Selective macroautophagy (autophagy) of ubiquitinated protein is implicated as a compensatory mechanism of the ubiquitin-proteasome system. p62/SQSTM1 is a key molecule managing autophagic clearance of polyubiquitinated proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913110", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 180, 
                    "offsetInEndSection": 623, 
                    "text": "Whole organelle turnover is mediated through macroautophagy, a process by which autophagosomes deliver mitochondria to the lysosome for hydrolytic degradation. While mitochondrial autophagy can occur as part of a nonselective upregulation of autophagy, selective degradation of damaged or unneeded mitochondria (mitophagy) is a rapidly growing area in development, cancer, and neurodegeneration, particularly with regard to Parkinson's disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21681022", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 192, 
                    "offsetInEndSection": 405, 
                    "text": "BAG3 was recently described as a mediator of a novel macroautophagy pathway that uses the specificity of heat shock protein 70 (HSP70) to misfolded proteins and also involves other protein partners, such as HSPB8."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 873, 
                    "offsetInEndSection": 1398, 
                    "text": "In addition to this nonselective or bulk autophagy, selective types of autophagy are used for biosynthetic transport (the cytoplasm-to-vacuole targeting [Cvt] pathway), and to recognize and degrade specific cargoes or organelles. These latter include the selective degradation of mitochondria (mitophagy), peroxisomes (pexophagy), and ribosomes (ribophagy; Reggiori et al., 2005; Kanki and Klionsky, 2008; Kraft et al., 2008; Geng et al., 2010). Among different kinds of selective autophagy, mitophagy is particularly crucial"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3443, 
                    "offsetInEndSection": 3626, 
                    "text": "Different from p38, which is a negative regulator of autophagy, Hog1 is a positive regulator only required for mitophagy, but not other types of selective autophagy or bulk autophagy."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3923, 
                    "offsetInEndSection": 4118, 
                    "text": "Atg32 is a mitophagy-specific receptor and is necessary for the recruitment of mitochondria to the PAS through interaction with Atg11, which is an adaptor protein for selective types of autophagy"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 6800, 
                    "offsetInEndSection": 6958, 
                    "text": "Considering the apparent role of Slt2 in mitophagy, we next asked whether this kinase is also involved in bulk autophagy or other types of selective autophagy"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7483, 
                    "offsetInEndSection": 7597, 
                    "text": ", it represents a selective type of autophagy and shares many of the same molecular components with bulk autophagy"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576396", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 460, 
                    "offsetInEndSection": 625, 
                    "text": "In this paper, we have shown that Slt2 and Hog1 are involved in mitophagy, as both slt2\u0394 and hog1\u0394 cells showed severe defects in selective mitochondria degradation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431350", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5126, 
                    "offsetInEndSection": 5263, 
                    "text": "Ubiquitin- and LC3-binding protein p62 is particularly involved in the selective degradation of ubiquitinated proteins via macroautophagy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431350", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5816, 
                    "offsetInEndSection": 5989, 
                    "text": "We used immunohistochemistry to assess cellular distribution of autophagosome-related proteins involved in selective degradation of ubiquitinated proteins via macroautophagy"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431350", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 845, 
                    "offsetInEndSection": 940, 
                    "text": "involved in the p62-mediated selective degradation of ubiquitinated proteins via macroautophagy"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431350", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 6788, 
                    "offsetInEndSection": 7102, 
                    "text": "In addition, the fact that MAP2 was co-localized with LC3, p62, and ubiquitin within clustered puncta suggests that the observed LC3-immunoreactive autophagosomes are localized to neuronal processes and that MAP2 undergoes turnover by means of the selective degradation of ubiquitinated proteins via macroautophagy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20798600", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 94, 
                    "offsetInEndSection": 254, 
                    "text": "two Parkinson disease (PD) associated genes, PINK1 and Parkin, were shown to mediate the degradation of damaged mitochondria via selective autophagy (mitophagy)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20798600", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 448, 
                    "offsetInEndSection": 520, 
                    "text": "Here we show that whole mitochondria are turned over via macroautophagy."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703094", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 56, 
                    "text": "Does Huntingtin play a role in selective macroautophagy?"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703094", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 847, 
                    "offsetInEndSection": 1002, 
                    "text": "In the discussion here I suggest that Htt may have a normal function in the lysosomal mechanism of selective macroautophagy involved in its own degradation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659474", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1010, 
                    "offsetInEndSection": 1199, 
                    "text": "Macroautophagy induced by ethanol seemed to be selective for damaged mitochondria and accumulated lipid droplets, but not long-lived proteins, which could account for its protective effects"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20543572", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 341, 
                    "offsetInEndSection": 520, 
                    "text": "Although macroautophagy can be nonspecific, there are many examples of selective sequestration including pexophagy, mitophagy and the cytoplasm to vacuole targeting (Cvt) pathway."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20364111", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 151, 
                    "text": "Mitochondria autophagy (mitophagy) is the process of selective degradation of mitochondria that has an important role in mitochondrial quality control."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20364111", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 367, 
                    "offsetInEndSection": 497, 
                    "text": "One of the genes identified, YLR356W, is required for mitophagy, but not for macroautophagy or other types of selective autophagy."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793921", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 81, 
                    "text": "<div class=\"row\"><div class=\"span7\"><h2 id=\"docTitle\">A genomic screen for yeast mutants defective in selective mitochondria autophagy.</h2> </div> </div>"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793921", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 140, 
                    "text": "Mitophagy is the process of selective mitochondrial degradation via autophagy, which has an important role in mitochondrial quality control."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19717456", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 363, 
                    "offsetInEndSection": 801, 
                    "text": "Analysis of this set of targeted deletion mutants demonstrated that loss of any of the 16 genes necessary for nonselective macroautophagy renders the fungus unable to cause rice blast disease, due to impairment of both conidial programmed cell death and appressorium maturation. In contrast, genes necessary only for selective forms of autophagy, such as pexophagy and mitophagy, are dispensable for appressorium-mediated plant infection."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19619495", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 480, 
                    "offsetInEndSection": 579, 
                    "text": "This gene is not required for other types of selective autophagy or for nonspecific macroautophagy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18539900", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 663, 
                    "offsetInEndSection": 1107, 
                    "text": "However, in contrast to the core autophagy genes such as atg5 and atg7, expression of ulk1 is not essential for induction of macroautophagy in response to nutrient deprivation or for survival of newborn mice. Together, these data suggest that the ATG1 homologue, Ulk1, is a component of the selective autophagy machinery that leads to the elimination of organelles in erythroid cells rather that an essential mechanistic component of autophagy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17622797", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 530, 
                    "text": "Growing evidence supports an active role for dysregulated macroautophagy (autophagic stress) in neuronal cell death and neurodegeneration. Alterations in mitochondrial function and dynamics are also strongly implicated in neurodegenerative diseases. Interestingly, whereas the core autophagy machinery is evolutionarily conserved and shared among constitutive and induced or selective autophagy, recent studies implicate distinct mechanisms regulating mitochondrial autophagy (mitophagy) in response to general autophagic stimuli."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17351330", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 381, 
                    "offsetInEndSection": 814, 
                    "text": "We discovered that activation of the UPR in yeast also induces a new branch of macroautophagy that selectively targets the ER. We term this process \"ER-phagy\", in analogy to pexophagy and mitophagy, the two other known forms of organelle-specific marcoautophagy. ER-phagy involves the generation of autophagosomes that selectively include ER membranes and whose delimiting double membranes also derive, at least in part, from the ER."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17204848", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1276, 
                    "offsetInEndSection": 1412, 
                    "text": "This suggests that in fungi an organism-specific form of selective autophagy may occur, for which specialized Atg proteins have evolved."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16874038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 112, 
                    "offsetInEndSection": 251, 
                    "text": "ransfer of Y. lipolytica cells from oleate/ethylamine to glucose/ammonium chloride medium leads to selective macroautophagy of peroxisomes."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12960228", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 109, 
                    "text": "Insulin-dependent signaling regulates azurophil granule-selective macroautophagy in human myeloblastic cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12960228", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 114, 
                    "text": "We show that insulin-dependent signals regulate azurophil granule-selective macroautophagy in human myeloid cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12960228", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 579, 
                    "offsetInEndSection": 773, 
                    "text": "By contrast, other organelles, including the mitochondria, endoplasmic reticulum, and Golgi apparatus remained intact, indicating that the macroautophagy selectively targeted azurophil granules."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12960228", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1453, 
                    "offsetInEndSection": 1589, 
                    "text": "Thus, insulin-dependent signals are responsible for the control of azurophil granule-selective macroautophagy via Akt-dependent pathways"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11739783", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 134, 
                    "text": "Eukaryotic cells have the ability to degrade proteins and organelles by selective and nonselective modes of micro- and macroautophagy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11739783", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 212, 
                    "offsetInEndSection": 316, 
                    "text": "For example, pexophagy is a selective process for the regulated degradation of peroxisomes by autophagy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9296392", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 293, 
                    "text": "We have characterized biochemically, morphologically, and genetically two distinct pathways for the selective degradation of peroxisomes in Pichia pastoris. These pathways are independently regulated and analogous to microautophagy and macroautophagy that have been defined in mammalian cells."
                }
            ], 
            "triples": [
                {
                    "o": "biological_process", 
                    "p": "http://linkedlifedata.com/resource/geneontology/namespace", 
                    "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/geneontology/regulates", 
                    "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0016241"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q12092"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/P25694"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q5RBA5"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q03818"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q07528"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q55CC5"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q501R9"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0016236", 
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess", 
                    "s": "http://purl.uniprot.org/uniprot/Q9VHH2"
                }
            ], 
            "type": "yesno"
        }
    ]
}